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ABSTRACT 
 
 
Malignant melanoma is one of the most aggressive types of human cancers and one of 
the deadliest malignancies with steadily increasing incidence rates globally. Although 
early detection and increased surveillance have undoubtedly contributed to the elevation 
of survival rates, its mortality rates still remain high as the disease does not respond to 
current therapeutic strategies. Hyperthermia, defined as the application of exogenous 
heat induction, is one of the most common therapeutic modalities and acts by either 
directly killing tumor cells and/or sensitizing them against other therapeutic means. 
Numerous reports have provided proof that it can trigger the activation of cell death 
pathways in various skin cancer cell lines. Hence, in the present study we have aimed to 
establish a hyperthermia-induced experimental platform in order to assess its therapeutic 
efficacy in an in vitro human skin cancer model consisting of (1) immortalized 
keratinocytes (non-malignant), (2) malignant melanoma and (3) epidermoid carcinoma 
(non-melanoma) cells as well as an in vivo mouse model of malignant melanoma (mice 
injected with mouse malignant melanoma cells). According to our kinetic analyses 
using our in vitro skin cancer model, the optimal hyperthermic experimental conditions 
range between 430C-450C, for 2 hours, as there was a significant cell death induction in 
malignant melanoma cells, whereas, interestingly, non-malignant cells seem to be more 
resistant. Furthermore, we utilized a real-time PCR microarray-based gene expression 
profiling system to identify critical gene targets involved at various stages of the 
apoptotic pathway(s). Moreover, in order to fully characterize the interactions and 
cross-talks between the different apoptotic cascades (intrinsic, extrinsic, ER- stress 
mediated), we studied changes in protein expression levels of various genes implicated 
in those pathways by means of Western immunoblotting. According to our results, there 
is differential regulation of gene expression of several pro- and anti-apoptotic genes 
which appears to depend on the hyperthermic exposure conditions. Finally, our previous 
findings were evaluated by utilizing an in vivo mouse malignant melanoma model and 
according to our data there was a considerable inhibition of tumor growth for both 
hyperthermic conditions accompanied by the respective changes in several apoptotic 
genes' expression levels. The results of this study further support hyperthermia's 
effectiveness in treating malignant melanoma by identifying the underlying molecular 
mechanisms and various molecules responsible for hyperthermia's beneficial effects on 
tumor growth inhibition.  
ii 
 
ACKNOWLEDGEMENTS 
 
First, I would like to thank my supervisor, Prof. Mihalis Panagiotidis, for his help and 
support during throughout this three-year PhD project. I really appreciate his assistance 
in every possible aspect, from providing guidance and advice to personal 
encouragement, for the completion of this project.  
Furthermore, I would like to thank my second supervisor Prof. George Goussetis for his 
help and support. In addition, I have to thank Dr. Aglaia Pappa, Dr. Katerina Chlichlia, 
Dr. Sotiris Botaitis, Stavros Vasiliadis, Ioannis Anestopoulos, Evaggelia Lampri for 
their support and assistance in several aspects of this study. 
I am also very thankful to Alejandro Espi, Aris Sfakianos, Sophie McConachie, 
Christodoulos Christodoulou, Ambar Ahmed, Danielle Adamson, Aithne Atkinson, 
Caitlin Newman, Robyn Adams and Angeline Maher for helping me at various stages 
throughout this project. 
I would like to say a HUGE thanks to my family and friends who continuously 
supported me whenever needed. A special thanks to Stavros, Christina, Natasa, Danae, 
Matina, Eleni and Yolanda for their non-stop efforts to cheer me up and help whenever 
needed.  
Finally, I would like to thank Heriot Watt University for funding this project. 
 
 
 
 
 
 
 
 
iii 
 
TABLE OF CONTENTS 
 
Abstract……………………………………………………………………………….....i 
Acknowledgements………………………………………………………………….….ii 
List of tables………………………………………………………………………...…vii 
List of figures………………………………………………………………………....viii 
 
Chapter 1 
1. Introduction…………………………………………………………………….1 
1.1 Skin Cancer…………………………………………………………………2 
1.1.1 Malignant melanoma……………………………………………………....2 
1.1.2 Cancer stem cells (CSTs) in skin cancer progression…………………5 
1.2 Cell death pathways………………………………………………………...7 
1.2.1 Apoptosis…………………………………………………………………….7 
1.2.2 Autophagy…………………………………………………………………...8 
1.2.3 Necrosis……………………………………………………………………...9 
1.3 Apoptotis and cancer development………………………………………12 
1.4 Apoptotic signaling………………………………………………………..13 
1.5 The unfolded protein response (UPR) signalling pathways…………….20 
1.5.1 The PERK–eIF2α pathway………………………………………………20 
1.5.2 The IRE-1α- XBP1 pathway…………………………………………….23 
1.5.3 The ATF6 pathway……………………………………………………….25 
1.6 ER-stress and UPR activation in cancer development…………………27 
1.7 Hyperthermia……………………………………………………………..28 
1.7.1 Alterations in cellular homeostasis…………………………………….29 
iv 
 
1.7.2 Cytotoxicity………………………………………………………………...31 
1.7.3 Physiological changes……………………………………………………32 
1.8 Hypothesis and Specific Aims…………………………………………….34 
 
Chapter 2 
2. Materials & Methods……………………...…………………………………..35 
2.1 Cell Culture Methodologies………………………………………………36 
2.1.1 Cell lines……………………………………………………………………36 
2.1.2 Materials for cell culture……………………………………………...…37 
2.1.3 Recovery of cells…………………………………………………………..38 
2.1.4 Propagation of cells………………………………………………………38 
2.1.5 Plating of cells…………………………………………………………….39 
2.1.6 Hyperthermia (HT) exposures (monotherapy)………………………..39 
2.1.7 Hyperthermia exposures combined with non-targeted and targeted 
therapeutic agents (adjuvant therapy)…………………………………40 
2.1.8 Cell viability assay……………………………………………………….40 
2.1.9 CytoTox-Fluor cytotoxicity assay………………………………………41 
2.1.10 Trypan blue staining……………………………………………………..42 
2.1.11 Caspase activity assay…………………………………………………..42 
2.2 Molecular Biology Methodologies………………………………………44 
2.2.1 RNA extraction………………………………………………………..…44 
2.2.2 cDNA synthesis……………………………………………………….…44 
2.2.3 Quantitative real-time polymerase chain reaction (qPCR)……….45 
 
v 
 
 
2.3 Protein Methodologies………………………………………………...…..46 
2.3.1 Preparation of cell lysates and protein determination by the 
bicinchoninic acid assay (BCA)…………………………………………46 
2.3.2 Western immunoblotting…………………………………………………47 
2.3.3 Stripping and re-probing of blots…………………………………….…51 
2.4 In Vivo Rodent Models of Melanoma and Colon Carcinoma………….51 
2.4.1 Cell lines………………………………………………………………..….51 
2.4.2 Animals……………………………………………………………………..52 
2.4.3 Ethics statement…………………………………………………………...52 
2.4.4 Hyperthermia exposures- tumor induction protocols………………..53 
2.4.5 Immunohistochemical analysis………………………………………….55 
2.5 Statistical analysis……………………………………………...………….57 
 
Chapter 3 
3. Results 
Results I- Effects of hyperthermia in an in vitro model of human malignant 
melanoma……………………………………………………………………...58 
3.1 Optimization of a hyperthermia-induced experimental platform by 
using an in vitro model of human malignant melanoma……………….59 
3.1.1 Kinetic analyses based on cell viability………………………………..59 
3.1.2 Hyperthermia-induced cytotoxicitty……………………………………65 
 
3.2 Hyperthermia induces the apoptotic pathway response in human 
malignant melanoma (A375) cells………………………………………..68 
vi 
 
3.3 Hyperthermia-induces alterations in the expression of key apoptotic 
genes in human malignant melanoma (A375) cells……………………...74 
Results II- Mechanisms of cell death induction in response to 
hyperthermia in an in vitro model of human malignant melanoma…...78 
3.4 Underlined apoptotic mechanisms characteristic of the hyperthermic 
response in human malignant melanoma (A375) cells………………….79 
3.4.1 Hyperthermia induces the activation of initiator caspases-8 and -9 in 
A375 cells…………………………………………………………………..79 
3.4.2 Hyperthermia induces the activation of executioner caspases-6, -7 
and -3 in A375 cells………………………………………………………81 
3.4.3 Hyperthermia induces the activation of death receptor molecules in 
A375 cells…………………………………………………………………..85 
3.4.4 Hyperthermia induces the upregulation of various proapoptotic 
proteins in A375 cells…………………………………………………….87 
3.4.5 Hyperthermia induces ER stress response in A375 cells…………….91 
3.4.6 Hyperthermia induced regulation of heat shock proteins in A375 
cells…………………………………………………………………………95 
Results III- Hyperthermia as an adjuvant therapy in an in vitro model of 
human malignant melanoma treatment…………………………………98 
3.5 The effect of Dacarbazine (DTIC) in combination with hyperthermia in 
A375 cells……………………………………………………..……………99 
 
3.6 The effect of a novel palladium-based chemotherapeutic agent as well as 
two targeted drug compounds (Vemurafenid and Dabrafenib) in 
combination with hyperthermia in A375 cells…………………………103 
Results IV- Therapeutic efficacy of hyperthermia in an in vivo model of 
rodent malignant melanoma………………………………………………...111 
3.7 The effect of hyperthermia at 43oC and 45oC in an in vivo rodent 
malignant melanoma model……………………………………………..112 
 
vii 
 
3.8 The effect of hyperthermia at 43oC and 45oC in an in vivo rodent colon 
carcinoma model…………………………………………………………116 
 
Chapter 4 
4. Discussion…………………………………………………………………….120 
 
Chapter 5 
5. Conclusions…………………………………………………………………...134 
 
References…………………………………………………………………………….138 
 
LIST OF TABLES 
 
Table 2.1: List of cell lines used for the in vitro human malignant melanoma model...36 
Table 2.2: Characteristics of the different cell lines used for the in vitro human 
malignant melanoma model……………………………………………………………36 
Table 2.3: List of materials used for cell culture………………………………………37 
Table 2.4: List of non-targeted (chemotherapeutic) and targeted (small molecule) 
therapeutic agents………………………………………………………………….…...40 
Table 2.5: List of various caspases and their respective peptide substrates for 
determining their activity levels after exposure to hyperthermic conditions….……….43 
Table 2.6: Thermal cycling conditions for running the TaqMan Array 96-well plates..45 
Table 2.7: List of apoptotic gene sub-families in the human apoptosis qPCR array…..46 
Table 2.8: List of materials used for Western immunoblotting………………………..48 
Table 2.9: List of antibodies used for Western immunoblotting………………………49 
Table 2.10: Characteristics of the cell lines used for the in vivo melanoma and colon 
carcinoma rodent models……………………………………………………………….51 
Table 2.11: List of materials used for immunohistological staining…………………..56 
Table 2.12: List of antibodies used for immunohistological staining………………….57 
viii 
 
LIST OF FIGURES 
 
Figure 1.1: The different types of cell death and their morphological characteristics...11 
Figure 1.2: The extrinsic and intrinsic pathways of apoptosis………………………...16 
Figure 1.3: The interactions and cross-talks among the three apoptotic pathways……19 
Figure 1.4: The PERK–eIF2α pathway……………………………... ……………..…22 
Figure 1.5: The IRE-1α- XBP1 pathway……………………………..……………..…24 
Figure 1.4: The ATF6 pathway……………………………………..…………..…..…26 
Figure 1.7: The different unfolded protein response (UPR) pathways……………..…28 
Figure 2.1: Images descriptive of handling C57BL/6J mice during the tumor induction 
protocol…………………………………………………………………………………54 
Figure 2.2: Images descriptive of handling BALB/c mice during the tumor induction 
protocol…………………………………………………………………………………55 
Figure 3.1.1: The effect of hyperthermia at various temperatures (37-50oC) on cell 
viability levels in A) a human epidermoid carcinoma (A431) and B) human malignant 
melanoma (A375) cell line……………………………………………………………..60 
Figure 3.1.2: The effect of hyperthermia (43oC and 45oC) at different time courses in a 
human epidermoid carcinoma (A431; A & C) and melanoma (A375; B & D) cell line.63 
Figure 3.1.3: The effect of hyperthermia at 43oC (A) and 45oC (B) in three different 
human skin cell (HaCaT, A431, A375) lines…………………………………………..64 
Figure 3.1.4: The effect of hyperthermia at 43oC (A), 45oC (B) and 50oC (C), expressed 
as relative levels of dead cells, in melanoma (A375) and normal, immortalized 
keratinocyte (HaCaT) cell lines………………………………………………………...66 
Figure 3.1.5: The effect of hyperthermia (43oC and 45oC) on cell viability (A) and dead 
cell (B) levels determined by trypan blue staining……………………………………..67 
Figure 3.1.6: The effect of hyperthermia (43oC and 45oC) on the activity levels of 
caspase 8, at various time points, in A375 cells………………………………………..69 
Figure 3.1.7: The effect of hyperthermia (43oC and 45oC) on the activity levels of 
caspase 9, at various time points, in A375 cells………………………………………..70 
ix 
 
Figure 3.1.8: The effect of hyperthermia (43oC and 45oC) on the activity levels of 
caspase 4, at various time points, in A375 cells………………………………………..71 
Figure 3.1.9: The effect of hyperthermia (43oC and 45oC) on the activity levels of 
caspase 6, at various time points, in A375 cells………………………………………..72 
Figure 3.1.10: The effect of hyperthermia (43oC and 45oC) on the activity levels of 
caspase 3, at various time points, in A375 cells………………………………………..73 
Figure 3.2.1: The activation of caspases-8 and -9 in response to hyperthermic 
exposures at 43oC and 45oC…………………………………………………………….80 
Figure 3.2.2: The activation of caspase-6 in response to hyperthermic exposures at 
43oC and 45oC………………………………………………………………………….82 
Figure 3.2.3: The activation of executioner caspases-7 and -3 in response to 
hyperthermic exposures at 43oC and 45oC……………………………………………..83 
Figure 3.2.4: The cleavage of Poly ADP Ribose Polymerase (PARP) in response to 
hyperthermic exposures at 43oC and 45oC……………………………………………..84 
Figure 3.2.5: The activation of death receptor (extrinsic) pathway activation in response 
to hyperthermic exposures at 43oC and 45oC…………………………………………..86 
Figure 3.2.6: The involvement of proapoptotic proteins Bak, Bax and Bad in response 
to hyperthermic exposures at 43oC and 45oC…………………………………………..89 
Figure 3.2.7: The involvement of proapoptotic proteins BID, BimEL, BimL and BimS in 
response to hyperthermic exposures at 43oC and 45oC………………………………...90 
Figure 3.2.8: The participation of PERK, IRE-1a and Grp78 in promoting ER stress 
response to hyperthermic exposures at 43oC and 45oC………………………………...93 
Figure 3.2.9: The participation of ATF-6, XBP-1s and CHOP in promoting ER stress 
response to hyperthermic exposures at 43oC and 45oC……………………………..….94 
Figure 3.2.10: The response of HSPs 90, 70 and 40 following hyperthermic exposures 
at 43oC and 45oC…………………………………………………………………….…96 
Figure 3.2.11: The response of HSP60 and HSF1 following hyperthermic exposures at 
43oC and 45oC………………………………………………………………………….97 
Figure 3.3.1: The effect of an adjuvant therapeutic protocol combining 41oC and DTIC 
at 24h (A), 48h (B) and 72h (C) post exposure in A375 cells………………………..100 
Figure 3.3.2: The effect of an adjuvant therapeutic protocol combining 43oC and DTIC 
at 24h (A), 48h (B) and 72h (C) post exposure in A375 cells……………………..…101 
Figure 3.3.3: The effect of an adjuvant therapeutic protocol combining 41oC and DTIC 
at 24h (A), 48h (B) and 72h (C) post exposure in A375 cells…………………..……102 
x 
 
Figure 3.3.4: The effect of a combined therapeutic protocol at 43oC and treatment with 
Vemurafenib (A) and Dabrafenib (B) 48h post exposure in A375 cells……………...105 
Figure 3.3.5: The effect of a combined therapeutic protocol at 43oC and treatment with 
Vemurafenib (A) and Dabrafenib (B) 48h post exposure in HaCaT cells……………106 
Figure 3.3.6: The effect of a combined therapeutic protocol at 43oC and treatment with 
a palladium-based drug compound in A375 (A) and HaCaT (B) cells 48h post 
exposure……………………………………………………………………………….107 
Figure 3.3.7: The effect of Vemurafenib, Dabrafenib and an experimental palladium-
based novel drug compounds on the levels of un-cleaved caspases-8 and -9 in the 
absence (370C) and presence (430C) of hyperthermia in A375 cells………………....108 
Figure 3.3.8: The effect of Vemurafenib, Dabrafenib and an experimental palladium-
based novel drug compounds on the levels of un-cleaved caspases-6 and Lamin A/C in 
the absence (370C) and presence (430C) of hyperthermia in A375 cells……………..109 
Figure 3.3.9: The effect of Vemurafenib, Dabrafenib and an experimental palladium-
based novel drug compounds on the levels of un-cleaved caspases-7 and -3 in the 
absence (370C) and presence (430C) of hyperthermia in A375 cells…………………110 
Figure 3.4.1: The effect of hyperthermia in an in vivo rodent malignant melanoma 
model………………………………………………………………………………….114 
Figure 3.4.2: The effect of hyperthermia on the expression levels of various proteins in 
an in vivo model of rodent malignant melanoma…………………….…………...…..115 
Figure 3.4.3: The effect of hyperthermia in an in vivo rodent colon carcinoma 
model………………………………………………………………………………….118 
Figure 3.4.4: The effect of hyperthermia on the expression levels of various proteins in 
an in vivo model of rodent colon carcinoma………………………………………….119 
 
 
 
 
1 
 
 
 
 
 
Chapter One 
 
Introduction 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2 
 
1. Introduction 
 
1.1 Skin Cancer 
Skin cancer is considered to be one of the most common types of cancer 
worldwide with steadily increasing incidence rates over the past decades (ACS, 2016). 
It is categorized into several types according to the kind of skin cells from which they 
arise. Briefly, there are three main types: (i) basal cell carcinoma (BCC) that originates 
from basal cells at the basal layer of the epidermis or the follicular epithelium and has 
the highest prevalence amongst skin cancer rates, (ii) squamous cell carcinoma (SCC) 
that derives from the cells that make up the top of epidermis and (iii) malignant 
melanoma that originates from the melanin-producing cells, called melanocytes, and is 
the most aggressive skin cancer type (Erb et al., 2008). BCC and SCC together are 
called non-melanoma skin cancers (NMSC) and are the most common histologic 
subtypes (20%) of all malignancies diagnosed in the UK every year (Brenn, 2014) with 
almost 132.000 cases (NCRAS, 2014). Approximately, 5.4 million patients are 
diagnosed with NMSC worldwide per annum, whilst 80% are BCC (Connolly, 2012). 
Presentation of NMSC has been associated with increased risk of other malignancies 
(Barton, 2017). BCCs are generally curable through surgical excision and are rarely 
metastatic or fatal, mainly eroding local anatomical structures, particularly on head and 
neck.  SCCs exhibit a less favorable prognosis with increased metastatic potential and 
mortality rates. They are characterized by the presence of atypical (dysplastic) 
keratinocytes although exhibiting a wide range of clinical manifestations. The average 
treatment costs in the US between 2007 and 2011 did escalate to $4.8 billion for NMSC 
and $3.3 billion for melanoma (Guy et al., 2015).  
 
1.1.1 Malignant melanoma 
Malignant melanoma is the most aggressive form of skin cancer and one of the 
most lethal amongst all solid tumor types with around 232.000 people diagnosed each 
year worldwide and incidence rates increasing globally over the past few decades (de 
Vries et al., 2005, Arnold et al., 2014). This trend is in accordance with recent 
demographic reports in UK, where 1 in 54 people are developing melanoma during their 
lifetime, rendering the disease the 5th most common type of cancer, accounting for 4% 
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of all new cases registered (15.400 in 2014). The disease incidence rates have increased 
dramatically (by 119%) over the last two decades, while it seems that it is one of the 
most common cancers among young (between ages 15-35) and fair-skinned people.  
The incidence rate projections report, for 2035, an estimated additional increase by 7%. 
Late stage diagnosis is occurring in 1 in 10 cases, whilst approximately 59.000 patients 
have been reported for 10-year survival post diagnosis (CRUK, 2014).   
The disease occurs from accumulation of genetic and metabolic abnormalities at 
the pigment-producing cells, the melanocytes, that reside in the neural crest and migrate 
to the skin or other sites during the embryonic development. Melanoma can originate 
from cutaneous melanocytes or occurs in mucosal surfaces (uveal tract of the eye, oral 
cavity, leptomeninges, gastrointestinal sites, genital mucosa) (Dennis, 1999, Stang et al., 
2003). The pathogenesis of melanoma remains still unclear, however skin phototype, 
hair color, numerous atypical naevi (benign proliferations of melanocytes), genetic 
predisposition and solar ultraviolet (UV) radiation have been associated with the 
disease. Interestingly, extended analysis of the melanoma genome has revealed a close 
link between frequent mutational events and UV radiation making it the leading risk 
factor (Russak, 2012 and Fu, 2017).  
Clinical diagnosis of malignant melanoma is usually unambiguous and accurate 
although some non-pigmented malignant melanocytic lesions might be often 
misinterpreted as NMSC (Ferrara et al., 2013). Clinical examination of the neoplasms 
can be aided by dermoscopy, computerized imaging, whole-body digital photography 
and confocal laser microscopy (Marchesini et al., 2002). Excisional biopsy is required 
for histological classification and staging of the tumor according to the American Joint 
Commission on Cancer (AJCC) TNM system (Balch et al., 2009, Amin et al., 2017). 
When diagnosed at an early stage, the disease can be cured by surgical removal, but 
upon the disease progression to metastatic stages the treatment options become poorer 
as the current therapeutic strategies do not seem to be quite efficient (Jerant et al., 
2000). Several therapeutic regimens based on combined treatment options have been 
applied in clinical trials. However, none of them have been proven to be advantageous 
in improving survival rates. Therefore, there is a vital need for the establishment of new 
strategies that will be able to ameliorate existing therapeutic protocols and/or make 
them more effective. 
Until recently, the major treatment would involve only surgical resection of the 
tumour. However, 10-15% of melanoma bearing patients develop distant metastases. 
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Recurrence is more common in subcutaneous tissue and lymph nodes (non-loco-
regional metastatic melanoma), lung, brain, gastrointestinal tract, liver and biliary tract, 
spleen and bone. Prognosis for most of the diagnosed metastatic deposits remains 
extremely poor, highlighting the need for a more effective eradication of the primary 
tumor deposits (Garbe et al., 2011, Shain and Bastian, 2016). In addition, increased 
surveillance as well as improvements in early diagnosis might have contributed to the 
dsease’s increased incidence rates. However, the main reason for the observed trends 
still remains the prolonged exposure to sunlight (Bataille et al., 2004, Parkin et al., 
2011, Rushton et al., 2017). Changes in socio-economic status and in lifestyle habits, 
such as intense and sporadical exposure to sun - especially during childhood- and use of 
sun-beds, have both been linked to the steadily rising numbers of new cases, 
highlighting the importance of sun-protection education programs as a prevention 
strategy (Perez-Gomez et al., 2008). Technological advances in molecular biology have 
allowed for the identification of several genes and pathogenic events responsible for 
melanoma tumorigenesis. UV-induced DNA damage (Cadet et al., 2015) and reactive 
oxygen species (ROS) production (Joosse et al., 2010) along with secretion of growth 
factors derived from keratinocytes and suppression of T-cell mediated immune 
responses are amongst the key drivers of melanoma formation. However, little is known 
about the primary somatic genetic mutations during melanoma carcinogenesis. The B-
Rapidly Accelerated Fibrosarcoma (BRAF) oncogene is well-established as one of the 
frontline therapeutic targets (Kozar et al., 2017). The mitogen-activated protein kinase 
(MAPK) pathway (Hartmann et al., 2015), the micropthalmia transcription factor 
(MITF) (Kawakami et al., 2017), the epidermal growth factor (EGFR) and the N-Ras 
sarcoma protein (NRAS) proto-oncogene (Posch et al., 2016) are frequently deregulated 
in melanomas (Griewank, 2016). To this end, more recent molecular drugs targeting 
melanoma focus on the MAPK pathway which is heavily involved in 90% of 
melanomas. In fact, 50% of cases present active mutations in BRAF.  
Vemurafenib and Dabrafenib are potent and selective BRAF inhibitors whereas 
Trametinib, a MAPK kinase (MEK) inhibitor, is effective in blocking pathway 
activation downstream of BRAF (Grimaldi et al., 2017). According to several reports, 
combinational treatment of BRAF and MEK inhibitors has elicited considerable tumor 
regression (Ribas et al., 2011, Latimer et al., 2016, Simeone et al., 2017). Another 
promising approach towards melanoma treatment is based on molecular immunotherapy 
(Margolin, 2016). Adoptive immunotherapy exploiting tumor infiltrating lymphocytes 
(TIL) or genetically-engineered T cells expressing chimeric antigen receptors (CAR-T 
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cells) has been correlated with 50-70% response rates (Sim et al., 2014, Merhavi-
Shoham et al., 2017). Administration of interleukin-2 (IL-2) or interferon-alpha (IFN-α) 
as a single-agent or adjuvant therapy is effective in sustaining the disease under control 
(Bright et al.,2017, Trinh et al., 2017, Daponte et al., 2013). Treatment with immune 
check-point regulators has been adopted as a strategy aiming to oppose the induction of 
immunological tolerance during melanoma formation. Cytotoxic T-lymphocyte 
associated protein 4 (CTLA4) inhibitors such as Ipilimumab or Tremelimumab are 
effective as a monotherapy or in combination with the cytotoxic drug Dacarbazine 
(DTIC) (Lee et al., 2016, Yun et al., 2016). Additionally, Nivolumab and 
Lambrolizumab are monoclonal antibodies targeting the pro-death receptor-1 ligand 1 
(PD-L1) frequently expressed at melanoma cells, giving hope for improvements in the 
therapeutic management of melanomas (Hassel et al., 2017, Hao et al., 2017). Patients 
diagnosed with advanced or even intermediate stage of the disease may also undergo 
adjuvant systemic therapy including administration of intermediate-dose IFN-α or 
adjuvant radiotherapy post-surgical clearance (Laks et al., 2013, Gonzalez et al., 2016). 
Moreover, single-agent chemotherapy involving treatment with Dacarbazine, 
Temozolamide and Fotemustine is frequently used, mainly due to the low toxicity and 
simplicity of administration although being associated with low response rates (10%) 
(Quereux et al., 2011). Finally, bio-chemotherapy combines the above mentioned 
regimens with administration of cytokines and it is considered a promising strategy with 
potentially better response rates (Diamantopoulos et al., 2016, Chatzistefanou et al., 
2016, Biteghe et al., 2017). Last but not least, radiation therapy is widely employed for 
the treatment of distant metastases (Gampa et al., 2017).  
 
1.1.2 Cancer stem cells (CSCs) in skin cancer progression 
It is well known that solid tumor as well as leukaemias do not consist of a single 
tumor cell type but a quite heterogenous tumor cell population. Over the last few 
decades, research has provided evidence supporting the stem cell theory of cancer. 
According to this theory, a small population of cancer cells within a specific tumor type 
appear to possess stem cell properties (cancer stem cells- CSCs), therefore being able to 
reproduce themselves, generate the range of cancer cells composing the tumor and 
retain malignant growth (Visvader, 2011; Visvader and Lindeman, 2008). A critical 
implication of this theory is that CSCs can promote metastasis of a tumor type to 
6 
 
different sites (migration properties), whereas if they are resistant to the treatment plan 
followed, they can potentially cause a future relapse (Shiozawa et al., 2013).  
One of the most commonly studied tissues with a well structured hierarchical 
organization is mouse skin, therefore it has been widely used for studying skin 
carcinogenesis. This process is characterized by multiple steps which evolve from the 
the development of hyperplasia, dysplasia and benign papilloma to squamus invasive 
carcinoma and spindle carcinoma (Klein-Szanto et al., 19993). Elevated levels in DNA 
changes of the target cells have been linked with the progression of this intricate process 
(Frame and Balmain, 2000), however it remains unclear whether the target CSCs pre-
possess the ability to reproduce indefinitely or the accumulation of genetic alterations 
results in the immortalization of more committed cells with limited life span. Results 
from studies using chemicals as carcinogenic factors have provided evidence that 
tumors of different malignancies can arise from different target cells. More specifically, 
it was argued that malignant tumors are developed from cells residing in the bulge of 
the hair follicle and have a high self-renewal potential, while papillomas may arise from 
stem cells of the intefollicular epidermis (Bailleul et al., 1990; Brown et al., 1998). In 
addition, when mice were treated first with 7,12- dimethylbenz[a]anthracene (DMBA) 
for the tumor initiation stage and then with the tumor promoter 12-O-tetradecanoyl 
phorbol-13-acetate (TPA) after 1 year, it appeared that they developed papilloma in the 
same pattern as if they were treated soon after the initiation. These findings imply that 
cells with mutations on RAS gene reside in the epidermis for extended time periods 
without initiating the formation of lesions, therefore suggesting that those cells belong 
to a stem cell population (Van Duuren et al., 1975).  
Several research reports have suggested the implication of CSCs in the 
development of malignant melanoma, progression of the disease as well as its resistance 
to current therapeutic means (Fang et al., 2005; Wang et al., 2006; Monzani et al., 
2007). Melanoma cells have been found to form spheres which are groups of non-
adherent cells that maintain their self-renewal properties over long time periods, thus 
supporting the presence of cells with stem cell features within the melanoma population 
(Fang et al., 2005). Development of melanoma tumors is often characterized by 
substantial changes in the genome including chromosomal translocations, deletions, 
amplifications or mutations which suggests the extensive heterogeneity in melanoma 
populations, however it has been shown that primary, metastatic as well as recurrent 
tumors arouse from the same initial clone (Chin et al., 2006; Wang et al., 2006). 
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Furthermore, there is evidence showing that specific factors secreted by melanoma cells 
are capable of directing the migration of hematopoietic progenitor cells to metastatic 
sites (Kaplan et al., 2005). Nodal which has been shown to be secreted by melanoma 
cells is known to act as a morphogen for progenitor cells and may play a role in 
determining the sites of tumor metastases (Topczewska et al., 2006). Other stem cell 
markers found to be upregulated in melanomas involve CD133, CD166, nestin, Notch, 
ALDH1A, etc. (Klein et al., 2007; Massi et al., 2006; Croteau et al., 2013). In contrast, 
a number of other reports propose that melanoma heterogeneity is based on clonal 
variation while the formation of tumors arising from different clones may be induced by 
different molecular mechanisms. Therefore, the potential participation and activation of 
different mechanisms in the progression of the disease is responsible for the commonly 
unsuccessful results of certain therapies while revealing the increasing need for 
developing diverse targeted therapeutic strategies (Brinckerhoff, 2017; Croteau et al., 
2013). 
 
1.2 Cell death pathways 
 The development and interaction of multicellular organisms with their 
environment is highly dependent on the achievement and maintenance of a relative state 
of equilibrium between cellular proliferation and death. Tissue homeostasis requires a 
plethora of tightly linked and regulated processes. However, cell death can also be the 
result of damage caused by various factors (e.g. UV radiation, viruses, etc.) leading to 
deregulation of cellular processes. Cellular death involves three major morphologically 
and biochemically distinct modalities: apoptosis (type I programmed cell death), 
autophagy (type II) and necrosis (type III) (Galluzzi et al., 2012). These processes are 
closely related and involve many common regulatory mechanisms.  
1.2.1 Apoptosis 
 This is an evolutionary conserved and precisely tuned mechanism of regulated 
death occurring in both physiological and pathological cell death instances, thus playing 
a pivotal role in maintaining cellular homeostasis (Henson et al., 2006) and various 
developmental processes (Brill et al., 1999) such as organogenesis and tissue 
architecture establishment (Meier et al., 2000) as well as immunity (Cohen et al., 1992). 
Apoptosis is a route of programmed cell death (PCD) including a set of morphologically 
diverse phenomena (as opposed to necrosis-associated processes) and was first reported 
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as a distinct mode of cell death by Kerr et al. (Kerr et al., 1972, Diamantis, 2008). It 
involves cell detachment and shrinkage, pyknosis (cellular volume reduction), 
pseudopodia retraction, chromatin condensation, nuclear fragmentation (karyorrhexis) 
and blebbing of the plasma membrane but minimal or no ultra-structural remodelling of 
the cytoplasmic organelles (Green, 2005). These processes facilitate cellular 
fragmentation and creation of membrane-enclosed structures, the apoptotic bodies, 
which are rapidly phagocytosed by adjacent or recruited cells in absence of triggering 
inflammatory responses (Khan, 2014). Principal biochemical features involve a set of 
energy-dependent processes like DNA breakdown, protein cleavage, mitochondrial 
dysfunction, display of phagocytic markers on the cell surface mediating phagocytic 
recognition and clearance, an increase in cytoplasmic Ca2+ concentration and 
phosphatidylserine externalisation (Elmore, 2007). The loss of mitochondrial potential 
and the concomitant lack of adenosine triphosphate (ATP) production elicit the 
permeabilization of the outer mitochondrial membrane. This event promotes the release 
of pro-apoptotic factors from the mitochondrial intermembrane space mediating the 
activation of inducer and effector protease-dependent cascades. These cysteine aspartyl 
proteases, the caspases, mediate the proteolytic cleavage of diverse cellular substrates 
(Martin et al., 1995).  
Apoptotic deregulation is well-known to be causally linked to various diseases 
(Hetts, 1998, Mirkes 2001). Excessive apoptosis is one of the key drivers of neuronal 
loss observed in a wide range of neurodegenerative diseases such as Parkinson’s and 
Alzheimer’s, amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA) 
(Thompson, 1995). Apoptosis has also been reported to be involved in the progression 
of infectious diseases such as the acquired immunodeficiency syndrome (AIDS) in 
addition to heart disease. On the contrary, a deficiency in apoptotis can trigger 
autoimmunity, allograft rejection and contribute to cancer development. Therapeutic 
interventions targeting the restoration of either the apoptotic cell death induction or 
suppression of its excessive triggering hold great promise for the successful treatment of 
any associated diseases (Elmore, 2007). 
 
1.2.2 Autophagy 
 This is an intracellular catabolic process involving the engulfment of 
cytoplasmic material and intracellular organelles though double-membrane vehicles, the 
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autophagosomes, and the fusion of the latter with lysosomes for the formation of 
autolysosomes which recycle the removed material by acidic hydrolases (Levine et al., 
2008).  Nutritional starvation or other environmental and hormonal reasons (trophic 
factor depletion, hypoxia, etc.) as well as various stress conditions and infections can 
trigger autophagic vacuolization thus eliciting degradation of intracellular organelles 
(mitochondria, endoplasmic reticulum, ribosomes) in order to ensure the supply of 
nucleotides, amino acids and fatty acids (Lin et al., 2015, Fitzwalter et al., 2015). 
Autophagy is present at low, constitutive levels in most mammalian cell types and 
therefore it is primarily considered as a rather cytoprotective process playing an 
important housekeeping role in the recycling of long-lived proteins or organelles. In 
particular, autophagy is critical for the homeostasis of post-mitotic differentiated cells, 
such as cardiomyocytes and neurons (Glick et al., 2010). However, excessive autophagy 
may be harmful as well. Data from genetic knock-out models supports the notion that 
suppression of autophagy can accelerate cell death (Vicencio et al., 2008). Silencing of 
key autophagy mediating genes such as BECLIN 1, autophagy protein 5 (ATG5), 
autophagy protein 10 (ATG10) and autophagy protein 12 (ATG12) evoked starvation-
linked cell death in HeLa cells (Boya et al., 2005). On the contrary, pharmacologic 
inhibition of autophagy has been proven to block cell death in nerve growth deprived 
sympathetic neurons (Xue et al., 1999) and anti-estrogen treated human mammary 
carcinoma cells (Bursch et al., 1996). Additionally, silencing of ATG5, ATG7, and 
BECLIN 1 under apoptotic inhibition conditions has been effective in cell death 
blockage (Yu et al., 2004). It should be noted that Yoshinori Ohsumi received the 2016 
Nobel Prize in Physiology or Medicine for his discoveries on the mechanisms of 
autophagy. According to his findings from experiments using mutated yeast cells which 
lacked vacuolar degradation enzymes, there appeared to be accumulation of small 
vesicles, the autophagic bodies, in the vacuole in response to starvation, thus proving 
the occurence of autophagy in yeast cells (Takeshige et al., 1992). Moreover, in his 
following studies he identified genes of critical importance in the autophagic pathway, 
therefore characterizing and elucidating the complex mechanisms of this cascade 
(Tsukada and Ohsumi, 1993, Mizushima et al., 1998, Ichimura et al., 2000).  
 
1.2.3 Necrosis 
 Tis is a rather passive, uncontrolled cellular process provoked by an acute, 
overwhelming trauma and is characterized by oncosis (cellular volume increase), 
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swelling of organelles, such as the endoplasmic reticulum (ER) and the mitochondria, 
rupture of plasma membrane and concomitant release of intracellular contents in the 
extracellular space. Unlike apoptosis, the nucleus remains intact although distended. 
These events evoke further damage to the surrounding cells in addition of inducing a 
robust inflammatory response as well (Leist et al., 2001, Los et al., 2002). Necrosis is 
typically independent of caspase activation and does not include unique morphological 
characteristics. The necrotic signalling cascade involves inflammatory responses 
orchestrated by the release of various factors inluding: (i) the high mobility group 
protein B1 (HMGB1) and (ii) the hepatoma derived growth factor (HDGF) that triggers 
the sensitization of the NOD-like receptor family pyrin domain containing 3 (NLRP3) - 
a core protein of the inflammasome through production of ATP by the mitochondria of 
the necrotic cells (Iyer et al., 2009). 
 Necroptosis is a form of programmed necrosis, sharing several key processes 
with apoptosis. This more physiological and programmed type of necrotic death is 
present in neurodegeneration and death provoked by ischemia or infection and is also 
being triggered by the same apoptotic-inducing death signals (Nikoletopoulou et al., 
2013). There is evidence that it is involved in the pathogenesis of traumatic brain injury, 
stroke, neurodegenerative diseases and brain tumour (Favaz et al., 2014). Necroptosis is 
induced when the pro-apoptotic signalling is blocked and this response is known to be 
orchestrated by (i) tumour necrosis factor types I (TNFR1) (Weinlich et al., 2016) and II 
(TNFR2) (Siegmund et al., 2016), (ii) death receptors including Fas (Vercammen et al., 
1998) and (iii) TNF related apoptosis inducing ligand receptor types I (TRAILR1) and 
II (TRAILR2) (Jouan-Lanhouet et al., 2012). The cytoplasmic death domain of TNFR1, 
following the binding of ligand, binds with TNF-receptor-associated death domain 
(TRADD), RIPK1 and E3 ligases for the creation of complex I. The removal of 
ubiquitin from RIP1, results in the formation of complex II which is capable of 
triggering the apoptotic or necrotic pathway. For apoptotic induction, RIP1 and TRADD 
recruit FADD and pro-caspase-8, thus leading to its activation. Necroptosis occurs when 
RIP1 binds to RIP3 and activates it in the absence of FADD and pro-caspase 8 (Green 
and Llambi, 2015). 
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Figure 1.1 The different types of cell death and their morphological characteristics. 
a) A healthy cell, b) a necrotic cell, c) an apoptotic cell and d) an autophagic cell. PCD: 
Programmed Cell Death. The activation of different cell death pathways can be 
triggered by diverse stimuli on healthy cells (a) therefore causing characteristic changes 
on their morphological features. Necrotic cells (b) are characterized by the disruption of 
their plasma membrane, swelling of organelles, intact nucleus and cell lysis. On the 
other hand, characteristics of apoptosis (c) include the permeabilization of 
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mitochondrial membrane, fragmentation of the nucleus, cell shrinkage, pyknosis and 
formation of apoptotic bodies.  The main feature of autophagy (d) is the formation of 
autophagosomes which help the cells degrade and recycle their components, however if 
it is excessive it can lead to the cell death activation. Adapted from (Nikoletopoulou et 
al., 2013). 
 
1.3 Apoptotis and cancer development 
 Cancer is a complex disease characterized by the uncontrolled and aberrant 
accumulation of atypical cells. Additionally, the disease is accompanied by dentrimental 
defects in apoptotic signalling (Hetts, 1998) as they affect malignant transformation, 
tumour formation, progression and metastasis (Cotter 2009). The seminal report 
“Hallmarks of Cancer” by Hanahan and Weinberg has summarised the characteristics 
that confer survival and growth advantage to cancer cells during tumorigenesis. These 
include: (i) sustaining proliferative signalling, (ii) evading growth suppressors, (iii) 
resisting cell death, (iv) enabling replicative immortality, (v) inducing angiogenesis and 
(vi) activating invasion and metastasis” (Hanahan et al., 2000). Their updated report 
included (vii) reprogramming of energy metabolism and (viii) evading immune 
destruction as two additional emerging hallmarks of cancer (Hanahan et al., 2011). 
Evasion of apoptosis arises from both the deregulation of the sensory machinery 
involved in intracellular and extracellular signalling but also from alterations in the pro-
apoptotic signalling. Tumour protein p53 (TP53) is a tumour suppressor protein capable 
of activating the expression of various apoptotic-inducing genes and has a crucial role in 
the pathogenesis of cancer, tumor aggressiveness and resistance to chemotherapy. Both 
p53 and its effector murine double minute (MDM2) are capable of regulating the cell 
cycle arrest in response to DNA damage through upregulation of pro-apoptotic genes 
(B-cell lymphoma 2; Bcl-2 family members) and genes capable of generating free 
radical production (Polyak et al, 1997). Furthermore, p53 and MDM2 can activate DNA 
repair. Overall, p53 is mutated in 55-70% of human cancers (Levine et al., 2009) and it 
exerts its pro-apoptotic signalling via induction of the breakdown of the outer 
mitochondrial membrane (Mihara et al.,2003). The activation of oncogenes which 
mediate apoptotic inhibition such as Bcl-2 and Myc represents another mechanism 
linking apoptosis with oncogenesis (Strasser et al., 1990). Moreover, the presence of 
mutations in genes involved in apoptotic suppression confers resistance to anti-
13 
 
neoplastic agents. Apoptosis-inducing compounds such as cisplatin (Barry et al., 1990), 
etoposide (Kaufmann et al., 1989) and 5-fluorouracil (Armstrong et al., 1992) have been 
widely used as the gold standard for the treatment of systemic tumours. A major 
challenge in enhancing the therapeutic outcome of these compounds is the clinical 
management of drug-resistant leading to disease recurrence due to positive selection of 
apoptosis-evading cells (Lowe et al., 2000, Pommier et al., 2004, Fernald et al., 2013).  
 
1.4 Apoptotic signaling 
 Given the continuously growing interest for a better understanding of the role of 
the apoptotic deregulation in carcinogenesis, a great number of enzymes and cellular 
components participating in this complex process have been identified (Elmore, 2007, 
Plati et al., 2011). Extended research has indicated that there are two main apoptotic 
pathways: the extrinsic (or death receptor pathway) (Ashkenazi et al., 1998) and the 
intrinsic (or mitochondrial) pathway (Green et al., 1998). The signalling cascades in 
both pathways are divided into the following phases: initiation, integration and 
execution.  
The extrinsic pathway is induced by an external ligand binding to its 
corresponding cell death receptor (DR) located on the cell surface, a process that leads 
to its activation and the resulting formation of an intracellular signalling complex. This 
receptor family consists of more than 20 members which belong to the tumor necrosis 
factor-α (TNF) receptor gene superfamily: (i) TNFR1 (Tartaglia et al.,1993), (ii) Fas 
(APO-1/CD95) (Dhein et al., 1995), (iii) TNF-related apoptosis inducing ligand 
(TRAIL/ Apo-2L) and its receptors 1 and 2 (MacFarlane et al.,1997, O’Rourke et al., 
1997) and (iv) DR3 (TRAMP) (Kitson et al., 1996), DR4, DR5 (Adams, 2003). Binding 
of extrinsic ligands (TNF, Lymphotoxin, Fas, Tweak and Trail) to their respective 
receptors leads to conformational changes that reveal the intracellular death domains 
(DD) and provokes the binding of adaptor proteins such as Fas-associated death domain 
(FADD) and TNFR1-associated death domain (TRADD) thus resulting in the formation 
of the death-inducing signal complex (DISC) (Thorburn, 2004). This complex interacts 
and eventually activates initiator caspases-8 and -10 which, in turn, trigger the 
activation of effector caspases. Moreover, the cleavage of caspase-8 can lead to the 
activation of BH3-interacting domain death antagonist (BID), with the subsequent 
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formation of truncated BID (tBID) which is capable of facilitating further the cross-talk 
between the extrinsic and intrinsic pathways (Tait and Green, 2010).  
The intrinsic pathway is initiated by intrinsic (non-receptor) death stimuli 
including (i) damage of an intracellular organelle (nucleus, ER, lysosome, Golgi 
apparatus, mitochondria), (ii) cellular stress signals (DNA damage, ischemia, increased 
intracellular Ca2+ concentrations, oxidative stress) or (iii) signalling from growth factors 
and cytokines. These signals activate the mitochondrial signalling pathway (Kroemer, 
2007) by affecting the balance between pro-apoptotic and anti-apoptotic proteins of the 
Bcl-2 family. The functional balance between the pro-apoptotic members of this family 
[such as Bcl-2-associated X protein (Bax), Bcl-2 associated death promoter (Bad), Bcl-2 
homologous antagonist/killer (Bak)] and anti-apoptotic members Bcl-2 and Bcl-xL  
plays a critical role in inducing the acyivation of this apoptotic pathway. As a 
consequence, events changing this balance provoke alterations in the mitochondrial 
membrane integrity (e.g. mitochondrial permeability transition; MPT) (Kim et al., 2003) 
which in turn results in the formation of the mitochondrial-apoptosis induced channel 
(MAC) in the outer mitochondrial membrane that facilitates the release of apoptogenic 
factors (Mayer et al., 2003). These factors include the following: (i) cytochrome c, (ii) 
the second-mitochondria derived activator of caspases/direct inhibitor of apoptosis 
(IAP)-associated binding protein with low pI (SMAC/ Diablo) (Du et al., 2000, Adrain 
et al., 2001), (iii) endonuclease G (Li et al., 2001), (iv) the apoptosis inducing factor 
(AIF) (Lorenzo et al., 1999) and (v) the high temperature requirement A2 (Omi/ HtrA2) 
(Suzuki et al., 2001).  As soon as cytochrome c is released in the cytoplasm, it binds to 
the adaptor protein apoptotic protease activating factor-1 (APAF-1) and along with pro-
caspase-9 they form a protein complex called the apoptosome which cleaves pro-
caspase-9 to its active form (caspase-9) and consequently activates the downstream 
effector caspase-3 (Zou et al., 1999). AIF and endonuclease G, upon nuclear 
translocation, elicit chromatin fragmentation and nuclear translocation. Furthermore, 
SMAC/Diablo and Omi/HtrA2 antagonize cytosolic IAPs namely c-IAP1, c-IAP2, 
survivin, X-linked IAP and deactivate them thus contributing to the apoptotic induction 
(Tait and Green, 2010).  
Caspases are key players in the activation and execution phases of the apoptotic 
machinery and can be distinguished into initiators and effectors. Initiator caspases (-2, -
8, -9 and -10) upon their response to various stimuli, are stimulated and cleave the 
inactive pro-forms of the effector caspases (-3, -7 and -6) which can subsequently 
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cleave other cellular substrates and thus trigger the apoptotic machinery (Green and 
Llambi, 2015). The targets of such proteolytic cleavage involve diverse cellular 
substrates including DNA repair enzymes [such as the poly-ADP-ribose-polymerase 
(PARP) (Lazebnik et al., 1994)], nuclear laminins (Lazebnik et al., 1995) and 
cytoskeletal proteins (Mashina et al., 1995). Caspase-independent forms of apoptosis 
have also been reported highlighting the role of other molecules (e.g.  cathepsins) as cell 
death executioners (Leist et al., 2001). The complex interaction of internal and external 
signals from numerous proteins participating in the apoptotic cascade ultimately leads to 
the initiation of apoptosis. Nevertheless, the progression of the apoptotic cascade is 
difficult to orientate due to the cross-talk between all pathways (Hao et al., 2010). 
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Figure 1.2 The extrinsic and intrinsic pathways of apoptosis. The intrinsic apoptotic 
pathway (a) is activated upon stimuli of intrinsic origin, such as DNA damage, 
endoplasmic reticulum stress, etc. and induces the activation of anti-apoptotic proteins 
of the BCL-2 family as well as pro-apoptotic proteins BAX and BAK, finally leading to 
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the permeabilization of the outer mitochondrial membrane (MOMP). Members of the 
anti-apoptotic family BCL-2 bind with active BAX or BAK, thus inhibiting MOMP. 
However, when the balance between pro- and anti-apoptotic proteins is disturbed, the 
initiation of the cascade is triggered. MOMP results in the release of cytochrome c 
along with numerous other proteins which induce apoptotic induction. The apoptosome 
is formed by the binding of cytochrome c with APAF1 and its following 
oligomerization and interaction with initiator caspase-9. Active caspase-9 then leads to 
the activation of executioner caspases-7 and -3. Furthermore, the release of SMAC and 
OMI from the mitochondrion prevents the action of XIAP which can inhibit apoptosis. 
The extrinsic pathway (b) is trigerred by the interaction of death receptors with their 
respective ligands which is followed by the formation of FADD domain and recruitment 
of initiator caspase-8. Subsequently, caspase-8 gets activated and can in turn cause the 
activation of caspase-3 and -7. Moreover, activation of caspase-8 can result in the 
cleavage of BID to tBID which is responsible for the cross-talk between the extrinsic 
and intrinsic pathways. Adapted from (Tait and Green, 2010).  
In addition, the existence of another apoptotic pathway, the ER-mediated one 
has also been shown to be induced by various apoptotic stimuli. Overall, the 
endoplasmatic reticulum (ER) is a eukaryotic cellular organelle with a stress-sensing, 
biosynthetic and signalling role. ER is responsible for synthesizing, modifying and 
regulating the folding and secretion of proteins along with exporting and transferring 
them to their final destination (Sasaki et al., 2016).  In addition, ER is involved in many 
cell housekeeping functions, besides folding of proteins, including Ca2+ regulation and 
lipid biosynthesis (Banhegyi et al., 2012, Csala et al., 2012). ER is a pool of molecular 
chaperone proteins including calnexin, calreticulin, the glucose-related protein 78/ 
immunoglobulin heavy-chain binding protein (GRP78/BiP or HSP5A), and protein 
disulfide isomerases (PDI) (Luo et al., 2013). ER-stress can be defined as the response 
of the organelle to stimuli like disruption of Ca2+ homeostasis, misfolding of proteins 
and abundant accumulation of unfolded ones. ER-stress has also been correlated with 
chronic pathological conditions, involving inflammation, including: diabetes, obesity, 
atherosclerosis, neurodegenerative diseases, inflammatory bowel syndrome, etc. (Zhang 
et al., 2008). Several studies have associated ER-stress with environmental or 
pathophysiological conditions like hypoglycemia, hypoxia, oxidative stress, ATP 
depletion, Ca2+ depletion, pathogens or inflammatory stimuli (Kaufman et al., 2002, 
Wang et al., 2014). Under such conditions, ER coordinates a signal transduction 
pathway, called the unfolded protein response (UPR) in order to maintain ER-
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homeostasis and promote cell survival (Schröder et al., 2005, Wang et al., 2014, 
Tameire et al., 2015, Bhat et al., 2017). UPR activation involves the orchestration of 
adaptive mechanisms such as attenuation of protein synthesis, increased capacity for 
protein trafficking, folding and transport through the ER, proteolytic activity including 
ER-associated degradation (ERAD) and induction of apoptosis or autophagy. When ER-
stress is triggered, cells respond by activating chaperone proteins responsible for 
degrading the excess misfolded proteins and/or assist them to re-fold and thus inhibit 
formation of protein aggregates. Firstly, mis-folded proteins bind to the chaperone 
GRP78/BiP (Ng et al., 1992, Kim et al., 1995, Yu et al., 1999, Leach et al., 2004). The 
reduced levels of unbound BiP exert a positive feedback loop mediating the 
transcription of BIP and other genes encoding chaperones (Kozutsumi et al., 1988, 
Dorner et al., 1989).  Amongst chaperones, calnexin is a Ca2+-binding protein located in 
the ER membrane and has the ability to keep newly synthesized glycoproteins inside the 
ER so that they are folded properly before reaching their final destination (Wada et al., 
1991, David et al., 1993, Gelman et al., 1995). Protein disulfide-isomerase (PDI) 
catalyzes the formation of disulfide bonds (Ellgaard et al., 2005). However, in case of 
prolonged and severe mis-folded protein-induced stress, the activation of particular 
pathways results in the induction of the apoptotic machinery. To this end, data from 
studies using murine cell lines have shown that an important enzyme participating in the 
ER-mediated apoptotic pathway is caspase-12 (Nakagawa et al., 2000) which ultimately 
activates caspases-3 and -7 resulting in the triggering of cell death. Other studies have 
reported that caspase-4 (Bian et al., 2009, Sollberger et al., 2012) is a human 
counterpart of caspase-12 since it can be activated in a similar way during ER-stress. As 
part of a third group of caspases, including caspases-1, -5 and -12, caspase-4 has been 
linked to the inflammatory response according to some studies. Caspase-1, being the 
best characterized member of that group, is activated and is consequently responsible 
for the induction of the inflammatory response. Recent studies have demonstrated that 
caspase-4 plays an essential role on the activation of caspase-1 in keratinocytes, thus 
supporting its importance in inflammation (Martinon et al., 2004, Sollberger et al., 
2012). Moreover, there is evidence suggesting a cross-talk between the mitochondria-
initiated and ER-mediated apoptotic pathways, but the underlying mechanisms still 
remain unclear (Kadowaki et al., 2004, Zhang et al., 2006).  
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Figure 1.3 The interactions and cross-talk among the extrinsic, intrinsic and ER-
induced apoptotic pathways. Activation of the extrinsic apoptotic pathway involves 
the interaction between death receptors with their respective ligands, formation of 
FADD domain and caspase-8 activation. tBID is cleaved and activated by caspase-8 
while it facilitates the cross-talk between the extrinsic and intrinsic pathways. The 
induction of the intrinsic pathway includes cytochrome c release from the 
mitochondrion in response to various stress factors that cause an imbalance between 
pro- and anti-apoptotic proteins. Caspase-9 is then activated following interaction with 
APAF1. ER stress causes the accumulation of mis-folded proteins which leads to the 
activation of caspase-4 and -12, thus triggering the ER-mediated pathway. All three 
apoptotic pathways finally result in the activation of executioner caspases -3, -6 and -7 
leading to apoptosis. Adapted from (Shellman et al., 2008).  
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1.5 The unfolded protein response (UPR) signalling pathways 
UPR involves three signalling cascades: (i) the PRKR-like ER kinase (PERK/ 
eIF2AK3) eukaryotic translation initiation factor 2α (eIF2α), (ii) the inositol-requiring 
protein 1α (IRE-1α/ ERN1)-X-box binding protein (XBP1) and (iii) the activating 
transcription factor 6α (ATF6α). (Fig.1.4). 
 
1.5.1 The PERK–eIF2α pathway  
PERK is a type I transmembrane protein residing at mitochondria-associated ER 
membranes (MAMs) (Verfaillie et al., 2012). In the absence of ER-stress, heat shock 
protein 90 (HSP90) and BiP bind to PERK in order to prevent its activation (Marcu et 
al., 2002). Under ER-stress conditions, the BiP-unfolded/misfolded proteins conjugates 
permits the release of PERK, enabling its homo-trimerization and auto-phosporylation 
and therefore its activation (Bertolotti et al., 2000, Liu et al., 2000). Then, activated 
PERK phosphorylates the eukaryotic translation initiation factor 2 α (eIF2α). This, in 
turn, is a subunit of the heterotrimeric eIF2 complex whose phosphorylation can exert 
transient abrogation of general protein synthesis (Harding et al., 2000). This event 
causes polysome disassembly and subsequent availability of ribosomes that can bind 
newly transcribed mRNAs that encode UPR adaptive functions. Furthermore, PERK is 
capable of affecting cell survival, function and differentiation through interaction with 
nuclear factor erythroid 2-related factor 2 (NRF2/ NFE2L2) (Cullinan et al., 2003), 
forkhead box O (FOXO) (Zhang et al., 2013) and diacylglycerol (Bobrovnikova-Marjon 
et al., 2012). In addition, membrane fluidity influences PERK oligomerization and 
activation (Volmer et al., 2013). The PERK- eIF2α activation promotes expression of 
ATF4/CREB2, ATF5 and amino acid transporters (Yaman et al., 2003). ATF4 promotes 
cell survival through activation of ER-stress response mediators such as the DNA 
damage-inducible protein (GADD34/ PPP1R15A). GADD34 in turn dephosphorylates 
eIF2α and re-establishes global mRNA translation. ATF4 also initiates transcription of 
C/EBP homologous protein (CHOP/ DDIT3/ GADD153) (Palam et al., 2011) which 
participates in ER-stress-mediated apoptosis (Marciniak et al., 2004, Song et al., 2008).  
Under chronic stress conditions, eIF2α is phosphorylated constitutively, thus 
resulting in the attenuation of the IRE1α–XBP1 and ATF6α pathways as well as 
subsequent pro-apoptotic signalling (Scheuner et al., 2006). Depending on the severity 
of stress, PERK stimulation promotes either adaptive or apoptotic responses varying 
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amongst cell types and environment, thus setting a particular threshold for ER-stress 
tolerance. CHOP has been shown to promote cell death through repression of BCL-2 
expression (McCullough et al., 2001), up-regulation of BCL-2-interacting mediator of 
cell death (BIM/ BCL2L11) (Puthalakath et al., 2007) and BAX translocation to 
mitochondria (Szegezdi et al., 2006). Furthermore, CHOP is able to induce expression 
of p53 up-regulated modulator of apoptosis (PUMA/ BBC3) (Galehdar et al., 2010), 
lipocalin 2 (LCN2) (Hsin et al., 2012), tribbles homologue 3 (TRIB3) (Ohoka et al., 
2005) and death receptor 5 (DR5/ TNFRSF10B) (Zou et al., 2008). The latter mediates 
ER stress-induced apoptosis via caspase-8 in cancer cells (Lu et al, 2014). Recent 
findings support the notion that CHOP coupling with ATF4 and CHOP-mediated 
protein synthesis serve as stimulus for ER-stress induced apoptosis through aggregation 
of mis-folded proteins and oxidative stress (Malhotra et al., 2008, Han et al., 2013). 
However, it cannot be excluded that tumor cells evade the indirect pro-apoptotic 
signalling of CHOP and exploit diverse pro-survival pathways that are activated 
downstream of CHOP. Mutations in CHOP have been reported in human tumors, 
although their impact on protein expression or function and tumorigenesis in general 
remains to be elucidated (Kan et al., 2010).  
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Figure 1.4 The PERK–eIF2α pathway. PERK oligomerizes in response to ER stress 
and causes the phosphorylation of eIF2α leading to its inactivation and inhibition of 
mRNA translation. Increased production of ATF4 results in induction of CHOP and 
GADD34 leading to the activation of cell death. Adapted from (Walter and Ron, 2011).   
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1.5.2 The IRE-1α- XBP1 pathway 
IRE-1α is a type I transmembrane protein ubiquitously and constitutively 
expressed. In the absence of ER-stress conditions, HSP90 and HSP72 bind to IRE-1α 
and retain its stability (Gupta et al., 2010). IRE-1α serves also as a target for BiP. Upon 
ER stress, unfolded and mis-folded proteins bind to BiP. This event results in IRE-1α 
release and subsequent oligomerization, autophosphorylation and activation of its 
kinase and endoribonuclease activities. Activated IRE-1α regulates the expression of the 
transcriptionally active form of XBP1 (XBP-1s) that moves to the nucleus and acts as 
an effector of the target genes (Lee et al., 2002, Calfon et al., 2002). Localization of the 
un-spliced Xbp-1u mRNA accelerates the response through interaction with IRE-1α 
(Yanagitani et al., 2009). Genes that are regulated by this UPR signalling branch resolve 
protein mis-folding through enhanced protein folding, trafficking and ERAD (Shaffer et 
al., 2004). XBP-1s expression prevents CHOP expression and thus promotes cell 
survival by facilitating the adaptation of cells to stress conditions (Guo et al., 2012).  
Sustained ER-stress attenuates IRE-1α activation via dephosphorylation, 
ubiquitylation and degradation (Ishiwata-Kimata et al., 2013, Qui et al., 2013). An ER-
resident protein disulphide isomerase family A member 6 (PDIA6), which is required 
for IRE-1α activation (Groenendyk et al., 2014), restricts IRE-1α signaling under 
chronic ER-stress conditions (Eletto et al., 2014). Additionally, XBP-1u promotes 
degradation of XBP1 and ATF6α pathways, thus blocking survival signals (Yoshida et 
al., 2009). On the other side, prolonged activation of IRE-1α triggers pro-apoptotic 
signaling and cleaves XBP1 (Tirasophon et al., 2000, Mishiba et al., 2013) through a 
process called IRE1-dependent decay (RIDD) (Hollien et al., 2006). The activation of 
IRE-1α kinase is followed by binding of the TNF receptor-associated factor 2 (TRAF2) 
that recruits apoptosis signal-regulating kinase 1 (ASK1/MAP3K5) and JUN N-terminal 
kinase (JNK) (Urano et al., 2000). These events mediate BIM activation and 
suppression of BCL-2. Loss-of-function mutations of IRE-1α and XBP1 have been 
identified in human cancers and are expected to be linked with reduced kinase/ 
endoribonuclease activity, suggesting a tumor-suppressive role for IRE-1α and XBP1 
(Leung-Hagesteijn et al., 2013). However, research on human triple-negative breast 
cancers revealed increased XBP1 splicing, suggesting a necessity for XBP1 activation 
in cancer stem-cell like populations (Chen et al., 2014).  
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Figure 1.5 The IRE-1α- XBP1 pathway. IRE1 oligomerizes in response to ER stress 
and when active it cleaves XBP1 mRNA at two specific positions, thus excising an 
intron. Ligation of the resulting exons leads to the translation of XBP1s which regulates 
the expression of genes associated with stress conditions. Adapted from (Walter and 
Ron, 2011).   
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1.5.3 The ATF6 pathway  
ATF6 is a type II transmembrane protein that resides in the ER through 
interaction with BiP during non-stress conditions. Formation of mis-folded protein 
aggregates results in the release of ATF6, translocation to the Golgi apparatus and 
initiation of a process regulating intramembrane proteolysis, generating the cleaved 
ATF6α, an active transcription factor (Ye et al., 2000). ATF6α promotes the 
transcription of genes enhancing ER capacity and the expression of XBP1, thus 
affecting the adaptive response to protein mis-folding (Yoshida et al., 2001, Wu et al., 
2007). Its homologue, ATF6β suppresses ATF6α-mediated transcription and activity 
(Guan et al., 2009). Interestingly, PERK–eIF2α signalling promotes ATF6α synthesis 
(Teske et al., 2011). The potential role of ATF6α in apoptosis has not been elucidated 
yet. Missense mutations in ATF6 have been reported for susceptibility to malignant 
transformation (Wu et al., 2014). Moreover, BiP, a downstream transcriptional target of 
ATF6α is overexpressed in many human cancers. Although BiP is localized in the ER 
under normal conditions, it has been detected on the cell surface of malignant cells 
(Arap et al., 2004). BiP is widely used as malignancy marker for histological grading of 
neoplasms and has attracted interest as useful prognostic marker and therapeutic target 
(Lee et al., 2007).   
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Figure 1.6 The ATF6 pathway. ATF6 resides in the ER as a transmembrane protein 
and gets transferred to the Golgi apparatus via transport vesicles in response to the 
accumulation of unfolded proteins due to ER stress. There it gets cleaved by S1P and 
S2P, therefore generating ATF6α (or ATF6(N) ) which then activates the expression of 
UPR associated genes after moving to the nucleus. Adapted from (Walter and Ron, 
2011).   
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1.6 ER-stress nd UPR activation in cancer developement 
Both ER-stress and UPR activation have been documented in oncogenic 
transformation, cancer development and even chemoresistance associated with various 
cancer types. Apart from its pro-survival function, unresolved or severe ER-stress leads 
to cell death, rendering UPR as a target of therapeutic interest.  
Various intrinsic factors mediate UPR activation in transformed cells. 
Hyperactivation of oncogenes or loss-of-function mutations in tumor suppressor genes 
can result in increased protein synthesis and ER trafficking with the subsequent 
stimulation of UPR (Ozcan et al., 2008, Kang et al., 2011). Additionally, intrinsic mis-
folding provokes UPR activation (Marada et al., 2013). Highly secretory tumor cells are 
prone to constitutive UPR activation in order to respond to their increased biosynthetic 
needs (Babour et al., 2010, Mahadevan et al., 2011).  
On the other hand, extrinsic factors such as the establishment of a hostile 
environment for malignant cells can implicate abrogated protein folding resulting in 
UPR activation. ER stress and UPR activation (i) stimulate angiogenesis, (ii) exert a 
cytoprotective effect on hypoxic or glucose-/nutrients-deprived cancer cells, (iii) 
suppress anti-angiogenic factors, such as thrombospondin 1 (THBS1), CXC chemokine 
ligand 14 (CXCL14) and CXCL10 and (iv) triggers the expression of pro-angiogenic 
factors like vascular endothelial growth factor A (VEGFA), fibroblast growth factor 2 
(FGF2), IL-1β, IL-6 and IL-8. The endothelial cells in the tumor surrounding area 
undergo ER stress and UPR activation due to VEGFA (Karali et al., 2014) or the 
accumulation of mis-folded proteins (Hu et al., 2006, Dong et al., 2008). 
To summarize, UPR activation can confer cytoprotective as well as deleterious 
effects to tumor cells and consequently facilitates or suppresses tumorigenesis 
respectively. Thus, UPR signalling may be targeted as a potentially promising cancer 
treatment strategy. To date, various ER-stress targeting approaches have been 
attempted. For instance, there seems to be great potential in the administration of 
proteasome inhibitors. These molecules aim for the chymotrypsin-like subunits in both 
the constitutive proteasome and the immuno-proteasome and thus resulting in the 
accumulation of ubiquitylated proteins leading to ER stress-induced apoptosis. 
Bortezomib was the first FDA-approved proteasome inhibitor for the clinical 
management of multiple myeloma and mantle cell lymphoma and it functions as an ER-
stress inducer in highly secretory cancer cells. However, in these patients, low levels of 
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XBP1, XBP-1s, ATF6α and/or loss-of-function mutations in IRE1α or XBP1 are 
associated with a poor response to the drug (Ling et al., 2012). However, this finding 
does support the notion that UPR activation can also function as a prognostic indicator 
of therapeutic outcome. Finally, a plethora of other phase-1/-2 compounds also act by 
suppressing BiP (BiP inhibitors) or disrupting HSP90 function (Corazzari et al., 2017). 
 
Figure 1.7 The different unfolded protein response (UPR) pathways. The three 
different signal transducers (IRE1α, ATF6α and PERK) sense the accumulation of 
unfolded and misfolded proteins in the ER and regulate the induction of various 
transcription regulators which lead to the translation of UPR related genes after moving 
to the nucleus. The expression of specific genes results in either cell survival or death. 
Adapted from (Wang et al,. 2014). 
 
1.7 Hyperthermia 
This is defined as the application of exogenous heat induction for treating a wide 
range of medical conditions including malignancies. Over the past few decades, 
hyperthermia raised a great interest as a therapeutic modality given that numerous 
studies aimed to understand the underlined mechanisms of its beneficial therapeutic 
effects. In principle, the application of exogenous heat results in either directly killing 
tumor cells, when applied alone (i.e. monotherapy), or sensitizing them against other 
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therapeutic means such as radiation, chemotherapy, etc. (i.e. adjuvant therapy) (Bettaieb 
et al., 2013). Mainly, there are two strategies of applying hyperthermia: (i) conventional 
hyperthermia (at temperatures ranging from 39-45oC) and (ii) ablation therapy (at 
temperatures over 70oC). The application of heat can be focused on a small area (such 
as a tumor) in local hyperthermia whereas larger areas of tissue (such as an organ or 
limb) are heated in regional hyperthermia or even in whole body in cases where 
metastases have been wide spread. There is a range of methodologies utilized in 
applying hyperthermia and include water baths and pads, ultrasound, radio frequencies, 
microwaves, lasers, etc. The great interest in finding new and better means of delivering 
hyperthermia has resulted in designing more efficient technological platforms and 
delivery systems with the additional benefit of providing a more accurate control of 
temperature (Wust et al., 2002).  
Early studies have shown that hyperthermia, when applied in combination with 
radiation therapy (i.e. adjuvant therapy) exerts positive effects in the context of a cancer 
therapy (Robinson et al., 1974, Gerner et al., 1975). Therefore, during the last decades 
there has been a rising increase in the number of studies investigating hyperthermia's 
therapeutic potential on various cancer types (e.g. mammary carcinoma, prostate cancer, 
osteosarcoma, glioma, melanoma, etc.) by utilizing various in vitro as well as in vivo 
models. However, it should be noted that the majority of them use hyperthermia in the 
context of an adjuvant therapy in combination with a wide range of other regimens (Ito 
et al., 2003, Garcia et al., 2012, Zhang et al., 2016, Hou et al., 2014). Overall, results 
from numerous studies have shown that hyperthermia (in the range of 41-47oC) is 
capable of exerting different effects including: (i) direct cytotoxicity of tumor cells, (ii) 
modifications in the tumor microenvironment, (iii) induction of heat shock proteins, (iv) 
alterations in the immune response, (v) stimulation of necrotic and apoptotic cascades, 
(vi) changes in cell cycle related signaling pathways (vii) changes in blood flow, 
oxygen and nutrient delivery to the site of tumor and (viii) enhancement of therapeutic 
outcome when applied in combination with other regimens (Hildebrandt et al., 2002, 
Dewhirst et al., 2005, Dewhirst et al., 2016).  
 
1.7.1 Alterations in cellular homeostasis 
 The physiological temperature which allows cells to function and proliferate 
ranges from 36.5-37.5oC therefore hyperthermia is responsible for triggering several 
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changes within the cell and results in the loss of homeostasis (Hildebrandt et al., 2002). 
Synthesis of DNA, RNA and proteins is inhibited at temperatures higher that 42.5oC  
(Roberts et al., 1985). In addition, elevated heat induction appears to lead to cell cycle 
arrest, denaturation of proteins, enhanced degradation of aggregated and mis-folded 
proteins, changes in cellular metabolism (due to reduced levels of ATP) and 
cytoskeletal structure as well as alterations in the permeability of the cell membrane 
(Sonna et al., 2002). Early studies have shown that hyperthermia was capable of 
inducing the generation of DNA breaks in CHO cells (Warters and Henle, 1982). 
Results from another group demonstrated that there was an increase in mis-rejoined and 
non-repairable double-stranded DNA breaks together with a reduction in the levels of 
successfully completed DNA repair after hyperthermia combined with irradiation in 
human fibroblasts. Therefore, it was suggested that hyperthermia affects the observed 
elevation in rates of DNA breaks by slowing down DNA repair mechanisms (El-Awady 
et al., 2001). Moreover, data from several reports demonstrated that there was an 
increase in γH2AX foci, which indicate the presence of double-stranded DNA breaks, as 
a response to heat treatments and it appeared to depend on the duration of treatment 
(Takahashi et al., 2004). In addition, elevated heat has an impact on DNA repair 
cascades as it appears to hinder the process of DNA replication by inhibiting the activity 
of DNA polymerases, which eventually results in the detection of increased levels of 
DNA breaks (Jorritsma et al., 1986, Raaphorst and Feeley, 1994). Denaturation and 
aggregation of nuclear proteins in response to hyperthermic exposures has an impact on 
the progression of DNA, RNA and protein synthesis by obstructing access to DNA due 
to modifications in chromatin (Lepock, 2004). Elevation of heat is capable of affecting 
the plasma membrane of cells as it causes changes in its fluidity while it also interferes 
with transmembranal transport proteins and receptors (Bates et al., 1985, Coss and 
Linnemans, 1996). This, in turn, can lead to changes in membrane functions including 
those of the sodium-potassium pump and calcium levels (Bates et al., 1985, Vidair and 
Dewey, 1986). Heat induction has been associated with elevated generation of ROS 
(Ahmed et al., 2015). According to a number of studies, elevated heat can cause 
changes in the cellular redox status by affecting the membrane of the mitochondrion 
thus leading to the induction of DNA damage (Dressler et al., 2006, Wang et al., 2013). 
In addition, the cytotoxicity of hydrogen peroxide was enhanced when combined with 
hyperthermia (Lord-Fontaine and Averill, 1999) thus suggesting that an increased 
production of ROS can result in oxidative damage to lipids, proteins and DNA.  
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1.7.2 Cytotoxicity 
 There is an extensive number of studies reporting hyperthermia’s effects in 
inducing cell death by activating the necrotic or apoptotic cascade all of which appear to 
be dependent on temperature, duration of exposure and cell type (Ahmed et al., 2015).  
An early study using CHO cells demonstrated that hyperthermia was able to cause a 
decrease in cell viability which was dependent on the phase of cell cycle and appeared 
to be attributed to the denaturation of cellular proteins (Westra and Dewey, 1971). At 
higher hyperthermic conditions (>50oC) cells become destructed due to the immediate 
denaturation of proteins, irreversible damage in structural proteins and major chemical 
changes within the cellular environment (Diederich, 2005). On the contrary, milder 
hyperthermic conditions (<45oC) are capable of delaying and preventing the progression 
of several cellular processes thus making cells more vulnerable against other regimens 
such as chemotherapy and radiation (Hildebrandt et al., 2002). In any case, cells are 
capable of activating specific mechanisms (such as the heat shock response) in order to 
protect themselves against such damage. Consequently, heat shock proteins (HSPs) are 
produced in order to facilitate the correct folding (and thus protection) of denatured 
proteins (Sonna et al., 2002). Still, in cases of prolonged heat stress, cells might not be 
able to overcome the denaturation and aggregation of these proteins which can then 
result in the stimulation of apoptotic cell death (Ahmed et al., 2015).  
As previously mentioned, hyperthermia-induced cytotoxicity is enhanced 
against cancer cells. The majority of studies conclude that apoptotis is the main form of 
cell death triggered under conditions of moderate heat stress. Most of these studies have 
aimed to characterize the activation of the apoptotic cascade, in response to 
hyperthermia, and so have provided evidence highlighting the role of the intrinsic 
apoptotic pathway. In fact, experiments in Jurkat cells demonstrated that initiator 
caspase-9 plays a crucial role in hyperthermia-induced apoptotic activation while tBid is 
involved in the process of cytochrome c release (Shelton et al., 2010). Caspase-2 has 
also been implicated in the initiation of the apoptotic cascade under hyperthermic 
conditions (Tu et al., 2006) and was also associated with Bid cleavage (Bonzon et al., 
2006). Recently, the interaction between pro-apoptotic protein Bim with Bak and Bax 
has been demonstrated to participate in the activation of the intrinsic pathway as a 
response to heat induction (Mahajan et al., 2014). Apart from triggering the intrinsic 
apoptotic pathway, hyperthermia has been suggested to affect the extrinsic pathway as 
well. In fact, the depletion of c-FLIP due to hyperthermia results in the activation of 
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death receptors and subsequently caspase-8 (Morle et al., 2015). Furthermore, heat 
induction has been reported to stimulated the ER-stress mediated apoptotic pathway by 
increasing calcium levels (Hou et al., 2014) and activating caspases-4 and -12 
(Shellman et al., 2008). Finally, the activation of caspase-3 mediates the completion of 
apoptotic death induction (Shelton et al., 2010, Shellman et al., 2008).  
Because of its interference in several cellular processes, hyperthermia has been 
shown to potentiate the cytotoxic effects of various therapeutic strategies, such as 
radiation or chemotherapy when applied in combination as an adjuvant therapy (Wust et 
al., 2002). Several reports have addressed hyperthermia’s ability to act as a sensitizer to 
radiation for treating various types of cancer (Horsman and Overgaard, 2007, Pandita et 
al., 2009). Moreover, numerous studies have shown an enhancement in the cytotoxic 
effects of a wide range of chemotherapeutic agents when they are administered in 
combination with hyperthermia (Hildebrandt et al., 2002, Mallory et al., 2015). 
However, the exact underlying mechanisms of hyperthermia’s potentiation effects still 
remain largely uknown. 
 
1.7.3 Physiological changes  
The sensitivity of cells against increased temperatures varies considerably 
amongst different tissues. Tumor cells display an increased sensitivity against 
hypethermia compared to normal tissue whilst specific regions within the same tumor 
might exert variable cytotoxicity at different temperatures. Delayed cell cycle 
progression (from phase G0/G1 to S-G2/M) (Yuguchi et al., 2002), glucose deprivation 
(Lord-Fontaine et al., 2002), differential expression of heat shock-induced proteins 
(HSPs) and relevant pathways and fluctuations in cellular ATP levels (Oleson et al., 
1988) have all been observed when cancer cells were exposed to heat induction. Poor 
vascularization of the -frequently hypoxic- core of the tumor has been associated with 
limited capability to dissipate high temperature by circulating blood (Song et al., 1993, 
Wike-Hooley et al., 1984, Fokas et al., 2012). This altered tumor vascularization allows 
the use of hyperthermia as a strategy to confer targeted nutrient and oxygen deprivation 
resulting in interstitial pH decrease and concomitant tumour vasculature breakdown 
(Song, 1982). These traits have been taken into consideration for the development of 
combinational treatment approaches (involving hyperthermia and radiation) in order to 
overcome chemoresistance and promote synergistic anti-proliferative effects (Bogovic 
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et al., 2001). Mild hyperthermia (39-42oC) is applied on heat-induced radiosensitization 
strategies, as it results in increasing blood flow around the tumor site in order to render 
it less hypoxic and thus more susceptible to radiotherapy and/or chemotherapy (Iwata et 
al., 1996, Song et al., 2001). In addition, hyperthermia has also been adapted as a 
stimulus aiming to enhance immune surveillance and restrain tumor growth (Wang et 
al., 2005, Calderwood et al., 2009, Peer et al., 2010). The elevation in temperature leads 
to increased levels of HSPs but also higher levels of intracellular tumour antigens (Mace 
et al., 2012, Toraya-Bron et al., 2014) that are taken up by dendritic cells and 
macrophages thus inducing specific anti-tumor immunity (Frey et al., 2012). The 
thermal regulation of immune effector cells has been proven to additionally favour: (i) 
immune cell migration and transfer to target sites, (ii) trigger the release of pro-
inflammatory cytokines (TNF, IL-1, IL-6, IL-10, IL-12), (iii) control immune cell 
growth and (iv) increase the cytotoxic effects of immune cells against malignant ones. 
Finally, hyperthermia utilization in combination with gene therapy has increased the 
efficacy of antibodies and drugs targeting different types of tumors (Mallory et al., 
2016). 
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1.8 Hypothesis and Specific Aims 
The working hypothesis of our study was that hyperthermia can induce cell 
death pathways and therefore can exert a therapeutic effect as a mono- and/or adjuvant 
therapy in malignant melanoma.  
To investigate our hypothesis, we focused on characterizing the underlying 
mechanisms of hyperthermia–induced cell death as the basis of its therapeutic 
effectiveness in a human in vitro and a rodent in vivo melanoma skin models. 
 The specific aims of the project were the following: 
(1) To determine the involvement of the apoptotic cell death pathways and reveal the 
underlined mechanisms in regulating the therapeutic effectiveness of hyperthermia in an 
in vitro model of human malignant melanoma.  
(2) To determine key apoptotic genes as targets of regulating the hyperthermia-induced 
apoptotic cell death response in an in vitro model of human malignant melanoma.  
(3) To determine hyperthermia’s efficacy in potentiating the therapeutic effectiveness of 
non-targeted (Dacarbazine and a novel palladium-based chemotherapeutic agent) versus 
targeted (Dabrafenib and Vemurafenib) pharmacological approaches when utilized as 
an adjuvant therapy in an in vitro model of human malignant melanoma. 
(4) To evaluate our in vitro findings of hyperthermia’s therapeutic effectiveness, in the 
context of monotherapy, by utilizing an in vivo rodent model of malignant melanoma. 
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2. Materials & Methods 
2.1 Cell Culture Methodologies 
2.1.1 Cell lines 
Our experimental system consists of three different human skin cell lines: (1) a normal, 
immortilized keratinocyte (HaCaT) cell line, (2) an epidermoid carcinoma (A431) cell 
line and (3) a malignant melanoma (A375) cell line.  
Table 2.1: List of cell lines used for the in vitro human malignant melanoma model. 
Cell line Company 
HaCaT A kind gift from Dr Sharon Broby (Dermal Toxicology and Effects 
Group; Centre for Radiation, Chemical and Environmental Hazards; 
Public Health England, UK). 
A431 Purchased from Sigma-Aldrich (St. Louis, MO, USA) 
A375 Purchased from Sigma-Aldrich (St. Louis, MO, USA) 
 
 
Table 2.2: Characteristics of the different cell lines used for the in vitro human 
malignant melanoma model. 
  
Characteristics HaCaT A431 A375 
Organism Homo sapiens 
(Human) 
Homo sapiens 
(Human) 
Homo sapiens 
(Human) 
Ethnicity Caucasian Caucasian Caucasian 
Age 62 years old 85 years old 54 years old 
Gender Male Female Female 
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Tissue Skin Skin/epidermis Skin 
Properties Monolayer, 
adherent 
Epithelial, adherent Epithelial, adherent 
Description In vitro 
spontaneously 
transformed 
keratinocytes from 
histologically 
normal skin 
Established from 
solid tumors in the 
skin/epidermis of an 
85-year-old patient. 
Derived from the 
skin of a 54-year-
old patient. 
Disease N/A Epidermoid 
carcinoma 
Malignant 
melanoma 
Tumorigenic No Yes Yes 
 
 
2.1.2 Materials for cell culture 
Table 2.3: List of materials used for cell culture [unless otherwise stated, chemicals 
were from Sigma-Aldrich (St. Louis, MO, USA), Applichem (Darmstadt, Germany), 
Invitrogen (Carlsbad, CA, USA) and were of analytical grade]. 
Reagent Components 
Complete Growth Media DMEM (Dulbecco's Modified Eagle 
Medium) (Labtech International Ltd, East 
Sussex, UK) high glucose was 
supplemented with 10% fetal bovine 
serum heat-inactivated (Labtech), 2mM 
L-glutamine (Labtech) and 1% (v/v) 
penicillin/streptomycin mix. 
Phosphate Buffered Saline (PBS) Concentration: 1X 
140mM NaCl, 2.7mM KCl, 10mM 
Na2HPO4, 1.7mM KH2PO4, pH 7.4 
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(Labtech) 
Trypsin-EDTA Solution Concentration: 1X 
Trypsin-EDTA 0.25% in PBS w/o Mg, 
w/o Ca. 
(Labtech) 
Cell Culture Plates & Flasks Corning Inc., NY, USA 
Stripettes Corning Inc., NY, USA 
 
 
2.1.3 Recovery of cells 
All cell lines were stored in the vapor phase of liquid nitrogen, for long term storage, in 
fetal bovine serum (FBS) containing 10% (v/v) DMSO. Prior to use, cells were rapidly 
thawed and resuspended in 5ml complete DMEM. Cells were then centrifuged at 
2,000rpm for 2min at room temperature. Normal and freezing media were removed by 
aspiration. Cells were resuspended in complete DMEM and placed in 25cm2 cell culture 
flasks. All cell lines were cultured for up to 25 passages before new aliquots were 
utilized.  
 
2.1.4 Propagation of cells 
All cell lines were cultured in flasks containing DMEM complete media and maintained 
in 5% atmospheric CO2, at 37oC, in a humidified incubator. Cells were subcultured via 
trypsinization 2-3 times per week prior to reaching 100% confluence. More specifically, 
cells were washed with 6-7ml PBS after aspirating growth media and were then washed 
with 1ml of trypsin-EDTA (1X). Fresh trypsin-EDTA was added in the flask (1ml for 
A375 cells or 2ml for HaCaT and A431 cells) and then cells were placed in the 
incubator until they detached from the flask's surface (5-10min). The cells were then 
observed under the microscope to ensure that they had detached and 4-5ml of complete 
growth media was added into the flask in order to deactivate trypsin-EDTA. Finally, 
cells were resuspended and the wanted number of them was returned in the flask while 
more media was added (10-15ml).  
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2.1.5 Plating of cells 
A previously described protocol was used (section 2.1.4) along with some modifications 
including additional steps. After trypsinization and suspension, the cells in complete 
media were transferred into a 15ml falcon tube and then centrifuged at 2,000rpm for 
2min at room temperature. Media was then aspirated, and cells were thoroughly 
suspended in fresh media (5-12ml according to the size of cell pellet) while a 50μl 
sample was transferred into a microcentrifuge tube. An equal amount of trypan blue 
solution 0.4% (v/v) (HyClone Inc, South Logan, USA) was added, into the tube, and 
mixed with the sample of cell suspension. For the determination of cell number, a small 
amount (10μl) of the previously mentioned mix was loaded into a Neubauer counting 
chamber (hemocytometer) and the number of viable cells were counted, under the 
microscope. The concentration of cells (number of cells/ml) was calculated by using the 
following formula:  
Concentration of cells = N/4 x dilution factor x 104 
where N= the number of cells counted in the 4 squares of the counting chamber, 
dilution factor = 2 (1:1 dilution with trypan blue solution) and 104 = conversion factor to 
convert 10-4ml to 1ml (calculated according to the dimensions of the small square). 
After estimating the concentration of cells in the suspension, the desired number of cells 
were seeded into 100mm3 cell culture dishes, 96-well plates, etc. (according to the 
requirements of the various experimental protocols).  
 
2.1.6 Hyperthermia (HT) exposures (monotherapy) 
Cells were exposed to various temperatures ranging from 37-50oC for different time 
courses in standard 5% CO2 incubators. Briefly, following trypsinization and estimation 
of cell concentration, the appropriate number of cells was plated and incubated at 37oC 
overnight. On the next day, cells were observed under the microscope to ensure that 
they reached confluency while media was changed prior to hyperthermic exposure. 
Plates were then transferred into a 5% CO2 incubator set at the desired hyperthermic 
temperature (37-50oC) and exposed for various periods of time. Finally, plates were 
allowed to cool down, for a few minutes, at room temperature and then were returned to 
the 37oC incubator for additional incubation periods.  
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2.1.7 Hyperthermia exposures combined with non-targeted and targeted therapeutic 
agents (adjuvant therapy) 
Cells were trypsinized, plated and incubated, at 37oC, overnight. On the following day, 
plates were transferred into an incubator set at 43oC (hyperthermia) or 37oC 
(normothermia) for 2h. After the end of the exposure period, all media was aspirated, 
and various concentrations of non-targeted and targeted therapeutic agents were added 
(after being dilluted in complete growth medium or in the appropriate solvent as 
recommended by the manufacturer).  
 
Table 2.4: List of non-targeted (chemotherapeutic) and targeted (small molecule) 
therapeutic agents. 
Drug Type of therapy Company 
Dacarbazine (DTIC) Chemotherapeutic  
(non-targeted therapy) 
Abcam 
Palladium (II) saccharinate 
complex of terpyridine 
Chemotherapeutic  
(non-targeted therapy) 
A kind gift from Prof. 
Engin Ulukaya (Uludag, 
University, Turkey) 
Vemurafenib (PLX4032, 
RG7204) 
Small molecule  
(targeted therapy) 
Selleckchem 
Dabrafenib (GSK2118436) Small molecule  
(targeted therapy) 
Selleckchem 
 
 
2.1.8 Cell viability assay 
Cell viability was determined by utilizing the Celltiter-Blue Assay (Promega, UK) 
which is based on the Alamar Blue Assay. The assay uses the indicator dye (resazurin) 
which is converted to a highly fluorescent product (resorufin) by metabolically active 
cells. Non-viable cells lose their metabolic capacity; thus, they are not able to reduce 
resazurin into the fluorescent product and consequently cannot generate a fluorescent 
signal. Briefly, a desired concentration of cells was plated into 96-well plates and 
incubated overnight at 37oC. On the following day, the media was aspirated and fresh 
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one was added into each well (100μl). Cells were exposed to various hyperthermic 
conditions, for various time periods, and then were returned to 37oC. At a range of time 
points (0, 24, 48 and 72h after exposure), 20μl of Celltiter-Blue reagent was added into 
each well of α 96-well plate and mixed by gentle shaking. The plates were incubated at 
37oC for 2h and then the samples were transferred into the wells of a black opaque 
plate. Fuorescence was monitored with an emission of 560nm and an excitation of 
590nm by using a SpectraMax M5 multimode plate reader (Molecular Devices, LLC, 
Sunnyvale, USA). The levels of viable cells were estimated according to the amount of 
fluorescent product that was produced. Cell viability was expressed as percentage of 
control cells (incubated at 37oC. Five replicates (N=5) of each condition were used in 
each experiment.  
 
2.1.9 CytoTox-Fluor cytotoxicity assay 
The CytoTox-Fluor cytotoxicity assay (Promega, UK) was utilized in a manner capable 
of determining the relative number of dead cells in any cell population. The assay 
involves a fluorigenic peptide substrate (bis-alanyl-alanyl-phenylalanyn-rhodamine 110; 
bis-AAF-R110) which can measure the activity levels of a specific protease released 
from dead cells which have lost membrane integrity. This particular peptide substrate 
cannot produce a signal in viable cells as it cannot cross their cell membrane. However, 
it should be mentioned that this method has some limitations; the activity of the 
protease has a limited half-life, so the assay is not recommended to be used at 
incubation periods longer than 24h. A375 and HaCaT cells (10,000 cells/well) were 
plated into 96-well plates and cultured overnight at 37oC. On the following day, the 
media was aspirated and fresh one was added into each well (100μl). Cells were 
exposed to 43oC or 45oC, for 2h, and then were transferred back to 37oC for additional 
incubation periods. For preparing the 2X working reagent an appropriate amount of bis-
AAF-R110 substrate was added to a specific volume of assay buffer (1:1000 dilution). 
The reagent was mixed by vortexing and then an equal volume (100μl) of the assay 
reagent was added into each well, samples were mixed briefly by orbital shaking and 
were incubated for 2h at 37oC. Finally, samples were transferred into the wells of a 
black opaque plate and fluorescence was monitored with emission at 485nm and 
excitation at 520nm by using a SpectraMax M5 multimode plate reader (Molecular 
Devices, LLC, Sunnyvale, USA). The generation of fluorescent product is proportional 
to the protease activity of the marker associated with cytotoxicity so that higher 
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fluorescence values represent increased levels of dead cells. Five replicates (N=5) of 
each condition were used in each experiment.  
 
2.1.10 Trypan blue staining 
The trypan blue staining protocol was utilized in order to determine the proliferating 
potential of cells. More specifically, A375 cells were plated in 100mm dishes 
(106cells/plate) and then were incubated at 37oC, overnight. The following day, they 
were exposed to 43oC or 45oC for 2h and then were then transferred back to 37oC for 
additional incubation periods. Control cells were kept at 37oC (normothermia). At 
specific time points (immediately after and 24h after exposures), cells were trypsinized 
and collected. A sample of each cell suspension was mixed with the trypan blue stain 
and cells were counted under the microscope (see section 2.1.5). According to their 
staining, cells were categorized into two groups: viable (unstained) and dead (blue 
colour-stained) while their total number, in the cell suspension, was calculated. Three 
replicates (N=3) of each condition were used in each experiment.  
 
2.1.11 Caspase activity assay 
The Caspase Family Fluorometric Substrate kit II Plus (Abcam, Cambridge, UK) was 
utilized in order to detect changes in the activity levels of various caspases after 
exposing cells to hyperthermic conditions. The assay is based on the ability of an active 
enzyme to cleave the chromophore from a peptide substrate specific for a respective 
caspase. The peptide substrates are specific for different caspases (Table 2.5) and they 
are linked with the fluorophore -AFC. During the assay, active caspases will cleave 
their substrate between the peptide and the fluorophore AFC, therefore generating 
highly fluorescent AFC which can be detected by using a fluorescence reader. 
Substartes will be cleaved only in the lysates of apoptotic cells so the amount of AFC 
produced is proportional to the number of apoptotic cells in the sample. Briely, an 
appropriate number of cells (based on specific experimental requirements) was seeded 
into 100mm3 plates and cultured overnight at 37oC. On the next day, their media was 
replaced, and cells were exposed to specific hyperthermic conditions. Then, cells were 
transferred back to 37oC for additional incubation periods while control cells were kept 
at 37oC at all times. At specific time points, cells were collected via trypsinization, 
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washed twice with PBS and stored in microcentrifuge tubes at -20oC until being further 
processed. For performing the assay, cell pellets were mixed with the appropriate 
amount of lysis buffer (depending on pellet size) (50mM HEPES, pH 7.4, 0.1% Triton 
X-100, 100mM NaCl, 0.1mM EDTA) and were kept on ice for 10-20min while being 
periodically vortexed. Then, they were centrifuged at 14,000 x g for 15min at 4oC. 
Supernatants were transferred into fresh pre-chilled microcentrifuge tubes and kept on 
ice until protein concentration was determined. Protein concentration was determined 
by utilizing the Bicinchoninic Acid Assay (BCA Assay) (see section 2.3.1). An 
appropriate sample volume (50μg of protein content) was diluted with lysis buffer up to 
50μl and was mixed with equal amount of reaction buffer 2X (50mM HEPES, pH 7.4, 
0.1% CHAPS, 10% glucose, 100mM NaCl, 1mM EDTA, 10mM DTT). Next, 5μl from 
1mM AFC conjugated substrate (final concentation = 50μM) was mixed with each 
sample individually and the samples were incubated at 37oC for 1h in the dark. The 
assay was performed in a 96-well black opaque plate. Fluorescence was monitored at 
400 Exc / 505 Emm (nm) by using a SpectraMax M5 multimode plate reader 
(Molecular Devices LLC, Sunnyvale, USA). Results were expressed as fold increase in 
caspase activity by comparing the readings of control samples with those of the treated 
ones. Three replicates (N=3) of each experimental condition were used for each 
experiment.  
 
Table 2.5: List of various caspases and their respective peptide substrates for 
determining their activity levels after exposure to hyperthermic conditions.  
Caspase Substrate 
Caspase-3/7 Ac-DEVD-AFC 
Caspase-4 Ac-LEVD-AFC 
Caspase-6 Ac-VEID-AFC 
Caspase-8 Ac-IETD-AFC 
Caspase-9 Ac-LEHD-AFC 
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2.2 Molecular Biology Methodologies 
2.2.1 RNA extraction 
Total RNA was extracted using the TRIzol Reagent according to the manufacturer’s 
instructions. Briefly, cells (1-5 x 106) were collected via trypsinization, washed twice 
with PBS, suspended in 1ml TRIzol Reagent and stored in microcentrifuge tubes at -
20oC until being further processed. Samples were allowed to thaw at room temperature 
for a few minutes before adding 0.2ml of chloroform per 1ml of TRIzol and tubes were 
then shaken vigorously by hand for 15sec and incubated for 5min at room temperature. 
Afterwards, they were centrifuged at 12,000 x g for 10min at 4oC. After this step, there 
were 3 layers formed: a lower red phenol-chloroform phase, an interphase and an upper 
aqueous phase. DNA and proteins were extracted from the interphase/organic phase 
while RNA remained exclusively in the aqueous phase. This phase was transferred, 
from each sample, into a fresh tube while avoiding the interphase containing the DNA. 
For precipitating the RNA, 0.5ml of 100% isopropanol (per 1ml of TRIzol used) was 
added to the aqueous phase and samples were incubated for 10min at room temperature. 
Then, they were centrifuged at 12,000 x g for 10min at 4oC and supernatant was 
removed from the tubes, while leaving the RNA pellet at the bottom. Pellets were 
washed with 1ml 75% ethanol (per 1ml of TRIzol used) vortexed briefly and 
centrifuged at 7,500 x g for 5min at 4oC. All ethanol was discarded and pellets were 
allowed to air dry on the bench for 5-10min before they were suspended in RNAase free 
water (20-50μl according to pellet size) and then stored at -20oC. RNA quantity was 
determined by using the NanoDrop (ThermoScientific, Waltham, MA, USA). RNA 
quality was assessed by running 2μg of each RNA sample on a 1% agarose gel as well 
as checking the A260/280 and A260/230 ratios. 
 
2.2.2 cDNA synthesis 
Complimentary DNA was synthesized by using the SuperScript VILO cDNA synthesis 
kit (Invitrogen, Waltham, MA, USA) according to the manufacturer’s instructions. 
Briefly, 2.5μg RNA was diluted in RNAase free water to a total volume of 14μl. Four μl 
of 5X VILO Reaction Mix (random primers, MgCl2, dNTPs) and 2μl 10X SuperScript 
Enzyme Mix (SuperScript III RT, RNaseOUT recombinant ribonuclease inhibitor and a 
proprietary helper protein) were then added to the diluted RNA (total reaction volume = 
20μl). The mixture was gently mixed and incubated at 25oC for 10min. Next, the 
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mixture was heated at 42oC for 60min to generate cDNA and then at 85oC for 5min to 
inactivate the enzyme before chilling to 4oC. The resulting product was stored at -20oC 
until further use.   
 
2.2.3 Quantitative real-time polymerase chain reaction (qPCR) 
The quantitative polymerase chain reaction was carried out by utilizing the TaqMan 
Array Human Apoptosis 96-well plates (Applied Biosystems, Carlsbad, CA, USA). 
Taqman qPCR was used as the primers and probes, specific for the gene of interest, 
provide accurate quantification of the cDNA present. The predesigned 96-well plates 
contained a collection of dried-down TaqMan gene expression assays, which were 
composed of gene-specific primers and probe sets, for screening candidate genes 
involved at various stages of the apoptotic pathway. TaqMan Universal master mix (2X) 
was thawed and 550μl were mixed with the equal amount of diluted in RNAase free 
water cDNA (5-50ng per well) up to a final volume of 1,100μl (increased 10% for 
running one 96-well plate). Then, the reaction mixture was gently vortexed and spinned 
down before adding 10μl into each well of the 96-well plate. The plate was covered 
with a clear adhesive film and was briefly centrifuged to ensure that the reaction 
mixture was collected at the bottom of the wells. The plates were run at the StepOne 
Plus Real-Time PCR system (Applied Biosystems, Carlsbad, CA, USA).  
 
Table 2.6: Thermal cycling conditions for running the TaqMan Array 96-well plates.  
Fast thermal cycling conditions for TaqMan array fast plates 
 
Hold 
 
Hold 
PCR (40 cycles) 
Melt Anneal/Extend 
50oC 95oC 95oC 60oC 
2min 20sec 3sec 30sec 
 
The TaqMan Array Human Apoptosis 96-well plates contain 90 assays for genes 
implicated at various stages of the apoptotic cascade along with 6 assays for candidate 
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endogenous control genes. Gene expression data were analyzed by the ΔΔCt method 
and differences observed were expressed as fold change in gene expression by using the 
DataAssist v3.01 software. 
  
 
Table 2.7: List of apoptotic gene sub-families in the human apoptosis qPCR array. 
Apoptosis Induction: BAD, BAK1, BAX, BID, DFFA, DFFB, DIABLO (SMAC), 
DAPK3, FASLG (TNFSF6), PARP1 
Anti-Apoptosis: ATM, BCL2, BCL2L1 (BCL-X), BCL2L11, CFLAR (CASPER), EGFR, 
ENDOG, IGF1, IGF1R, NFKB1 
Apoptosis Regulation: (i) Negative Regulation: BCL2, BCL2L1 (BCL-X), BCL2L11, 
BIRC2 (c-IAP2), IGF1, IGF1R, TP53; (ii) Positive Regulation: AKT1, BAD, BAK1, 
BAX, BBC3 (PUMA), BCL2L11, BID, CDKN2A, CFLAR, CHEK2, CHUK, CYCS, 
DIABLO (SMAC), FADD, FASLG (TNFSF6), HTRA2, PMAIP1, TNFRSF10A, 
TNFSF10 (TRAIL), TP53, TRADD, TRAF2, VDAC1, VDAC2, VDAC3 
Death Domain Proteins: FADD, FAS (TNFRSF6), DAXX, RIPK1, TNF, TNFRSF10A, 
TNFRSF1A, TNFSF10, TNFSF12, TRADD, TRAF2 
Caspases & Regulators: CASP3, CASP7, CASP8, CASP9, APAF1 
Endogenous controls: 18S, AIFM1, AKT1, GAPDH, GUSB, HPRT1 
 
 
2.3 Protein Methodologies 
2.3.1 Preparation of cell lysates and protein determination by the bicinchoninic acid 
assay (BCA) 
Cells were exposed to the required experimental conditions and then collected at various 
time points by trysinization, washed twice with PBS and stored at -20oC until further 
use. Cell pellets were suspended in the appropriate amount of lysis buffer containing: 
10mM HEPES, pH 7.9, 10mM KCl, 0,1mM EDTA, 1,5mM MgCl2, 0,2% NP40, 
supplemented with protease inhibitors cocktail tablets (ThermoFisher), as well as 10mM 
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NaF, 20mM β-glycerophosphate and 0,2mM Na3VO4 (phosphatase inhibitors) and were 
left on ice while periodically being vortexed for 15min. Then, they were sonicated (by 
using a probe sonicator) at 30% amplitude for 3 cycles of 15sec (with 30sec intervals) 
on ice. Cell lysates were centrifuged at 14,000 x g for 15min at 4oC and supernatants 
were transferred into fresh microcentrifuge tubes. Protein content was determined by 
utilizing the Bicinchoninc Acid assay (BCA) kit from ThermoScientific (Waltham, MA, 
USA) according to the manufacturer's recommendations. To carry out the protein 
concentration quantification, a standard curve using Bovine Serum Albumin (BSA) was 
used. Briefly, a series of various BSA concentrations (0, 0.2, 0.5, 1, 2μg/μl) were added 
into the wells of a 96-well plate by mixing the appropriate volumes of dH2O and BSA 
stock to a final volume of 20μl. Samples were also added at a 1:10 dilution. All 
standards and samples were run in duplicates. The appropriate volume of working 
reagent was prepared by mixing 50 parts of BCA reagent A with 1 part of BCA reagent 
B (50:1), 200μl was added to each well and the plate was shaken gently by hand so that 
samples were thoroughly mixed. The plate was covered and incubated at 37oC for 
30min. Next, the plate was centrifuged at 2,000rpm for 2min to avoid presence of 
bubbles in the wells (responsible for false readings) before the absorbance was 
measured at 562nm by using a SpectraMax M5 multimode plate reader (Molecular 
Devices LLC, Sunnyvale, USA). The unknown protein concentrations of the samples 
were calculated by preparing a standard BSA curve. The required volume of samples 
was transferred to new microcentrifuge tubes and loading buffer (5X) was added as 4 
parts of sample in 1 part of loading buffer. Then, the samples were either immediately 
used or they were stored at -20oC until future usage. 
 
2.3.2 Western immunoblotting 
Samples were heated on a heat-block at 95oC for 5min (to denature proteins and reduce 
protein-protein interactions), were allowed to cool down for a few minutes and then 
vortexed and spinned down briefly. Proteins were separated by using SDS-
polyacrylamide gels of different acrylamide concentration (8, 10, 12, 10-20%) 
according to the molecular weight of the protein of interest. Fifty micrograms (50μg) of 
protein extracts were loaded onto a polyacrylamide gel and electrophoresis was carried 
out in SDS running buffer 1X at 160V for 2h.  A protein ladder (PageRuler Plus 
Prestained Protein Ladder, 10-250kDa, ThermoScientific), containing multiple proteins 
of known molecular weights labeled with dye for visualization, was used to determine 
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approximately the molecular weight of the proteins of interest. Separated proteins were 
then transferred electrophoretically onto PVDF membranes (ThermoScientific), 0.2 or 
0.45μm depending on protein molecular weight, by wet transfer in transfer buffer 1X at 
predetermined running conditions. The blots were blocked in 5% (w/v) non-fat milk 
powder in TBST buffer for 1h at room temperature under gentle agitation. Then, the 
blots were incubated with the desired primary antibody (see table) overnight at 4oC 
under gentle agitation. On the following day, the membranes were washed in TBST 
buffer for 10min for three times and then were incubated with the appropriate secondary 
antibody (Table 2.9) for 1h at room temperature under agitation. Moreover, the blots 
were incubated with SuperSignal West Pico Chemiluminescent Substrate 
(ThermoScientific) according to the manufacturer’s protocol. Finally, the reagent 
contains an enhanced chemiluminescent HRP (horseradish peroxidase) substrate which 
maintains and enhances the light emitted from the oxidation of luminol in the presence 
of HRP and H2O2. The blots were imaged by using a ChemiDoc XRS+ system from 
Bio-Rad (Perth, UK).  
 
Table 2.8: List of materials used for Western immunoblotting. 
Reagents Components 
SDS running buffer 10X 250mM Tris-base, 1.92M Glycine, 1% SDS, pH 8.3-8.5 
SDS running buffer 1X 100ml SDS running buffer 10X diluted with 900ml dH2O 
25mM Tris-base, 192mM Glycine, 0.1% SDS, pH 8.3-8.5 
Transfer buffer 10X 250mM Tris-base, 1.92M Glycine, pH 8.3-8.5 
Transfer buffer 1X 100ml Transfer buffer 10X, 5ml SDS 10% (w/v), 695ml 
dH2O, 200ml methanol 
25mM Tris-base, 192mM Glycine, 0.5% SDS, 20% (v/v) 
methanol, pH 8.3-8.5 
Tris Buffered Saline-
Tween 20 (TBS-T) 
buffer 1X 
20mM Tris, 150mM NaCl, 0.1% Tween 20 in dH2O, pH 7.6 
49 
 
Stripping buffer 25mM Glycine, 0.1% SDS, 1% Tween 20 diluted in dH2O 
pH 2.2 
 
 
Table 2.9: List of antibodies used for Western immunoblotting. 
Antibody Dilution Blocking buffer Isotype Company Catalogue 
Number 
Anti-caspase-3 
(8G10) 
1:1000 5% dry milk in 
TBS-T 
Rabbit Cell 
Signaling 
#9665 
Anti-caspase-6 1:1000 5% dry milk in 
TBS-T 
Rabbit Cell 
Signaling 
#9762 
Anti-caspase-7 
(D2Q3L) 
1:1000 5% BSA in TBS-T Rabbit Cell 
Signaling 
#12827 
Anti-caspase-8 
(1C12) 
1:1000 5% BSA in TBS-T Mouse Cell 
Signaling 
#9746 
Anti-caspase-9 
(C9) 
1:1000 5% dry milk in 
TBS-T 
Mouse Cell 
Signaling 
#9508 
Anti-lamin A/C 
(4C11) 
1:1000 5% dry milk in 
TBS-T 
Mouse Cell 
Signaling 
#4777 
Anti-PARP 1:1000 5% dry milk in 
TBS-T 
Rabbit Cell 
Signaling 
#9542 
Anti-Bad 
(D24A9) 
1:1000 5% BSA in TBS-T Rabbit Cell 
Signaling 
#9239 
Anti-Bax 
(D2E11) 
1:1000 5% BSA in TBS-T Rabbit Cell 
Signaling 
#5023 
Anti-Bim 
(C34C5) 
1:1000 5% BSA in TBS-T Rabbit Cell 
Signaling 
#2933 
Anti-BID 1:1000 5% dry milk in 
TBS-T 
Rabbit Cell 
Signaling 
#2002 
Anti-Bak 
(D4E4) 
1:1000 5% BSA in TBS-T Rabbit Cell 
Signaling 
#12105 
Anti-TNF-R1 
(C25C1) 
1:1000 5% BSA in TBS-T Rabbit Cell 
Signaling 
#3736 
Anti-FADD 1:1000 5% BSA in TBS-T Rabbit Cell 
Signaling 
#2782 
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Anti-TRADD 
(7G8) 
1:1000 5% BSA in TBS-T Rabbit Cell 
Signaling 
#3684 
Anti-RIP 
(D94C12) 
1:1000 5% BSA in TBS-T Rabbit Cell 
Signaling 
#3493 
Anti-BiP 
(C50B12) 
1:1000 5% BSA in TBS-T Rabbit Cell 
Signaling 
#3177 
Anti-IRE1a 
(14C10) 
1:1000 5% BSA in TBS-T Rabbit Cell 
Signaling 
#3294 
Anti-PERK 
(D11A8) 
1:1000 5% BSA in TBS-T Rabbit Cell 
Signaling 
#5683 
Anti-CHOP 
(L63F7) 
1:1000 5% BSA in TBS-T Mouse Cell 
Signaling 
#2895 
Anti-HSP60 
(D6F1) 
1:1000 5% BSA in TBS-T Rabbit Cell 
Signaling 
#12165 
Anti-HSP70 1:1000 5% BSA in TBS-T Rabbit Cell 
Signaling 
#4872 
Anti-HSF1 1:1000 5% BSA in TBS-T Rabbit Cell 
Signaling 
#4356 
Anti-HSP40 
(C64B4) 
1:1000 5% BSA in TBS-T Rabbit Cell 
Signaling 
#4871 
Anti-HSP90 
(C45G5) 
1:1000 5% dry milk in 
TBS-T 
Rabbit Cell 
Signaling 
#4877 
Anti-β-tubulin 
(SAP.4G5) 
1:20000 5% dry milk in 
TBS-T 
Mouse Sigma-
Aldrich 
#T7816-
.2ML 
Anti-β-actin 
(AC-74) 
1:2000 5% dry milk in 
TBS-T 
Mouse Sigma-
Aldrich 
#2228 
Rabbit Anti-
mouse HRP 
conjugated 
secondary 
antibody 
1:5000 5% dry milk in 
TBS-T 
Mouse Sigma-
Aldrich 
#A9044-
2ML 
Horse Anti-
mouse HRP 
conjugated 
secondary 
antibody 
1:2000 5% dry milk in 
TBS-T 
Mouse Cell 
Signaling 
#7076 
Goat Anti-rabbit 
HRP conjugated 
secondary 
antibody 
1:2000 5% dry milk in 
TBS-T 
Rabbit Cell 
Signaling 
#7074 
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2.3.3 Stripping and re-probing of blots 
Membranes were stripped (using mild stripping buffer; see table) to remove all primary 
and secondary antibodies in order to allow for re-probing for various other proteins 
(depending on their molecular weight). Briefly, the membranes were incubated twice 
with stripping buffer for 10-15min at room temperature on a shaker and then were 
washed twice in PBS for 10min. Another two washes with TBS-T buffer for 5min 
followed before proceeding to blocking in 5% (w/v) non-fat dry milk powder in TBS-T 
for 1h at room temperature. The blot was then incubated with different primary 
antibodies as previously described.  
 
2.4 In Vivo Xenograft Rodent Models of Melanoma and Colon Carcinoma 
2.4.1 Cell lines 
For the in vivo xenograft model of malignant melanoma, the B16-F10 cell line was 
obtained from American Type Culture Collection (ATCC; Manassas, VA, USA) while 
cells were cultured in DMEM, high glucose, supplemented with 10% fetal bovine serum 
heat-inactivated, 2mM L-glutamine and 1% (v/v) penicillin/streptomycin mix. On the 
other hand, the colon carcinoma (CT26) cell line was a kind gift from Dr. Chlichlia 
(Departnment of Molecular Biology & Genetics, Democritus University of Thrace, 
Alexandroupolis, Greece) and was used for the in vivo model of colon carcinoma. CT26 
cells were grown in DMEM, high glucose, supplemented with 10% fetal bovine serum 
heat-inactivated, 4mM L-glutamine and 1% (v/v) penicillin/streptomycin mix. Both cell 
lines were kept at 37oC, 5% CO2 in a humidified incubator. Materials and protocols 
used for cell culturing were described previously (see paragraphs 2.1, 2.1.1, 2.1.2, 
2.1.3).  
 
Table 2.10: Characteristics of the cell lines used for the in vivo xenograft melanoma and 
colon carcinoma rodent models. 
Cell lines 
Characteristics B16-F10 CT26 
Organism Mus Musculus (Mouse) Mus Musculus (Mouse) 
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Strain C57BL/6 BALB/c 
Tissue Skin Colon 
Properties Adherent 
Mixture of spindle-shaped and 
epithelial-like cells 
Adherent 
Morphology: fibroblast 
Description B16-F10 were derived from the 
parental B16 cell line as they 
display significantly greater tissue-
invasive abilities  
CT26 cells were derived 
from BALB/c mice treated 
with N-nitroso-N-
methylurethane. 
Disease Malignant melanoma Colon carcinoma 
Tumorigenic Yes Yes 
 
 
2.4.2 Animals 
C57BL/6J mice were purchased from the Hellenic Pasteur Institute (Athens, Greece) 
and were raised in the Animal House Unit (Laboratory of Experimental Surgery and 
Surgical Research at Democritus University of Thrace, Alexandroupolis, Greece Nr. 
EL71 BIO2). BALB/c mice were kindly provided by Dr. Chlichlia (Departnment of 
Molecular Biology & Genetics, Democritus University of Thrace, Alexandroupolis, 
Greece) and were maintained at the Animal House Unit. A total of 30 female mice (8-12 
weeks old, weight 20-25gr) were used under each experimental group. They were 
housed in sterile polycarbonate cages (maximum 5 mice per cage) at room temperature, 
on a 12h light-12h dark cycle. Finally, all mice were provided with tap water and 
commercial pelleted diet (Mucedola).  
 
2.4.3 Ethics statement 
All animal experiments were approved by the Animal Care and Use Committee 
of the Veterinary Department of Evros Prefecture (License No. EL1BIOexp1) and 
complied with the requirements set by Directive 86/609/EEC and PD160/91 (the 
legislation in force at the time of experimentation). All experiments were conducted in 
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light of the 3R’s (Replacement, Refinement, Reduction) policy while all mice were not 
subjected to any painful or discomforting conditions. 
 
2.4.4 Hyperthermia exposures- tumor induction protocols 
All experiments were performed at the Department of Molecular Biology and Genetics 
and Laboratory of Experimental Surgery and Surgical Research, Democritus University 
of Thrace, Alexandroupolis, Greece. Thirty female C57BL/6J mice (8-12 weeks old) 
were separated into 3 groups (10 mice per group): Group 1: control at 37oC (untreated), 
Group 2: hyperthermia-treated (at 43oC) and Group 3: hyperthermia-treated (at 45oC). 
B16-F10 melanoma cells were plated in 100mm3 dishes and on the following day were 
exposed to either hyperthermic (43oC and 45oC) or normothermic (37oC) conditions for 
1h. Then, the cells were returned to 37oC for an additional 24h incubation period. All 
cells were trypsinized and collected while their total number was determined as 
described previously. Overall, 0.5 x 106 cells were suspended in 150µl PBS and then 
injected subcutaneously into the tissue of the back of the neck of each mouse. Tumors 
were allowed to grow for a period of 12-14 days until they became visible. Then the 
animals were sacrificed by cervical dislocation and the tumors were excised. Tumor 
volume and incidence were determined. Tumor dimensions were measured by an 
electronic caliper and tumor volume was calculated by using the modified ellipsoid 
formula (width2 x length) / 2. The weight of each mouse was monitored during the 
course of the experiment, as well as signs of disease and/or discomfort. All efforts were 
made to ameliorate suffering whereas two independent experiments were performed in 
order to confirm the results.  
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Figure 2.1: Images descriptive of handling C57BL/6J mice during the tumor induction 
protocol. 
 
 
On the other hand, thirty female BALB/c mice (8-12 weeks old) were separated into 3 
groups (10 mice per group): Group 1: control at 37oC (untreated), Group 2: 
hyperthermia-treated (at 43oC) and Group 3: hyperthermia-treated (at 45oC). CT26 
colon carcinoma cells were plated, exposed to hyperthermia and further processed as 
already described above for the C57BL/6J mice during the tumor induction protocol.  
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Figure 2.2: Images descriptive of handling BALB/c mice during the tumor induction 
protocol. 
 
2.4.5 Immunohistochemical analysis 
Tumors were fixed in 10% formalin and then dehydrated in graded concentrations of 
ethanol and xylole and then embedded in paraffin. Serial sections (3µm thick) from the 
formalin-fixed paraffin-embedded tissue blocks were prepared and floated onto charged 
glass slides. A hematoxylin and eosin stained section was obtained from each tissue 
block. Immunostaining was performed on formalin-fixed, paraffin-embedded tissue 
sections by the streptavidin-biotin peroxidase labeled (LSAB) method. Sections were 
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deparaffinized after being washed 3 times (for 5min each) in xylene. Afterwards, they 
were hydrated by using graded concentrations of ethanol to dH2O, 2 washes in 100% 
ethanol (for 10min each), 2 washes in 95% ethanol (for 10min each), 2 washes in 70% 
ethanol for (5min each), 2 washes in 50% ethanol (for 5min each) and finally 2 washes 
in dH2O (for 5min each). Tissue sections were subjected to antigen retrieval (by heating 
them in 1X citrate unmasking solution using a microwave until boiling was initiated) 
and then were incubated at a sub-boiling temperature (95-98oC) for 10min. After being 
allowed to cool down (on the bench top for 30 minutes), they were washed 3 times in 
dH2O (for 5min each). For blocking endogenous peroxidase activity, the slides were 
incubated with 3% (v/v) hydrogen peroxide (for 10min), washed twice with dH2O (for 
5min each) and once in TBST buffer (for 5min). During the next step, the sections were 
incubated with blocking buffer (for 1h at room temperature) followed by overnight 
incubation with primary antibody at 4oC. The sections were washed with TBST buffer 3 
times (for 5min each) after removing the primary antibody, covered with a few drops of 
SignalStain Boost Detection Reagent (HRP, rabbit) and then were further incubated in a 
humidified chamber (for 30min at room temperature). Moreover, they were washed 3 
times with TBST buffer (for 5min each) before adding DAB chromogen solution onto 
each slide, incubated for further 1-10min (while staining was monitored under a 
microscope) washed 3 times with TBST buffer (for 10min each) and finally washed in 
dH2O. Staining was followed by counterstaining with hematoxylin and eventually 
mounted and covered with coverslips. An image analysis system composed of the 
Olympus BX43 upright microscope, digital camera Olympus Cam-SC30 and soft 
analysis (analySISH) was used for all tumor sections (stained with antibodies and 
counterstained with hematoxylin). Immunostaining was assessed by a developed 
continuous score system where the number of immunopositive cells was divided by the 
total number of the counted cells while the expression was defined as the percentage of 
positive cells of the total number of counted cells. 
 
Table 2.11: List of materials used for immunohistological staining. 
Reagents 
Formalin (Sigma-Aldrich) Paraffin (Sigma-Aldrich) Hematoxylin (Sigma 
Aldrich) 
Eosin (Sigma-Aldrich) Xylene (Sigma-Aldrich) Ethanol (VWR) 
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1X Citrate buffer, pH 6.0 
(Cell Signaling) 
Hydrogen Peroxide solution 
(Sigma-Aldrich) 
Bovine Serum Albumin 
(BSA) (Amresco, VWR) 
1X TBST buffer SignalStain Antibody 
Diluent #8112 (Cell 
Signaling) 
SignalStain Boost 
Detection Reagent (HRP, 
rabbit) #8114 (Cell 
Signaling) 
SignalStain DAB 
Substrate kit #8059 (Cell 
Signaling) 
SignalStain Mounting 
Medium #14177 (Cell 
Signaling) 
 
 
 
Table 2.12: List of antibodies used for immunohistological staining. 
Antibody Dilution Antibody 
diluent 
Incubation 
time 
Isotype Company Cat # 
Anti-
COX2 
(D5H5) 
1:600 SignalStain 
Antibody 
Diluent 
#8112 
1h at RT Rabbit Cell 
Signaling 
#1228
2 
Anti-
cleaved-
caspase 3 
(Asp175) 
(5A1E) 
1:1000 SignalStain 
Antibody 
Diluent 
#8112 
O/N at 4oC Rabbit Cell 
Signaling 
#9664 
Anti-
phospho-
H2A.X(Se
r139) 
(20E3) 
1:250 SignalStain 
Antibody 
Diluent 
#8112 
O/N at 4oC Rabbit Cell 
Signaling 
#9718 
 
2.5 Statistical analysis 
Experimental conditions for all set of experiments were identical and 
comparisons were made between control and treatment groups. Calculations were 
performed by using the Microsoft Office Excel 2007 software. Means were compared 
by one-way ANOVA with Tukey’s test for multiple comparisons. SPSS or PRISM 
software were used for statistical tests. A value of p<0.05 was considered statistically 
significant. At least two independent experiments were performed for each experimental 
design while results were repeatable with similar SEM values for independent 
experiments.  
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3. Results 
3.1 Optimization of a hyperthermia-induced experimental platform by using an in 
vitro model of human malignant melanoma 
 
3.1.1 Kinetic analyses based on cell viability 
The first step in setting up our experimental exposure platform was to determine 
the optimal experimental conditions capable of inducing cell death in human malignant 
melanoma (A375) and epidermoid carcinoma (A431) cell lines. For this purpose, we 
performed kinetic analyses including temperature-response and time-course 
experiments where cells were exposed to various temperatures (37-50oC) (Fig.3.1.1). 
Cell viability levels were determined (by utilizing the Alamar-Blue assay) immediately 
after the 2h exposure to hyperthermia as well as after a further 24h incubation, at 37oC, 
which provided the time needed for the potential activation of cell death pathways.  
Overall, exposure to temperatures below 43oC did not seem to have a significant 
effect on cell viability levels in both cell lines. On the other hand, when cells were 
exposed to higher temperatures (43oC onwards), there was a decline in the number of 
viable cells which was to a greater extent in the case of A375 cells. In addition, at 
temperatures above 45oC, there was excessive reduction in cell viability suggesting 
complete cellular destruction. Collectively, our data suggest that the optimum 
hyperthermic temperatures for our in vitro model of human malignant melanoma were 
those of 43oC and 45oC as there was a significant reduction in cell viability levels in 
both cell lines.  
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Figure 3.1.1: The effect of hyperthermia at various temperatures (37-50oC) on cell 
viability levels in A) a human epidermoid carcinoma (A431) and B) human 
malignant melanoma (A375) cell line. Briefly, cells were exposed to different 
temperatures, ranging from 37oC to 50oC, for 2h, and cell viability was determined by 
utilizing the Alamar-Blue assay either immediately after the exposures or after an 
additional 24h incubation period at 37oC. Cell viability was expressed as percentage of 
control (37oC) cells. Data shown are mean values (n=5) ± SEM and represent one of 
three independent experiments. Asterisk (*) indicates statistical significance at p<0.05. 
  
 
A) 
B) 
* 
* 
* 
* 
* 
* 
* 
* 
* 
* 
* 
* 
* 
* 
* 
61 
 
Furthermore, we aimed to determine the optimum time course response at 43oC 
and 45oC of hyperthermic exposures (Fig.3.1.2). In this set of experiments, we exposed 
A431 and A375 cell lines to these temperatures over various time courses (30, 60 and 
120 min). Cell viability levels were determined immediately after the hyperthermic 
exposure or following an additional 24h incubation period at 37oC by using the Alamar-
Blue assay. According to our results, we did not observe any significant reduction in 
A431 cells when exposed to 43oC at shorter incubation periods (i.e. 30 and 60min) 
(Fig.3.1.2.A), whereas A375 cells appeared to be more sensitive, although the decline in 
cell viability observed was around 10-15% (Fig.3.1.2.B). Overall, it was shown that 
short exposures of A375 and A431 cells, at 43oC, had a minor effect on cell viability, 
while a 15-25% reduction was observed (at 24h after exposure) in each cell line 
respectively when treated for 2h (Fig.3.1.2.A & B). On the contrary, exposure of both 
cell lines at 45oC had a much more profound effect even after shorter time courses of 
exposure when compared to 43oC. Overall, there was a  40-60% decrease in cell 
viability levels for each of the cell lines when incubated for a further 24h after the 
original 2h exposure (Figs.3.1.2.C & D). Collectively, our data suggest that the 
optimum experimental hyperthermic conditions were those at 43oC and 45oC, for 2h, 
either immediately after or 24h after the initial (2h) exposure period. 
In another set of experiments, we introduced an additional non-tumorigenic, 
immortalized human keratinocyte (HaCaT) cell line in an attempt to investigate if 
hyperthermia would exert the same effects in non-tumorigenic cells as it did with the 
A375 and A431 cancer cell lines. This cell line was utilized in the context of healthy, 
non-tumorigenic cells that surround the primary tumor. Once again, cells were exposed 
to hyperthermia either at 43oC or 45oC, for 2h, and cell viability was determined right 
after and/or 24, 48 or 72h post hyperthermic exposure at 37oC. The reason for the 
extended incubation periods was to determine if these were associated with a more 
prolonged decline in cell viability levels suggestive of increased rates of cytotoxicity. 
According to our data, A375 cells were more sensitive to 43oC as there was a significant 
decline in the levels of viable cells (around 20-30%) at 24 and 48h respectively while 
A431 cells were more resistant (Fig.3.1.3.A). Moreover, exposure at 45oC induced a 
more profound decrease in cell viability (around 30-40%) for each of the A375 and 
A431 cell lines respectively at 24h post hyperthermic exposure while even lower 
viability rates were observed at 48 and 72h post hyperthermic exposure respectively 
(Fig.3.1.3.B). Finally, the HaCaT cell line was shown to be more resistant to 
hyperthermia irrespectively of the experimental condition (Fig.3.1.3.A & B). More 
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specifically, it was evident that exposure of HaCaT cells to 43oC did not cause a 
significant decline in cell viability levels while this was also the case even at 45oC 
exposure (Fig.3.1.3.A & B). 
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Figure 3.1.2: The effect of hyperthermia (43oC and 45oC) at different time courses in a human epidermoid carcinoma (A431; A & C) and 
melanoma (A375; B & D) cell line. Cells were exposed to 43oC and 45oC over 30, 60 and 120min. Cell viability was determined by utilizing the 
Alamar-Blue assay immediately after each exposure (filled bars) as well as 24h after the initial (2h) exposure (hatched bars), at 37oC. Cell viability was 
expressed as percentage of control cells incubated at 37oC. Data shown are mean values (n=5) ± SEM and represent one of three independent 
experiments. Asterisk (*) indicates statistical significance at p<0.05.
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Figure 3.1.3: The effect of hyperthermia at 43oC (A) and 45oC (B) in three 
different human skin cell (HaCaT, A431, A375) lines . Cells were seeded into 96-well 
plates and on the next day, cells were exposed to 43oC or 45oC for 2h. Cell viability was 
determined by using the Alamar-Blue assay immediately after the exposures and 24, 48 
or 72h post exposure at 37oC. Cell viability was expressed as percentage of control cells 
incubated at 37oC. Data shown are mean values (n=5) ± SEM and represent one of three 
independent experiments. Asterisk (*) indicates statistical significance at p<0.05. 
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3.1.2 Hyperthermia-induced cytotoxicitty 
In addition to cell viability, we also utilized cytotoxicity as another endpoint of 
the hyperthermia exposure platform optimization. For this reason, we used the CytoTox 
Fluor assay (Promega, UK) which is capable of determining relative levels of dead 
cells. The assay utilizes a specific fluorigenic peptide substrate (bis-AAF-R110) in 
order to measure the activity levels of a protease which is released from cells that have 
lost membrane integrity. Due to the fact that the activity of this protease marker has a 
short half-life, it is not recommended that the assay is used for extensive incubation 
times (longer than 24h). Given that, we utilized the assay for time courses equal or 
shorter than 24h post exposure (6, 12 and 24h). Our data indicate that there was a much 
higher increase of fluorescence levels in A375 compared to HaCaT cells, at all time 
points, when exposed to 43oC (Fig.3.1.4.A) or 45oC (Fig.3.1.4.B) suggestive of 
increased levels of dead cells at both hyperthermic temperatures. In addition, we have 
used exposure to 50oC, for 2h, as a positive control because according to our previous 
experiments there was excessive cell death observed at temperatures above  45oC 
(Fig.3.1.4.C).  
In another set of experiments, we utilized trypan-blue staining as an additional 
means of determining the levels of viable and dead cells after exposing A375 cells to 
hyperthermia. Similarly to our previous findings, A375 cells were exposed to 43oC or 
45oC, for 2h, and then were collected immediately after the exposures and 24h post 
exposure at 37oC. Our data indicated that there was a slight increase in the levels of 
dead cells immediately after the exposure to 45oC, however, a dramatic change was 
observed 24h incubation post exposure (Fig.3.1.5.B). Furthermore, data showed that 
when A375 cells were exposed to 43oC they appeared to have a reduced proliferating 
potential compared to control cells whereas the levels of dead cells were the same as 
those indicated at control conditions (Fig.3.1.5.A). It should be noted that although 
trypan-blue staining is not a preferred method for determining levels of cell 
proliferation, it nevertheless provides an indication that perturbations in the levels of 
viable cells, at 43oC, might be related to cell cycle which could potentially induce 
growth arrest. 
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Figure 3.1.4: The effect of hyperthermia at 43oC (A), 45oC (B) and 50oC (C), 
expressed as relative levels of dead cells, in melanoma (A375) and non-
tumorigenic, immortalized keratinocyte (HaCaT) cell lines. Briefly, cells were 
plated into 96-well plates and  on the following day they were exposed to 43oC or 45oC, 
for 2h. Cytotoxicity was determined by the CytoTox-Fluor Cytotoxicity assay 
(Promega, UK) immediately after (2h) and 6, 12 and 24h post exposure to 
hyperthermia. In addition, both cell lines were exposed to 50oC, for 2h, to demonstrate 
the significance of a positive control. Cytotoxicity is expressed as fluorescence values 
(485nmExc/520nmEm). Data shown are mean values (n=5) ± SEM and represent one of 
two independent experiments. Asterisk (*) indicates statistical significance at p<0.05. 
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Figure 3.1.5: The effect of hyperthermia (43oC and 45oC) on cell viability (A) and 
dead cell (B) levels determined by trypan blue staining in human malignant 
melanoma (A375) cells. Briefly, cells were plated in 100mm dishes and incubated 
overnight at 37oC. The following day, they were exposed to 43oC and 45oC, for 2h, and 
then were returned to 37oC for an additional 24h incubation period (post exposure). 
Control cells were kept at 37oC. Cells were collected and stained with trypan-blue. Data 
shown are mean values (n=3) ± SEM and represent one of three independent 
experiments. Asterisk (*) indicates statistical significance at p<0.05. 
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3.2 Hyperthermia induces the apoptotic pathway response in human malignant 
melanoma (A375) cells 
In this set of experiments, we aimed to investigate the involvement of the 
apoptotic machinery in an attempt to better characterize the apoptotic response to 
hyperthermia in A375 cells. To this end, different caspases were chosen (caspases-3, -4, 
-6, -8 and -9) given that they are involved at different stages and pathways of the 
apoptotic cascade. In these experiments, we determined caspase activity levels at 
various time points [immediately after 2h exposure (0h) as well as 2, 4, 8, 24, 48 and 
72h post exposure]. Justification for the inclusion of each caspase comes from the 
rationale that each one of them represents a different apoptotic cascade by participating 
at a different stage within such cascade. For instance, caspase-8 is known to participate 
in the activation of the extrinsic apoptotic pathway by involving the activation of death 
receptors. Data showed that there was a slight induction of caspase-8 activity levels, in 
A375 cells, at 45oC reaching a peak value at 24h (>1.5 fold) and then returning to 
control levels at the longer post exposure time points (48 and 72h) (Fig.3.1.6). On the 
other hand, caspase-9 is known to participate in the intrinsic apoptotic pathway (also 
known as mitochondria-dependent apoptotic pathway) by taking part in the formation of 
the apoptosome. This caspase was shown to be activated immediately after exposure 
(0h) and up to 8h post exposure, at both 43oC and 45oC, while its activity was elevated 
only at 45oC, 24h post exposure (Fig.3.1.7). Finally, the involvement of the ER stress-
mediated apoptotic pathway was determined by examining the activation levels of 
caspase-4. According to our data, its activity levels were shown to be elevated by about 
a 3-fold induction after exposure to 45oC, at 24h, whereas there was no change observed 
at 43oC (Fig.3.1.8).  
Moreover, we monitored the activation levels of two more executioner caspases 
namely caspases-3 and -6. Both of these enzymes although do not represent the 
activation of a specific apoptotic pathway they are, however, involved in the execution 
signal of the various apoptotic stimuli. To this end, data showed a substantial increase 
(4-5-fold) in the activity levels of caspase-6 at both 43oC and 45oC immediately after 
exposure and up to 8h post exposure. However, at longer time points (24 and 48h) there 
was only activation at 45oC (Fig.3.1.9). On the other hand, the activity of caspase-3 was 
elevated 8h post exposure (3.5 fold), at 45oC, onwards with a peak (16-fold) at 24-48h 
post exposure. On the contrary, a modest increase (2-fold) was observed at 43oC at 24h 
post exposure with a more substantial increase at 48-72h (Fig.3.1.10). 
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Figure 3.1.6: The effect of hyperthermia (43oC and 45oC) on the activity levels of caspase 8, at various time points, in A375 cells. Briefly, cells 
were exposed to 43oC and 45oC for 2h (0h) and then were returned back to 37oC for an additional 2-72h while control cells were kept at 37oC. Samples 
were collected at each time point and following lysis, cell extracts were incubated with the appropriate caspase substrate with fluorescence being 
monitored. Results shown are expressed as fold increase of caspase activity compared to untreated control. Data shown are mean values (n=3) ± SEM 
and represent one of three independent experiments. Asterisk (*) indicates statistical significance at p<0.05.
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Figure 3.1.7: The effect of hyperthermia (43oC and 45oC) on the activity levels of caspase 9, at various time points, in A375 cells. Briefly, cells 
were exposed to 43oC and 45oC for 2h (0h) and then were returned back to 37oC for an additional 2-72h while control cells were kept at 37oC. Samples 
were collected at each time point and following lysis, cell extracts were incubated with the appropriate caspase substrate with fluorescence being 
monitored. Results shown are expressed as fold increase of caspase activity compared to untreated control. Data shown are mean values (n=3) ± SEM 
and represent one of three independent experiments. Asterisk (*) indicates statistical significance at p<0.05.
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Figure 3.1.8: The effect of hyperthermia (43oC and 45oC) on the activity levels of caspase 4, at various time points, in A375 cells. Briefly, cells 
were exposed to 43oC and 45oC for 2h (0h) and then were returned back to 37oC for an additional 2-72h while control cells were kept at 37oC. Samples 
were collected at each time point and following lysis, cell extracts were incubated with the appropriate caspase substrate with fluorescence being 
monitored. Results shown are expressed as fold increase of caspase activity compared to untreated control. Data shown are mean values (n=3) ± SEM 
and represent one of three independent experiments. Asterisk (*) indicates statistical significance at p<0.05.
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Figure 3.1.9: The effect of hyperthermia (43oC and 45oC) on the activity levels of caspase 6, at various time points, in A375 cells. Briefly, cells 
were exposed to 43oC and 45oC for 2h (0h) and then were returned back to 37oC for an additional 2-72h while control cells were kept at 37oC. Samples 
were collected at each time point and following lysis, cell extracts were incubated with the appropriate caspase substrate with fluorescence being 
monitored. Results shown are expressed as fold increase of caspase activity compared to untreated control. Data shown are mean values (n=3) ± SEM 
and represent one of three independent experiments (p<0.05). Asterisk (*) indicates statistical significance at p<0.05. 
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Figure 3.1.10: The effect of hyperthermia (43oC and 45oC) on the activity levels of caspase 3, at various time points, in A375 cells. Briefly, cells 
were exposed to 43oC and 45oC for 2h (0h) and then were returned back to 37oC for an additional 2-72h while control cells were kept at 37oC. Samples 
were collected at each time point and following lysis, cell extracts were incubated with the appropriate caspase substrate with fluorescence being 
monitored. Results shown are expressed as fold increase of caspase activity compared to untreated control. Data shown are mean values (n=3) ± SEM 
and represent one of three independent experiments (p<0.05). Asterisk (*) indicates statistical significance at p<0.05.
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3.3 Hyperthermia-induces alterations in the expression of key apoptotic genes in 
human malignant melanoma (A375) cells 
We have utilized a genomic approach for screening critical gene targets 
descriptive of the various stages of the apoptotic response by means of a real-time PCR 
microarray-based gene expression profiling system. A total of 90 candidate genes were 
screened in order to profile their differential gene expression pattern in response to 43oC 
and 45oC at 24h post exposure time point and compare it to 37oC. Our data showed that 
there were several fold differences in the induction of various apoptotic genes after 24h 
post exposure to 43oC and 45oC. For the purpose of simplicity, we categorized such 
altered gene expression into three apoptotic pathways namely (i) the intrinsic, (ii) 
extrinsic and (iii) ER stress-mediated ones (Table 3.1.1). According to our data, a 
number of genes, in the intrinsic apoptotic pathway, were found to be up-regulated 
(after exposure to 43oC and 45oC) including the following: APAF1, BAK1, BBC3, 
BCL2L11, BIRC2, CASP7, KIT, PMAIP1 and VDAC2. It is noteworthy that although all 
of these genes were up-regulated at 45oC, only BAK1, BBC3 and BIRC2 demonstrated 
higher expression levels at 43oC (Table 3.1.1).  In the case of the extrinsic pathway, 
DAPK3, FAS and FASLG were shown to be up-regulated at both 43oC and 45oC while 
TNF, TNFRSF10A, TNFSF10, TNFSF12 and TRAF2 were up-regulated only at 45oC. 
Finally, BBC3 (implicated in the intrinsic as well as ER-mediated apoptotic pathways) 
showed increased expression levels at both temperatures (Table 3.1.1). Moreover, we 
further categorized genes into three additional groups involved in other cellular 
processes namely (i) immune response and inflammation, (ii) cell growth and 
proliferation and (iii) the p-53 dependent apoptotic pathway. Our data showed that a 
number of genes involved in the immune response and inflammation appeared to be up-
regulated in response to either one of the temperatures including: IL6, NFKBIA, 
NFKBIE and PIK3CD whereas CHUK, NFKB2, NFKBIB and RELB demonstrated an 
increase in expression levels only at 45oC (Table 3.1.2). Furthermore, IGF-1 was shown 
to be up-regulated at both hyperthermic temperatures while KDR exhibited elevated 
expression levels at 43oC and KIT at 45oC respectively. These three genes are known to 
play a role in cell growth and proliferation processes (Table 3.1.2). Another group of 
genes with increased expression levels were those participating in the p53-dependent 
apoptotic pathway and more specifically MDM2 and P53AIP1. These were up-regulated 
at both temperatures whereas PMAIP1 demonstrated higher expression levels only at 
45oC (Table 3.1.2).  
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Table 3.1.1: List of apoptotic genes being differentially regulated as a response to 
hyperthermic exposures at 43oC and 45oC. 
 
PATHWAY 
 
GENE 
 
DESCRIPTION 
Fold 
induction 
43oC 
Fold 
induction 
45oC 
 
 
 
 
Intrinsic 
BAK1 BCL2-Antagonist/Killer 1  2.1     31.7 
BBC3 BCL2-Binding Component 
3 
 4.3     16.0 
KIT Mast/stem cell growth 
factor receptor Kit 
-     2.4 
APAF1 Apoptotic Protease 
Activating Factor 1 
-     2.9 
BCL2L11 Bcl-2-like protein 11 -     2.2 
CASP7 Caspase 7 -     2.2 
PMAIP1 Phorbol-12-Myristate-13-
Acetate-Induced Protein 1 
-     4.0 
VDAC2 Voltage-Dependent Anion-
selective Channel protein 2 
-     2.3 
BIRC2 Baculoviral IAP Repeat 
Containing 2 
 2.5     2.2 
 
 
 
 
Extinsic 
CASP7 Caspase 7 -    2.0 
DAPK3 Death-associated protein 
kinase 3 
 2.1     2.0 
FAS Fas Cell Surface Death 
Receptor 
 3.0  11.6 
FASLG Fas Ligand (TNF 
Superfamily, Member 6) 
   5.0      176.0 
TNF Tumor Necrosis Factor -     186.0 
TNFRSF10A Tumor Necrosis Factor 
Receptor Superfamily, 
member 10a 
-  2.0 
TNFSF10 Tumor Necrosis Factor 
ligand Superfamily 
member 10 
-  4.1 
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TNFSF12 Tumor Necrosis Factor 
Ligand Superfamily 
member 12 
-  2.0 
TRAF2 TNF Receptor-Associated 
Factor 2 
-  2.0 
ER- 
mediated 
BBC3 BCL2-Binding Component 
3 
 4.3    16.0 
 
 
Table 3.1.2: List of genes associated with other cellular processes being differentially 
regulated as a response to hyperthermic exposures at 43oC and 45oC. 
 
CELLULAR 
PROCESS 
 
GENE 
 
DESCRIPTION 
Fold 
induction 
43oC 
Fold 
induction 
45oC 
 
 
 
 
Immune 
response, 
Inflammation 
CHUK Conserved Helix-Loop-Helix 
Ubiquious Kinase 
-     2.0 
IL6 Interleucin 6   23.8     23.0 
NFKB2 Nuclear Factor Kappa B 
Subunit 2 
-     2.2 
NFKBIA 
 
NFKB Inhibitor Alpha  2.1     6.3 
NFKBIB 
NFKB Inhibitor Beta 
 
-     2.0 
NFKBIE NFKB Inhibitor Epsilon  2.2     2.0 
PIK3CD Phosphatidylinositol-4,5-
Bisphosphate 3-Kinase 
Catalytic Subunit Delta 
 2.5     2.2 
RELB RELB Proto-Oncogene, NF-
KB Subunit 
-     6.3 
Cell growth, 
Cell 
proliferation 
IGF-1 Interleucin 6 Insulin Like 
Growth Factor 1 
 4.4     2.0 
KDR Kinase Insert Domain 
Receptor 
 3.0 - 
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KIT 
KIT Proto-Oncogene 
Receptor Tyrosine Kinasewe 
-  2.0 
p-53 
dependent 
pathway 
MDM2 
MDM2 Proto-Oncogene 
 6.1    16.2 
P53AIP1 P53 Regulated Apoptosis 
Inducing Protein 1 
 2.2  5.7 
PMAIP1 Phorbol-12-Myristate-13-
Acetate-Induced Protein 1 
-  4.0 
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3. Results - Part II 
3.4 Underlined apoptotic mechanisms characteristic of the hyperthermic response 
in human malignant melanoma (A375) cells 
3.4.1 Hyperthermia induces the activation of initiator caspases-8 and -9 in A375 cells 
In this part of the study, we aimed to characterize in more depth the molecular 
mechanisms underlying the activation of cell death in response to 43oC and 45oC. To 
this end, we focused on determining protein expression levels of several molecules 
involved at different stages and pathways of the apoptotic machinery. A375 cells were 
treated with 43oC and 45oC, for 2h, and protein expression levels of initiator caspases-8 
(extrinsic pathway) and -9 (intrinsic pathway) were monitored by means of Western 
blotting at several time points including immediately after hyperthermic exposure 
(0min) and (2, 4, 8, 24, 48 and 72h) post exposure.  
According to our data, there was a drop in protein levels of the uncleaved form 
of caspase-8 at both temperatures but it was even more evident at 45oC. Caspase-8 
appeared to be activated immediately after hyperthermic exposure (0min) and up to 8h 
post exposure at 43oC in comparison to 45oC where the enzyme remained active even at 
24h post exposure. At 48h and 72h post exposure, caspase-8 was retained at control 
levels at both temperatures (Fig.3.2.1). Furthermore, the pattern of caspase-9 activation 
was remarkably similar to that of caspase-8. More specifically, there was a reduction of 
its protein levels at both 43oC and 45oC temperatures. In the case of 43oC, the enzyme 
was activated up to 8h post exposure as opposed to 45oC at which temperature the 
enzyme remained active even at 24h post exposure (Fig.3.2.1). 
Collectively, our data suggest that at shorter post exposure periods of time (2-
8h), the initiator caspases-8 and -9 were activated as a response to hyperthermia (at both 
temperatures) and that the activation was more intense at 45oC than 43oC. Such protein 
expression pattern was not observed at longer post exposure periods of time (24h) 
during which only caspase-9 was activated at 45oC alone (Fig.3.2.1). 
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Figure 3.2.1: The activation of caspases-8 and -9 in response to hyperthermic exposures at 43oC and 45oC. Image shows changes in protein 
expression levels of initiator caspases-8 and -9 immediately after exposure to 43oC and 45oC, for 2h, (0min) as well as at 2-72h post exposure in A375 
cells. Cells were grown overnight at 37oC followed by exposure to hyperthermia and then transferred back to 37oC for the indicated post exposure 
incubation times. Cell lysates were prepared (for all indicated time points) before being subjected to western blotting conditions. Control cells were 
kept at 37oC. β-tubulin was used as loading control. 
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3.4.2 Hyperthermia induces the activation of executioner caspases-6, -7 and -3 in A375 
cells 
In this set of expetiments, we aimed to study the protein expression profile of 
caspase-6 which is one of the executioner caspases along with caspases-7 and -3. 
According to our data, there was a significant reduction in the protein levels of its un-
cleaved form after exposing A375 cells to 43oC and 45oC for 2h. This observation 
indicated the activation of the enzyme which appeared to have a more profound effect at 
45oC as it was completely active up to 24h post exposure (Fig.3.2.2). On the contrary, 
after exposure to 43oC, the protein levels of the pro-caspase form increased from 2-8h 
post exposure until reaching control levels after 8h and onwards (Fig.3.2.2). Next, we 
intended to determine the protein expression levels of Lamin A/C, as it represents the 
target molecule for cleavage by activated caspase-6. As shown in Figure 3.2.2 there is a 
reduction in the protein levels of the uncleaved Lamin A/C form in response to 43oC 
and 45oC. In the case of 43oC, the molecule appeared to be cleaved immediately after 
exposure (0min) and up to 8h post exposure. On the other hand, the molecule was 
shown to get cleaved all the way through from 2h to 72h post exposure after exposure to 
45 oC. This data is supportive of the increased activation levels of caspase-6 at these 
time points as well. 
On the other hand, caspase-7 and -3 are the two major executioner caspases 
responsible for cleaving downstream target molecules and account for the well-
described characteristics of apoptosis. Our data revealed that caspase-7 was activated 
from 2-24h post exposure but only after cells were exposed at 45oC (and not at 43oC) 
(Fig 3.2.3). In the case of caspase-3, we found that the protein remained inactive at 43oC 
throughout the entire post exposure time course whereas its activity was evidently 
induced 24-48h post exposure at 45oC. The latter results were in agreement even when 
determining changes in protein expression levels of the cleaved form of the enzyme. 
More specifically, we showed that there was a substantial increase in the protein levels 
of cleaved caspase-3 at 24-48h post exposure at 45oC (Fig 3.2.3). Finally, we also chose 
to monitor alterations in protein levels of Poly ADP Ribose Polymerase (PARP) as it is 
one of the main cleavage targets of caspase-3. According to our data, PARP remained 
uncleaved at each time point post exposure to 43oC while its cleaved form was evident 
between 24-48h post exposure to 45oC (Fig 3.2.4). In turn, these data is concominant 
with the protein expression profile of caspase-3. 
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Figure 3.2.2: The activation of caspase-6 in response to hyperthermic exposures at 43oC and 45oC. Image shows changes in protein expression 
levels of executioner caspase-6 and downstream target Lamin A/C immediately after exposure to 43oC and 45oC, for 2h, (0min) as well as at 2-72h 
post exposure in A375 cells. Cells were grown overnight at 37oC followed by exposure to hyperthermia and then transferred back to 37oC for the 
indicated post exposure incubation times. Cell lysates were prepared (for all indicated time points) before being subjected to western blotting 
conditions. Control cells were kept at 37oC. β-tubulin was use as a loading control. 
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Figure 3.2.3: The activation of executioner caspases-7 and -3 in response to hyperthermic exposures at 43oC and 45oC. Image shows changes in 
protein expression levels of executioner caspases-7 and -3 immediately after exposure to 43oC and 45oC, for 2h, (0min) as well as at 2-72h post 
exposure in A375 cells. Cells were grown overnight at 37oC followed by exposure to hyperthermia and then transferred back to 37oC for the indicated 
post exposure incubation times. Cell lysates were prepared (for all indicated time points) before being subjected to western blotting conditions. Control 
cells were kept at 37oC. β-tubulin was used as loading control. 
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Figure 3.2.4: The cleavage of Poly ADP Ribose Polymerase (PARP) in response to hyperthermic exposures at 43oC and 45oC. Image shows 
changes in protein expression levels of the un-cleaved and cleaved forms of Poly ADP Ribose Polymerase (PARP) immediately after exposure to 43oC 
and 45oC, for 2h, (0min) as well as at 2-72h post exposure in A375 cells. Cells were grown overnight at 37oC followed by exposure to hyperthermia 
and then transferred back to 37oC for the indicated post exposure incubation times. Cell lysates were prepared (for all indicated time points) before 
being subjected to western blotting conditions. Control cells were kept at 37oC. β-tubulin was used as loading control. 
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3.4.3 Hyperthermia induces the activation of death receptor molecules in A375 cells 
 
 In this part of the study, we aimed to characterize in more detail the involvement 
of the extrinsic (death receptor) apoptotic pathway, at 43oC and 45oC, as indicated by 
our previous findings regarding caspase-8 activation. Firstly, we determined changes in 
protein levels of TNF-R1 (one of the two receptors for TNFa which, in turn is 
implicated in initiating a caspase-dependent apoptosis). Our data showed that when 
cells were exposed to 43oC, TNF-R1 levels were reduced at 2-8h post exposure, 
suggestive of its activation as opposed to 45oC when its levels were further reduced up 
to 48h post exposure (Fig.3.2.5).  
Another protein playing an important role in the formation of the death domain 
is TRADD. This protein interacts and binds with TNF-R1 for the creation of the death 
domain. Alterations in protein expression levels of TRADD presented a similar pattern 
to those of TNF-R1. More specifically, there was a decline in protein levels at 43oC 
between 2-8h post exposure while at 45oC the decline was sustained up to 48h post 
exposure (Fig.3.2.5).  
Last but not least, we aimed to look into the involvement of the death domain 
receptor Fas by monitoring the action of RIP, which contains a death domain known to 
interact with that of Fas and TRADD. Results demonstrated a reduction in the protein 
levels of RIP at 45oC at each time point up to 48h post exposure. In contrast, at 43oC 
there was no activation of RIP at any time point (Fig.3.2.5). In any case, the data thus 
far seem to support the notion of an interaction between TNF- and Fas-induced extrinsic 
pathways leading to the subsequent activation of a caspase-8 induced triggering of 
apoptosis evident at 45oC. 
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Figure 3.2.5: The activation of death receptor (extrinsic) pathway activation in response to hyperthermic exposures at 43oC and 45oC. Image 
shows changes in protein expression levels of RIP, TNF-R1 and TRADD immediately after exposure to 43oC and 45oC, for 2h, (0min) as well as at 2-
72h post exposure in A375 cells. Cells were grown overnight at 37oC followed by exposure to hyperthermia and then transferred back to 37oC for the 
indicated post exposure incubation times. Cell lysates were prepared (for all indicated time points) before being subjected to western blotting 
conditions. Control cells were kept a t 37oC. β-tubulin was used as loading control. 
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3.4.4 Hyperthermia induces the upregulation of various proapoptotic proteins in A375 
cells 
The next set of experiments, was focused on investigating the role of several 
pro-apoptotic proteins in hyperthermia-induced cell death. It is well known that an 
imbalance between pro-apoptotic and anti-apoptotic factors can lead to the activation of 
programmed cell death. For this reason, several pro-apoptotic proteins were selected 
and their expression levels were determined by Western blotting.  
Bak is located on the outer mitochondrial membrane and plays a role in the 
formation of channels in the membrane in order to facilitate the cytochrome c release 
when apoptosis is triggered. According to our results, there was an up-regulation of Bak 
when A375 cells were exposed immediately after 45oC and up to 8h post exposure. 
Similarly, at 43oC, there was also an up-regulation of the protein at 4-8h post exposure 
(Fig.3.2.6).  
On the other hand, Bax is responsible for increasing the mitochondrial 
membrane permeability by interacting with other proteins. It was also found to be 
slightly elevated immediately after exposure and up to 48h post exposure, in the case of 
43oC. In contrast, exposure at 45oC was also associated with increased protein 
expression levels but only up to 8h post exposure (Fig.3.2.6).  
Finally, we aimed to determine Bad protein levels as it is a molecule known to 
act by displacing Bax from binding to antiapoptotic proteins such as Bcl-2 and Bcl-xL. 
Our data demonstrated that there was an elevation in the protein levels of Bad 
immediately after 45oC followed by a slight decrease for both hyperthermic conditions 
following longer incubation periods (from 2 to 24-48h) (Fig.3.2.6). Overall, all such 
observations support further the complexity of the interactions amongst apoptotic 
pathways in promoting cell death as a response to hyperthermia. 
Furthermore, we decided to examine the involvement of BID in regulating 
apoptosis as it represents a critical molecule participating in the apoptotic machinery. In 
doing so, it interacts with caspase-8 which, in turn, cleaves BID thus causing the 
translocation of its cleaved fragment (t-BID) to the outer mitochondrial membrane 
where it interacts with caspase-9 and aids in cytochrome c release. In fact, this molecule 
is known to act as a cross talk point between the extrinsic (caspase 8 induced) and 
intrinsic (caspase 9 induced) apoptotic pathways. According to our findings, both 
hyperthermic temperatures were shown to cause an elevation in the protein expression 
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levels of BID immediately after exposures (0min), an effect which was maintained up to 
8h post exposure at 43oC. In contrast, there was a significant decrease in the protein’s 
content from 2-48h post exposure at 45oC (Fig.3.2.7).  
In addition, we determined changes in protein expression levels of three 
different isoforms of Bim, namely BimEL, BimL, BimS as all of them have been 
implicated in promoting apoptosis. The protein expression levels of BimEL were shown 
to be slightly increased up to 24h post exposure at 45oC while the opposite effect (a 
reduced protein content) was observed at the same time points of post exposure at 43oC. 
Moreover, there were no major changes in the protein expression levels of BimL at both 
hyperthermic temperatures. Finally, BimS, was found to be elevated immediately after 
exposure to both hyperthermic temperatures while such increase was even more 
apparent up until 8h post exposure at 43oC and 24-48h post exposure at 45oC 
(Fig.3.2.7).  
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Figure 3.2.6: The involvement of proapoptotic proteins Bak, Bax and Bad in response to hyperthermic exposures at 43oC and 45oC. Image 
shows alterations in protein expression levels of Bak, Bax and Bad immediately after exposure to 43oC and 45oC, for 2h, (0min) as well as at 2-72h 
post exposure in A375 cells. Cells were grown overnight at 37oC followed by exposure to hyperthermia and then transferred back to 37oC for the 
indicated post exposure incubation times. Cell lysates were prepared (for all indicated time points) before being subjected to western blotting. Control 
cells were kept at 37oC. β-tubulin was used as loading control. 
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Figure 3.2.7: The involvement of proapoptotic proteins BID, BimEL, BimL and BimS in response to hyperthermic exposures at 43oC and 45oC. 
Image shows alterations in protein expression levels of BID, BimEL, BimL and BimS immediately after exposure to 43oC and 45oC, for 2h, (0min) as 
well as at 2-72h post exposure in A375 cells. Cells were grown overnight at 37oC followed by exposure to hyperthermia and then transferred back to 
37oC for the indicated post exposure incubation times. Cell lysates were prepared (for all indicated time points) before being subjected to western 
blotting. Control cells were kept at 37oC. β-tubulin was used as loading control. 
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3.4.5 Hyperthermia induces ER stress response in A375 cells 
 
In this part of the study, we focused on investigating the role of hyperthermia-
induced ER stress response in regulating apoptosis. For this purpose, alterations in 
protein expression levels of several regulators taking part in ER stress induction (UPR 
response) and also playing a role in activating the apoptotic cascade were studied. First, 
we examined changes in protein content of Grp78/BiP, a chaperone protein which is 
induced due to irregular protein folding taking place in ER. This molecule is known to 
bind to PERK, IRE-1a and ATF-6, under normal conditions, however when ER stress is 
induced it dissociates from them and thus activates their respective UPR pathways. 
According to our results, there was a significant increase in Grp78 protein expression 
levels up until 8h post exposure at 43oC and 24-48h post exposure at 45oC (Fig.3.2.8). 
Second, we looked at PERK as it is responsible for increasing the phosphorylation of 
eIF2a which in turn promotes a decrease in protein translation. Data showed a reduction 
in PERK protein levels up to 24h post exposure at 45oC. In contrast, there were no 
alterations in its protein content at any time point post exposure at 43oC (Fig.3.2.8). 
Third, we monitored the protein expression levels of IRE-1a, a molecule capable of 
splicing X-box binding protein (XBP-1) mRNA leading to the up-regulation of 
additional genes implicated in UPR. According to our findings, there was a profound 
decrease in IRE-1a protein levels up to 8h post exposure at both hyperthermic 
temperatures. Finally, the observed decline was even more profound at 24-72h post 
exposure at 45oC only (Fig.3.2.8). 
 ATF-6 upon cleavage and subsequent translocation to the nucleus, activates the 
transcription of various ER stress-related genes. Upon examining alterations in the 
protein content of the uncleaved ATF-6 form, our findings revealed a decrease in its 
protein expression levels, at 43oC, immediately after (0min) and up to 8h post exposure 
while this decline was maintained immediately after as well as at all time points post 
exposure at 45oC (Fig.3.2.9). As mentioned previously, one of the downstream targets 
of UPR is XBP-1. According to our data, XBP-1s was found to be induced immediately 
after exposure (0min) and 2h post exposure at 43oC and 4-8h post exposure at 45oC. 
Finally, its protein levels were completely undetected at any time point after 8h post 
exposure at both temperatures (Fig.3.2.9). Last but not least, CHOP is known to be a 
major contributor in regulating the ER stress response and consequently ER-induced 
apoptosis. Our data revealed a significant alteration in its protein expression levels, at 
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43oC, immediately after (0min) and 2-8h post exposure whereas at 45oC its induction 
became evident only after 24h post exposure (Fig.3.2.9). 
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Figure 3.2.8: The participation of PERK, IRE-1a and Grp78 in promoting ER stress response to hyperthermic exposures at 43oC and 45oC. 
Image shows alterations in protein expression levels of PERK, IRE-1a and Grp78 immediately after exposure to 43oC and 45oC, for 2h, (0min) as well 
as at 2-72h post exposure in A375 cells. Cells were grown overnight at 37oC followed by exposure to hyperthermia and then transferred back to 37oC 
for the indicated post exposure incubation times. Cell lysates were prepared (for all indicated time points) before being subjected to western blotting. 
Control cells were kept at 37oC. β-tubulin was used as loading control. 
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Figure 3.2.9: The participation of ATF-6, XBP-1s and CHOP in promoting ER stress response to hyperthermic exposures at 43oC and 45oC. 
Image shows alterations in protein expression levels of ATF-6, XBP-1s and CHOP immediately after exposure to 43oC and 45oC, for 2h, (0min) as 
well as at 2-72h post exposure in A375 cells. Cells were grown overnight at 37oC followed by exposure to hyperthermia and then transferred back to 
37oC for the indicated post exposure incubation times. Cell lysates were prepared (for all indicated time points) before being subjected to western 
blotting. Control cells were kept at 37oC. β-tubulin was used as loading control. 
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3.4.6 Hyperthermia induced regulation of heat shock proteins in A375 cells 
  
 In this part of the study, we aimed to document the effect of hyperthermia on 
various heat shock protein regulators. Two major proteins induced by heat stress are 
HSP90 and HSP70 known to act as molecular chaperones capable of binding and 
interacting with unfolded proteins thus preventing their aggregation.  
Based on our data, protein expression levels of HSP90 were increased following 
4-48h post exposure hyperthermic exposures at 45oC whereas remained at control 
levels, at 43oC, at any time point right after or post exposure (Fig.3.2.10).  
In addition, our data showed a remarkable elevation in protein expression levels 
of HSP70 at both 43oC and 45oC although evidently more profound at 43oC. This trend 
was shown to persist right after exposure (0min) and all the way up to 48h post 
exposure (Fig.3.2.10).  
Next, we studied alterations in protein expression levels of HSP40. Results 
demonstrated that its levels were significantly higher right after exposure (0min) and all 
the way to 8h post exposure at 43oC when compared to 45oC. It was only until 24h post 
exposure at 45oC when its protein expression levels were significantly higher than 43oC 
(Fig.3.2.10).  
On the other hand, HSP60 is considered to act as a mitochondrial chaperonin 
responsible for transporting and refolding proteins from the cytoplasm to the 
mitochondrial matrix. An increase in the protein expression levels of HSP40 was 
detected in a manner where it was more apparent from 2-24h post exposure at both 43oC 
and 45oC and 24-72h post exposure only at 45oC (Fig.3.2.11).  
Finally, the highly conserved (in multicellular organisms) HSF1 is known to act 
not only by ensuring the proper folding of damaged proteins but as an important 
transcription factor for heat shock proteins. Results showed a decrease in HSF1 in the 
protein expression levels in a manner where it was more evident right after (0min) and 
up to 4h post exposure at 43oC while this trend continued at each time point post 
exposure thereafter (2-72h) at 45oC (Fig.3.2.11). 
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Figure 3.2.10: The response of HSPs 90, 70 and 40 following hyperthermic exposures at 43oC and 45oC. Image shows alterations in protein 
expression levels of HSP90, HSP70 and HSP40 immediately after exposure to 43oC and 45oC, for 2h, (0min) as well as at 2-72h post exposure in A375 
cells. Cells were grown overnight at 37oC followed by exposure to hyperthermia and then transferred back to 37oC for the indicated post exposure 
incubation times. Cell lysates were prepared (for all indicated time points) before being subjected to western blotting. Control cells were kept at 37oC. 
β-tubulin was used as loading control. 
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Figure 3.2.11: The response of HSP60 and HSF1 following hyperthermic exposures at 43oC and 45oC. Image shows alterations in protein 
expression levels of HSF1 and HSP60 immediately after exposure to 43oC and 45oC, for 2h, (0min) as well as at 2-72h post exposure in A375 cells. 
Cells were grown overnight at 37oC followed by exposure to hyperthermia and then transferred back to 37oC for the indicated post exposure incubation 
times. Cell lysates were prepared (for all indicated time points) before being subjected to western blotting. Control cells were kept at 37oC. β-tubulin 
was used as loading control. 
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3. Results - Part III 
3.5 The effect of Dacarbazine (DTIC) in combination with hyperthermia in A375 
cells 
In this part of the study, we aimed to investigate the role of hyperthermia in 
potentiating the therapeutic effectiveness of other treatments (targeted and non-targeted) 
and more specifically the efficacy of various chemotherapeutic drugs (a non-targeted 
treatment) when applied as a combinational protocol. For this reason, we have utilized 
DTIC which is used widely as an FDA-approved therapy in patients with malignant 
melanoma. Firstly, we determined changes in cell viability levels of A375 cells after 
exposure to various concentrations of DTIC at different time periods, 24-72h, (data not 
shown). We chose 7.81μM and 31.25μM concentrations of DTIC for the reason of the 
first one being associated without any significant cytotoxicity while the second one 
showed considerable cytotoxicity when administered individually. For the combined 
treatment protocol, we exposed A375 cells at 41, 43 and 45oC, for 2h, and immediately 
after each hyperthermic exposure we administered each DTIC concentration for 
different time courses (24-72h). Finally, the levels of viable cells were monitored by 
using the Alamar Blue assay (described in “Materials & Methods”). According to our 
results, exposure at 41oC showed no statistically significant differences when comparing 
the effect of 41oC on each concentration of DTIC at 24h post exposure. However, 
considerable reduction in cell viability levels was recorded at 48h and 72h post 
exposure in the case of 31.25μM combined with 41oC (from 75% to 55.5% and from 
43.0% to 31.0% respectively) (Fig.3.3.1). Next, we used a combinational exposure 
protocol involving 43oC with both DTIC concentrations. Similarly, there was no 
potentiation effect observed at 24h post exposure with neither DTIC concentration 
whereas significant reduction in cell viability levels was recorded at 48h post exposure 
with 31.25μM DTIC (from 53% to 36.0%). Moreover, considerable reduction was also 
observed with 7.81μΜ and 31.25μΜ DTIC at 72h post exposure (from 59% to 34.0% 
and from 37.0% to 15.0% respectively) (Fig.3.3.2). Finally, at 45oC, our data showed 
that the reduction in cell viability was of the same magnitude for both DTIC 
concentrations at all time points (24-72h). The rates of viable cells were recorded to be 
around 40%, 20% and 10% at 24h, 48h and 72h post exposure respectively (Fig.3.3.3). 
This observation indicated that no potentiation effect could be observed under this 
experimental condition due to the great degree of cytotoxicity observed at 45oC on its 
own (monotherapy).  
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Figure 3.3.1: The effect of an adjuvant therapeutic protocol combining 41oC and 
DTIC at 24h (A), 48h (B) and 72h (C) post exposure in A375 cells. Briefly, cells 
were seeded in 96 well-plates and kept at 37oC overnight. Next day, cells were 
subjected at 41oC, for 2h, and 7.81μΜ as well as 31.25μΜ DTIC concentrations were 
added. Cells were then returned at 37oC for additional post exposure incubation periods 
(24-72h). Cell viability levels were recorded by utilizing the Alamar Blue assay. 
Control cells were kept at 37oC. Data shown are mean values ± SEM (n=5). Asterisk (*) 
indicates statistical significance at p<0.05. 
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Figure 3.3.2: The effect of an adjuvant therapeutic protocol combining 43oC and 
DTIC at 24h (A), 48h (B) and 72h (C) post exposure in A375 cells. Briefly, cells 
were seeded in 96 well-plates and kept at 37oC overnight. Next day, cells were 
subjected at 43oC, for 2h, and 7.81μΜ as well as 31.25μΜ DTIC concentrations were 
added. Cells were then returned at 37oC for additional post exposure incubation periods 
(24-72h). Cell viability levels were recorded by utilizing the Alamar Blue assay. 
Control cells were kept at 37oC. Data shown are mean values ± SEM (n=5). Asterisk (*) 
indicates statistical significance at p<0.05. 
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Figure 3.3.3: The effect of an adjuvant therapeutic protocol combining 41oC and 
DTIC at 24h (A), 48h (B) and 72h (C) post exposure in A375 cells. Briefly, cells 
were seeded in 96 well-plates and kept at 37oC overnight. Next day, cells were 
subjected at 41oC, for 2h, and 7.81μΜ as well as 31.25μΜ DTIC concentrations were 
added. Cells were then returned at 37oC for additional post exposure incubation periods 
(24-72h). Cell viability levels were recorded by utilizing the Alamar Blue assay. 
Control cells were kept at 37oC. Data shown are mean values ± SEM (n=5). Asterisk (*) 
indicates statistical significance at p<0.05. 
A) 
B) 
C) 
* * 
* 
* * * 
* 
* 
* 
* 
* 
* * * 
* * * * * 
* 
103 
 
3.6 The effect of a novel palladium-based chemotherapeutic agent as well as two 
targeted drug compounds (Vemurafenib and Dabrafenib) in combination with 
hyperthermia in A375 cells 
 
In this set of experiments, we utilized two targeted drugs compounds 
(Vemurafenib and Dabrafenib) which have been very recently FDA approved and are 
also currently used in clinical trials. Their mechanism of action is based upon acting and 
inhibiting a mutated (V600E) BRAF form present in almost 40-50% of all melanoma 
patients. Firstly, we determined the effect of various concentrations of each targeted 
drug alone (monotherapy) in A375 cells at different time courses (24-72h) (data not 
shown). Next, we chose a range of concentrations of each drug for combining with 
hyperthermia. Given, from our previous observations, that an optimal hyperthermic 
temperature was exposure at 43oC, we tested this temperature in its ability to potentiate 
the therapeutic efficacy of each of these two targeted drug compounds. In addition, we 
included an experimental palladium-based novel compound, which has never been 
tested in melanoma before, in order to determine its ability to induce cytotoxicity and if 
so, whether it is also potentiated in the presence of hyperthermia (Fig.3.3.4 & 3.3.6). 
Briefly, A375 cells were exposed at 43oC, for 2h, then a wide range of predetermined 
concentrations for each drug compound was utilized over different time courses (24-
72h) and finally cell viability levels were determined. We selected the 48h post 
exposure time point as it was shown to be the optimum experimental condition, for each 
drug compound, in detecting significant changes in their cell viability levels. Data 
showed a decline in A375 viability levels when combined with hyperthermia at 43oC 
indicating a possible potentiation effect. Interestingly, this decline appeared to be more 
profound in the case of the palladium-based drug compound and to a lower extent with 
the two targeted ones (Figs.3.3.6.A). More specifically, when looking at the EC50 
(effective concentration which kills 50% of cells) value for each drug compound (50nM 
for Vemurafenib, 5nM for Dabrafenib and 0.2μM for the palladium-based one), it was 
apparent that exposure at 43oC induced a lower than 10% reduction in both targeted 
drug compounds and slightly higher in the palladium-based one (Fig.3.3.4 & 3.3.6.A). 
Next, we included the non-tumorigenic, immortalized human keratinocyte (HaCaT) cell 
line in our exposure protocol in order to examine if the cytotoxicity observed at the 
above-mentioned EC50 values was also the case in HaCaT cells. The rationale for the 
inclusion of this cell line (as a control one) is based on the fact that, under normal 
conditions, melanocytes are surrounded by keratinocytes and so when a non-targeted 
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drug is administered it is expected to induce cytotoxicity in the surrounding “healthy” 
area as part of its non-targeted action. According to our results, when HaCaT cells were 
exposed to the same experimental conditions, their viability rates remained either at 
control levels or at much higher levels compared to the corresponding ones for each 
drug’s concentration tested in A375 cells (Fig.3.3.5).  
In another set of experiments, we selected two concentrations of each drug (one 
at an EC50 level and another one of a more cytotoxic profile) and we determined their 
potential to induce an apoptotic response either on its own (37oC) or in combination 
with hyperthermia (43oC) by using western immunoblotting. According to our findings, 
the combination of 43oC and Vemurafenib treatment caused the activation of initiator 
caspase-9 whereas caspase-8 did not get activated at these experimental conditions 
(Fig.3.3.7). Moreover, there were no profound changes in protein expression levels of 
pro-caspase-6 (and its downstream target Lamin A/C) as well as that of pro-caspase-7 
and -3 (Fig.3.3.8). On the other hand, the combinational treatment of Dabrafenib and 
hyperthermia at 43oC was shown to induce a reduction in protein expression levels of 
pro-caspase 8 thus indicating its activation whereas no changes in the protein content of 
un-cleaved caspase 9 were detected (Fig.3.3.7). A minor decline in protein levels of pro-
caspase 6 was also observed, while it was even more obvious for Lamin A/C, therefore 
showing the activation of the corresponding proteins (Fig.3.3.8). Moreover, there were 
no significant changes detected in protein expression levels of procaspase-3 at these 
experimental conditions (Fig.3.3.9). Finally, exposure to 43oC followed by treatment 
with the palladium-based drug compound resulted in the activation of initiator caspase-8 
but not of initiator caspase-9 whose protein content remained unchanged (Fig.3.3.7). In 
addition, effector caspases-6 and -7 appeared to be activated under these experimental 
conditions as a modest decline in the protein content of their un-cleaved enzyme forms 
was observed (Fig.3.3.8 & 3.3.9). The activation of caspase-6 was also indicated by a 
reduction in the protein levels of Lamin A/C (Fig.3.3.8). In contrast, effector caspase-3 
did not appear to be induced since there were no changes in the protein content of the 
un-cleaved enzyme form (Fig.3.3.9). Collectively, it was evident that each of the drug 
compounds was capable of triggering the apoptotic process by activating different 
caspases thus implying the involvement of different apoptotic pathways (e.g. extrinsic, 
intrinsic) in inducing cell death. 
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Figure 3.3.4: The effect of a combined therapeutic protocol at 43oC and treatment 
with Vemurafenib (A) and Dabrafenib (B) 48h post exposure in A375 cells. Briefly, 
cells were seeded in 96 well-plates and kept at 37oC overnight. Next day, cells were 
subjected at 43oC, for 2h, and different concentrations of each drug were added. Cells 
were then returned to 37oC for an additional 48h post exposure incubation period. Cell 
viability levels were recorded by utilizing the Alamar Blue assay. Control cells were 
kept at 37oC. Data shown are mean values ± SEM (n=5). Asterisk (*) indicates 
statistical significance at p<0.05. 
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Figure 3.3.5: The effect of a combined therapeutic protocol at 43oC and treatment 
with Vemurafenib (A) and Dabrafenib (B) 48h post exposure in HaCaT cells. 
Briefly, cells were seeded in 96 well-plates and kept at 37oC overnight. Next day, cells 
were subjected at 43oC, for 2h, and different concentrations of each drug were added. 
Cells were then returned to 37oC for an additional 48h post exposure incubation period. 
Cell viability levels were recorded by utilizing the Alamar Blue assay. Control cells 
were kept at 37oC. Data shown are mean values ± SEM (n=5). Asterisk (*) indicates 
statistical significance at p<0.05. 
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Figure 3.3.6: The effect of a combined therapeutic protocol at 43oC and treatment 
with a palladium-based drug compound in A375 (A) and HaCaT (B) cells 48h post 
exposure. Briefly, cells were seeded in 96 well-plates and kept at 37oC overnight. Next 
day, cells were subjected at 43oC, for 2h, and different concentrations of the drug were 
added. Cells were then returned to 37oC for an additional 48h post exposure incubation 
period. Cell viability levels were recorded by utilizing the Alamar Blue assay. Control 
cells were kept at 37oC. Data shown are mean values ± SEM (n=5). Asterisk (*) 
indicates statistical significance at p<0.05.                                  
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Figure 3.3.7: The effect of Vemurafenib, Dabrafenib and an experimental palladium-based novel drug compounds on the levels of un-cleaved 
caspases-8 and -9 in the absence (37oC) and presence (43oC) of hyperthermia in A375 cells. Image shows protein expression levels of initiator 
caspases -8 and -9 at 37oC and 43oC (for 2h) after an initial incubation period with each drug compound, at 37oC, for 48h in A375 cells. Cells were 
grown overnight before any exposures. Cell lysates were prepared before being subjected to western blotting. β-tubulin was used as loading control. 
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Figure 3.3.8: The effect of Vemurafenib, Dabrafenib and an experimental palladium-based novel drug compounds on the levels of un-cleaved 
caspases-6 and Lamin A/C in the absence (37oC) and presence (43oC) of hyperthermia in A375 cells. Image shows protein expression levels of 
initiator caspases -8 and -9 at 37oC and 43oC (for 2h) after an initial incubation period with each drug compound, at 37oC, for 48h in A375 cells. Cells 
were grown overnight before any exposures. Cell lysates were prepared before being subjected to western blotting. β-tubulin was used as loading 
control. 
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Figure 3.3.9: The effect of Vemurafenib, Dabrafenib and an experimental palladium-based novel drug compounds on the levels of un-cleaved 
caspases-7 and -3 in the absence (37oC) and presence (43oC) of hyperthermia in A375 cells. Image shows protein expression levels of initiator 
caspases -8 and -9 at 37oC and 43oC (for 2h) after an initial incubation period with each drug compound, at 37oC, for 48h in A375 cells. Cells were 
grown overnight before any exposures. Cell lysates were prepared before being subjected to western blotting. β-tubulin was used as loading control. 
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3. Results - Part IV 
3.7 The effect of hyperthermia at 43oC and 45oC in an in vivo xenograft rodent 
malignant melanoma model 
 
In the final part of this study, an in vivo xenograft malignant melanoma murine 
model was utilized in order to evaluate and validate our previous findings. This model 
was chosen to study hyperthermia’s therapeutic effectiveness as it resembles better the 
disease’s pathophysiology. To this end, the mouse malignant melanoma B16-F10 cell 
line was utilised for the induction of tumours in C57BL/6 female mice. Our first 
experiments included establishing optimal in vitro hyperthermic conditions for this cell 
line. More specifically, B16-F10 cells were exposed to 43oC and 45oC for various time 
periods and cell viability levels were recorded by using the Alamar blue assay 
immediately after the exposure as well as at 24h post exposure incubation at 37oC. 
According to our data, 1h of hyperthermia at 43oC and 45oC led to significant drop in 
the levels of viable cells as recorded 24h post exposure. More specifically, the 
percentage of living cells declined to around 80% and 45% after being exposed to 43oC 
and 45oC respectively (Fig.3.4.1.A). Shorter or longer hyperthermia exposure protocols 
caused either no significant or very extensive induction of cell death, so the 1h 
hyperthermic exposure protocol was chosen as the optimal one for this model. For the 
induction of tumours, B16-F10 cells were exposed at 43oC, 45oC (hyperthermia) and 
37oC (physiological conditions) and 24h post exposure they were injected 
subcutaneously in female C57BL/6 mice and were allowed to grow for 12-14 days. 
Then, all animals were sacrificed, tumours were removed and their size was determined. 
According to our findings, there was a significant effect of hyperthermia on the 
inhibition of tumour growth at 43oC with an even more profound one at 45oC 
(Fig.3.4.1.B & 3.4.1.C). More specifically, the average tumour size dropped from 
around 3,000mm3 (at 37oC) to approximately 2,000 (at 43oC) and lower than 1,000mm3 
(at 45oC) (Fig.3.4.1.B & 3.4.1.C). 
 Apart from determining the size of the excised tumours, we sought to determine 
any changes in protein expression levels of different markers descriptive of therapeutic 
effectiveness by means of immunohistochemistry. First, we determined changes in the 
protein levels of activated caspase-3 as an endpoint of apoptotic induction in response to 
hyperthermia. According to our data, there was a clear elevation in the protein levels of 
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cleaved caspase-3 in the samples from both hyperthermia-exposed groups (at 43oC and 
45oC) compared to those from the control (37oC) one (Fig.3.4.2). Second, COX-2 was 
tested as an additional marker whose inhibition has been associated with the activation 
of cell death pathways as well as the prevention of proliferation. Our findings showed 
that there was a substantial reduction in its levels in the tumours from the hyperthermia-
treated groups in contrast to those obtained from the control group (Fig.3.4.2). Last, we 
stained for phosphoH2A.X (Ser139), a common DNA damage marker. Results 
demonstrated a clear increase in the protein levels of phosphoH2A.X (Ser139) in the 
samples exposed to hyperthermia at 43oC and 45oC (Fig.3.4.2). Overall, the data from 
these experiments confirmed the therapeutic efficacy of hyperthermia in inducing cell 
death and inhibiting the growth of cancer cells in an in vivo xenograft rodent model of 
malignant melanoma. 
 
 
114 
 
       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4.1: The effect of hyperthermia in an in vivo xenograft rodent malignant 
melanoma model. A) Cell viability levels of B16-F10 cells immediately after and 24h 
post exposure at 37oC, 43oC and 45oC for 1h (n=5). B) Boxplot showing average tumor 
volume growth of B16-F10 cells at 37oC, 43oC and 45oC (n=10). Asterisk (*) indicates 
statistical significance at p<0.05. C) Image showing representative tumors at 37oC, 43oC 
and 45oC.  
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Figure 3.4.2: The effect of hyperthermia on the expression levels of various 
proteins in an in vivo xenograft model of rodent malignant melanoma. (A) 
Immunohistological staining for caspase-3 (upper panel), COX-2 (middle panel) and 
H2A.X (Ser139) (lower panel) for the following treatment groups: i, iv and vii (control 
group at 37oC), ii, v and viii (hyperthermia-treated group at 43oC) and iii, vi and ix 
(hyperthermia-treated group at 45oC). (B) Table showing quantification of protein 
expression levels for the above-mentioned proteins in all three experimental groups 
(37oC, 43oC and 45oC).  
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3.8 The effect of hyperthermia at 43oC and 45oC in an in vivo xenograft rodent 
colon carcinoma model 
 
In this set of experiments, we utilized an additional in vivo model in order to 
examine if hyperthermia would exert the same therapeutic efficacy in a different type of 
cancer. In this case, an in vivo xenograft rodent colon carcinoma model was used by 
utilizing the CT-26 cell line. Similarly to our previous in vivo xenograft rodent 
malignant melanoma model, a series of in vitro experiments determined the optimum 
experimental conditions for the hyperthermic exposures of CT-26 cells. The cells were 
exposed at 43oC and 45oC over different time courses and the level of viable cells was 
determined by the Alamar blue assay immediately after exposure and 24h post exposure 
at 37oC. Our results showed that 1h at 43oC and 45oC respectively had a similar effect 
on the rates of viable cells as the one observed in the case of B16-F10 cells. In 
particular, cell viability levels declined to 80% and 40% following exposure at 43oC and 
45oC respectively (Fig.3.4.3.A). Based on these observations, we used an 1h exposure 
protocol at 43oC and 45oC in the next set of experiments. CT-26 cells were injected 
subcutaneously in female BALB/c mice and allowed to grow for 12-14 days. The 
animals were then sacrificed and their tumours were removed. The size of these tumours 
was determined by using an electronic calliper and according to the results there was a 
considerable reduction in tumour size in both hyperthermia-treated groups (43oC and 
45oC) compared to the control (37oC) group. More specifically, average tumour size for 
the control was about 2,000mm3 whereas it was reduced to about 1,500mm3 and lower 
than 1,000mm3 at the 43oC and 45oC hyperthermia-treated groups respectively 
(Fig.3.4.3.B & 3.4.3.C). Overall, hyperthermia was shown to inhibit tumour growth in 
two different in vivo mouse carcinoma models thus supporting hyperthermia’s 
beneficial effects in experimental cancer treatment.  
Next, various tumour sections, from BALB/c mice, were subjected to 
immunohistological staining with the same markers used in the in vivo xenograft 
malignant melanoma rodent model. Staining with the cleaved caspase-3 antibody 
demonstrated a considerable increase in its protein expression levels in the tumours 
from the 43oC hyperthermia-treated group compared to the control (37oC) group. 
Moreover, it should be noted that the tumour sections from the 45oC hyperthermia-
treated group exhibited a much stronger staining of the protein (Fig.3.4.4). Protein 
expression levels of COX-2 were also affected by exposure to hyperthermic conditions 
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as we detected a remarkable decrease in its protein expression levels in the tumours 
from both hyperthermia-treated groups (Fig.3.4.4). Finally, according to our results with 
phosphoH2A.X (Ser139) staining, the levels of its protein content were elevated in the 
tumour sections from the two hyperthermia-treated groups (at 43oC and 45oC) compared 
to those from the control (37oC) group (Fig.3.4.4). Overall, our data document that 
hyperthermia could potentially exert its beneficial effects in other distinctively different 
types of cancers including colon carcinoma, etc.  
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Figure 3.4.3: The effect of hyperthermia in an in vivo xenograft rodent colon 
carcinoma model. A) Cell viability levels of B16-F10 cells immediately after and 24h 
post exposure at 37oC, 43oC and 45oC for 1h (n=5). B) Boxplot showing average tumor 
volume growth of B16-F10 cells at 37oC, 43oC and 45oC (n=10). Asterisk (*) indicates 
statistical significance at p<0.05. C) Image showing representative tumors at 37oC, 43oC 
and 45oC.  
 
A) 
C) 
B) 
37
o
C                   43
o
C               45
o
C 
* 
* 
* 
* 
119 
 
 
Figure 3.4.4: The effect of hyperthermia on the expression levels of various 
proteins in an in vivo xenograft rodent model of colon carcinoma. (A) 
Immunohistological staining for caspase-3 (upper panel), COX-2 (middle panel) and 
H2A.X (Ser139) (lower panel) for the following treatment groups: i, iv and vii (control 
group at 37oC), ii, v and viii (hyperthermia-treated group at 43oC) and iii, vi and ix 
(hyperthermia-treated group at 45oC). (B) Table showing quantification of protein 
expression levels for the above-mentioned proteins in all three experimental groups 
(37oC, 43oC and 45oC).  
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4. Discussion 
 
Malignant melanoma is considered one of the deadliest types of cancer and the 5 th 
most common type, in UK (2014), while its incidence rates have been steadily  
increasing over the last decades, according to Cancer Research UK, 2014. Its survival 
rates are increased when it is diagnosed at an early stage, however if it progresses to a 
metastatic stage then current treatment options become less efficient (Cancer Research 
UK, 2014). Therefore, there is an increasing number of studies focusing on the 
establishment of new strategies which will improve the existing therapeutic protocols 
and make them more effective (Harries et al., 2016). Since the 1970s there has been a 
rising interest in investigating hyperthermia’s therapeutic potential as a cancer treatment 
modality as the need for more effective therapeutic strategies has increased 
dramatically. Early studies showed that when hyperthermia is applied, in combination 
with radiation therapy, it can exert beneficial effects in treating tumor cells (Gerner et 
al., 1975). Various studies utilizing different cancer cell lines and models have looked 
into the role of apoptosis as a consequence of heat application and according to their 
findings, the induction of cell death pathways (apoptosis and/or necrosis) is dependent 
on the cancer cell type, temperature and duration of heat exposure (Hildebrandt et al., 
2002, Wrzal et al., 2008). The aim of this study was to investigate hyperthermia’s 
effectiveness in triggering cell death pathways as a therapeutic basis for treating 
malignant melanoma.  
To this end, we have utilized an in vitro human malignant melanoma model 
consisting of three different cell lines: a human, non-tumorigenic immortalized 
keratinocyte (HaCaT) cell line, an epidermoid human carcinoma (A431) cell line and a 
human malignant melanoma (A375) cell line. During the initial experiments of this 
study, we optimized the experimental hyperthermic conditions for inducing cell death in 
A431 and A375 cell lines. According to our results, exposing cells to mild temperatures 
(39-41oC) had no significant effect on cell viability levels whereas when they were 
exposed to higher temperatures (>43oC) the activation of cell death was more 
prominent. Temperatures higher than 45oC were shown to result in an excessive cell 
death induction (Fig.3.1.1). In addition, time course experiments determined the 
optimum duration for hyperhermic exposures (Fig.3.1.2). Overall, the optimal exposure 
conditions for our hyperthermia-inducing platform were 2h at 43oC and 45oC as these 
conditions caused a significant drop in the rates of viable cells thus indicating the 
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activation of cell death pathways. Our results (with the Alamar blue assay) are 
consistent with other studies using different viability assays (on A375 cells) as well as 
utilizing other malignant melanoma cell lines (Shellman et al., 2008). Furthermore, it 
was evident that the epidermoid carcinoma cells (A431) appeared to be more resistant to 
heat treatments when compared to melanoma ones. Moreover, we monitored changes in 
cell viability levels after more extended post hyperthermic exposure incubation times (at 
37oC) including 24, 48 and 72h in order to determine the presence of a more prolonged 
decline in cell viability rates or whether there would be a recovery by the cells 
representing their adaptation to hyperthermia (Fig.3.1.3). An important advantage of our 
study is that we have further validated the cytotoxic effects of hyperthermia in non-
tumorigenic keratinocytes in an attempt to obtain a “perspective” of a non tumor (i.e. 
control) cell line representing the majority of cells, in epidermis, that are normally 
surrounding the malignant melanocytes (Choi and Lee, 2015). Our results indicated that 
HaCaT cells showed significantly higher rates of cell viability after being exposed at 43 
and 45oC compared to A431 and/or A375 cells. Most specifically, they appeared to 
maintain high levels of cell viability (around 60%) even when utilizing hyperthermic 
exposure at 45oC (Fig.3.1.3). These findings were further validated when utilizing an 
additional cytotoxicity assay capable of determining levels of dead cells. In doing so, 
we determined a remarkable induction of cell death in A375 cells while HaCaT cells 
were more resistant (Fig.3.1.4). Finally, we selected trypan-blue staining as an 
additional means of determining the levels of viable as well as dead cells, in the same 
sample, in order to confirm all our previous findings with A375 cells. As expected, 
there was a considerable increase in the rates of dead cells while the rates of viable cells 
declined at 45oC, however cells exposed at 43oC did not exert significant induction of 
cell death although reduced proliferation potential was observed (Fig.3.1.5). 
Interestingly, the observed reduction in cell viability levels, at 43oC, could be attributed 
to hyperthermia’s interaction with other cellular processes (e.g. cell cycle observation) 
rather than induction of cell death. In fact, several research reports have associated 
hyperthermia’s anti-proliferative effects with alterations in cell cycle regulation as well 
as DNA repair mechanisms in various cell lines (Furusawa et al., 2012, Harnicek et al., 
2016, Oei et al., 2015). Collectively, our data support the therapeutic effectiveness of 
hyperthermia against malignant melanoma (A375) and non-melanoma (A431) cell lines, 
at 43oC and 45oC, presumably by inducing relevant cell death pathways and/or altering 
cell cycle, DNA repair mechanisms, etc., while at the same time had no (or very 
limited) cytotoxic effect in non-tumorigenic keratinocyte (HaCaT) cells.  
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There is a vast number of studies addressing the involvement of the apoptotic 
pathway in hyperthermia-induced cell death by using a wide range of in vitro and in 
vivo models (Shellman et al., 2008, Ahmed et al., 2015, Hildebrandt et al., 2002). To 
this end, the next part of our study was focused on elucidating the underlying 
mechanisms of apoptotic cell death in our in vitro human malignant melanoma model. 
According to our results, all three apoptotic pathways (intrinsic, extrinsic and ER-
mediated) were activated as a response to hyperthermic exposures at 43oC and 45oC 
although it should be noted that the activation of various caspases appeared to be 
temperature-dependent. For instance, initiator caspases-8 and -9 were both found to be 
activated after hyperthermic exposures at 43oC and 45oC, however it became apparent 
that both remained active over a short period of time in the case of 43oC while they 
appeared to be further activated at longer periods of time (e.g. 24h post exposure) at 
45oC (Fig.3.2.1). The activation of caspases 8 and 9 provides evidence for the triggering 
of the extrinsic and intrinsic apoptotic pathways respectively. This observation was 
further supported by real-time PCR data as several genes were shown to be implicated 
and up-regulated in both apoptotic pathways. More specifically, regarding the extrinsic 
pathway DAPK3, FAS and FASLG were shown to be up-regulated at 43oC and 45oC 
while TNF, TNFRSF10A, TNFSF10, TNFSF12 and TRAF2 were up-regulated only at 
45oC. As for the intrinsic pathway, BAK1, BBC3 and BIRC2 demonstrated higher 
expression levels at 43oC while APAF1, BCL2L11, CASP7, KIT, PMAIP1 and VDAC2 
were additionally up-regulated at 45oC (Table.3.1.1). The importance of caspase-9 
activation (intrinsic pathway) in hyperthermia-induced apoptotic cell death has been 
previously reported in Jurkat cells (Shelton et al., 2010) while the implication of the 
death receptor (extrinsic) pathway has also been shown to be activated (Bettaieb and 
Averill-Bates, 2008). However, conflicting data from another study has shown no 
activation of both initiator caspases in melanoma cells (Shellman et al., 2008). This 
observation can be attributed to the utilization of different experimental conditions 
and/or protocols including the hyperthermia-induced platforms, exposure kinetics, etc. 
Regarding the involvement of the effector caspases, we found that only caspase-6 
becomes activated after a hyperthermic exposure at 43oC, whereas all of them (i.e. 
caspase-3, -6 and -7) are induced at 45oC (Fig.3.2.2 & 3.2.3). Taking into account these 
findings, it can be hypothesized that hyperthermic exposure at 43oC induces the 
activation of both intrinsic and extrinsic pathways driven by the effector caspase-6 in a 
manner that is time dependent and up to 8h post treatment. On the other hand, exposure 
at 45oC induces the activation of all caspases (e.g. initiator as well as effector) 
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determined by our experimental methodologies. Our results are consistent with previous 
reports demonstrating the induction of caspases-3 and -7 in response to hyperthermic 
stress (Jeon et al., 2016, Shellman et al., 2008). Finally, in an attempt to further validate 
our previous findings confirming the role of the extrinsic pathway in hyperthermia-
induced apoptosis, we investigated the activation of several molecules involved in this 
pathway. Our data support the activation of TNF-R1 and TRADD, in response to both 
hyperthermic conditions at 43oC and 45oC, as there was a significant reduction in their 
protein levels indicating their interaction in forming a death domain which can then 
recruit caspase-8 (Fig.3.2.5). Other studies have also demonstrated the induction of 
death receptors as a response to thermal stress (Morle et al., 2015) while additional 
reports have shown that combined administration of TNFa with hyperthermia appears to 
have promising results in clinical trials (Bonvalot et al., 2009, Bonvalot et al., 2012). 
Moreover, our data demonstrated the activation of RIP1, only in the case of exposure at 
45oC, an observation which could be indicative either of the protein’s interaction with 
FADD and TRADD (in stimulating the extrinsic pathway) (Festjens et al., 2007) or 
alternatively, its interaction with RIP3 for the formation of the necrosome (which is 
required for necroptotic cell death) (Cho et al., 2009, Li et al., 2012). Taken together, 
our results propose the induction of both necroptotic and apoptotic pathways as a 
response to higher hyperthermic temperatures (45oC) in contrast to milder ones (43oC), 
however further experiments are needed in formulating such hypothesis. Another 
important factor in contributing towards activation of the apoptotic cascade is changes 
in the balance between pro- and anti-apoptotic proteins. To obtain further insight into 
possible alterations causing this imbalance, as a response to hyperthermic exposures, we 
selected various pro-apoptotic proteins and monitored changes in their expression 
levels. Our data illustrated that Bak, Bax, Bad and Bim were all up-regulated, at both 
hyperthermic exposures, although the increase in their protein levels was detected at 
different time periods post exposures (Fig.3.2.6 & 3.2.7). Several anti-apoptotic proteins 
such as Bcl-2 and Bcl-xL have been shown to be down-regulated whereas several pro-
apoptotic ones like Bak, Bax, Puma and Noxa are up-regulated under heat stress 
conditions (Glory et al., 2014, Hou et al., 2014). Bim, on the other hand, has been 
reported to be of critical importance in promoting ER-stress mediated apoptotic cell 
death as its up-regulation is modulated by CHOP (Puthalakath et al., 2007). On the 
contrary, down-regulation of Bim prevents melanoma cells from undergoing apoptotis 
induced by ER stress conditions (Tay et al., 2012). Altogether, our data support 
triggering of the apoptotic mechanisms by enhancing the expression levels of numerous 
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pro-apoptotic proteins with Bim being the most important factor shown to be up-
regulated under hyperthermia-induced ER stress. Finally, Bid (another pro-apoptotic 
protein) was shown to be considerably reduced after exposure at 45oC (Fig.3.2.7) 
which, in turn, can indicate its cleavage to t-Bid thus promoting the cross-talk between 
the extrinsic and intrinsic apoptotic pathways (Billen et al., 2008). Our previous 
findings documenting the participation of both apoptotic pathways (extrinsic and 
intrinsic) in activating cell death, at 45oC, might also be supported by the possible 
formation of t-Bid, however its presence does not seem to be necessary for the 
modulation of the apoptotic process at 43oC. Nevertheless, in order to highlight the 
importance of t-Bid further experiments are needed in utilizing this form of the 
molecule instead of its total protein content.  
Next, we aimed to investigate the participation of the ER-mediated pathway in 
triggering hyperthermia-induced cell death. According to our findings, there was a clear 
increase in the protein content of Grp78 following hyperthermic exposure at 43oC and 
45oC (Fig.3.2.8). This observation is consistent with the existing literature and can be 
explained in the context of cellular adaptation by means of producing higher quantities 
of chaperone proteins that will bind to denatured proteins (caused by hyperthermia) and 
help them regain their normal form and function (Shellman et al., 2008). Interestingly, a 
slight decrease in protein levels of PERK was only detected at 45oC exposure 
(Fig.3.2.8), which can be explained by its increased homodimerisation for 
phosphorylating the eIF2 factor in order to inhibit protein synthesis in stressed cells 
(Teske et al., 2011). The determination of the expression protein levels of the 
phosphorylated forms of both proteins (PERK and eIF2) could further validate the 
activation of this pathway. In contrast, exposure to both hyperthermic temperatures 
were shown to trigger the induction of IRE-1a and ATF-6 as well. This was indicated 
by a marked decline in their protein expression levels suggesting that IRE-1a gets 
homodimerised and binds to downstream proteins while ATF-6 is cleaved to its active 
form under ER-stress conditions (Fig.3.2.8 & 3.2.9). Consistent with these results, the 
downstream target of IRE-1a, XBP-1s, was shown to be up-regulated and along with 
active ATF-6 are responsible for directing the activation of UPR pathways (Yoshida et 
al., 2001, Zhang and Kaufman, 2004). Finally, induction of CHOP was shown to be 
dependent on ATF-6 and XBP-1s activation as well (Nishitoh, 2012). Furthermore, the 
presence of active caspase-4 and CHOP, at 45oC, can be associated with the stimulation 
of apoptosis (Fig.3.1.8 & 3.2.9) (Bettaieb and Averill-Bates, 2008, Shellman et al., 
2008). Collectively, our data suggest that PERK, IRE-1a and ATF-6 pathways take part 
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in the UPR-induced response at 45oC whereas only the IRE-1a and ATF-6 pathways are 
activated at 43oC. Interestingly, the induction of IRE-1a and ATF-6 pathways has been 
suggested to play an anti-apoptotic role under ER stress conditions, in contrast to PERK 
pathway which was demonstrated to have pro-apoptotic effects instead (Lin et al., 2007, 
Lin et al., 2009, Rutkowski et al., 2006). Moreover, the continuous induction of IRE-1a 
and ATF-6 pathways has been shown to provide a survival advantage to melanoma cells 
undergoing prolonged ER stress according to a recent report (Tay et al., 2014). Taking 
into consideration all our previously described findings, it can be proposed that 
activation of IRE-1a and ATF-6 pathways appears to exert anti-apoptotic effects when 
cells are exposed at 43oC hyperthermia as there is no induction of active caspase-3 
following CHOP up-regulation. On the other hand, stimulation of PERK signaling is 
presented to be of great importance in leading towards apoptotic induction in the case of 
45oC hyperthermic exposure. On another note, it is well known that heat shock proteins 
(HSPs) are produced in higher rates in cells in response to several stress conditions as a 
means of protecting them from proteins’ misfolding and aggregation that could, in turn, 
provoke the induction of cell death. Since hyperthermia is the main reason for the up-
regulation of this group of proteins, we examined alterations in the expression levels of 
several of them as a response to our hyperthermia exposure protocols. In particular, our 
data showed that the expression of HSP70, HSP40 and HSP60 was up-regulated, 
whereas that of HSF1 was down-regulated at both hyperthermic temperatures while 
HSP90 was elevated but only at 45oC (Fig.3.2.10 & 3.2.11). The up-regulation of 
HSP70 and HSP90 has been found to have anti-apoptotic effects by preventing the 
formation of the apoptosome (Beere et al., 2000, Pandey et al., 2000). Furthermore, 
inhibition of HSP70 appears to have anti-cancer effects by preventing tumor growth and 
enhancing the cytotoxic effects of cisplatin in an in vivo melanoma model (Schmitt et 
al., 2006). According to results from a recent paper, the absence of JB12 (an ER-
associated HSP40 protein) is linked with the stimulation of ER-stress-mediated 
apoptosis (Sopha et al., 2017). Similarly, HSP60 is known to exert its anti-apoptotic 
effects by acting as a mitochondrial chaperone while its inhibition is responsible for 
promoting apoptosis and preventing tumor growth in an in vivo glioblastoma model 
(Ghosh et al., 2008, Ghosh et al., 2010). Interestingly, the suppression of HSF1 
appeared to exert anti-proliferative effects in melanoma cells under hyperthermic 
conditions (Nakamura et al., 2010). Collectively, our findings suggest that the up-
regulation of HSP70, HSP40 and HSP60 might prevent apoptotic induction at 43oC, an 
observation which is additionally supported by the absence of cleaved caspase-3. On the 
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contrary, down-regulation of HSF-1 (which has opposing effects) was determined only 
for a short post exposure period of time. On the other hand, the prolonged decrease in 
HSF-1 protein levels is capable of enhancing apoptotic stimulation at 45oC, due to the 
delayed up-regulation of all other HSFs (HSP90, HSP70, HSP40, HSP60) as they 
display maximum expression levels at 24h post exposure to hyperthermia (Fig.3.2.10 & 
3.2.11). To the best of our knowledge, our study provides novel insights into 
characterizing and consequently understanding the interplay between different apoptotic 
cascades and the complex apoptotic signaling amongst them, as a response to 
hyperthermia, in an in vitro model of human malignant melanoma.   
In the next part of our study, we focused on investigating the effect of hyperthermia 
in potentiating the induction of cell death when applied in combination with other 
chemotherapeutic agents (combinational treatment). The rationale for such 
combinational protocol is based on hyperthermia’s ability to activate cell death 
pathways and thus sensitize human malignant melanoma cells  to the action of various 
chemotherapeutic agents. If this is so, then the cytotoxic effects of various 
chemotherapeutic agents could be enhanced (in the presence of hyperthermia) in a way 
where their lower concentrations are comparable to the ones observed at higher 
concentrations thus eliminating the risk for any potential side effects (Bettaieb et al., 
2013). The first chemotherapeutic drug we tested was Dacarbazine (DTIC) and our data 
showed that hyperthermic exposure of A375 cells at mild temperatures (41oC and 43oC) 
potentiated the drug’s cytotoxicity potential (Fig.3.3.1 & 3.3.2). It should be noted that 
exposure at 43oC was the most effective one since it potentiated the cytotoxic effect of 
both DTIC concentrations whereas exposure at 41oC was capable of increasing the 
cytotoxicity of the highest DTIC concentration only. The latter was also supported by 
other studies where lower hyperthermic temperatures (<41oC) combined with the use of 
chemotherapy were accompanied by a limited effect on cell viability levels. This 
appeared to due to the thermo-tolerance or thermo-sensitivity of different cell lines used 
(Kalamida et al., 2015, Hildebrandt et al., 2002). The reason behind the observed 
hyperthermia-induced potentiation of DTIC could be attributed to the impairment of 
DNA repair pathways which would otherwise act by repairing any DTIC-induced 
damage (Oei et al., 2015, Mantso et al., 2016). Moreover, we tested the effect of a 
higher temperature (45oC) in this combined protocol, although we had previously 
shown that exposing cells at this hyperthermic temperature resulted in a dramatic 
increase in the rate of dead cells (Fig.3.3.3). Our results are in agreement with the 
existing literature suggesting that the combination of mild hyperthermia (40-43oC) and 
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chemotherapy can present increased cytotoxicity against cancer cells (Hildebrandt et al., 
2002, Issels, 2008) whereas higher temperatures (>45oC) are associated with the 
induction of necroptotic death (Harmon et al., 1990, Shellman et al., 2008), thus not 
being suitable for combinational treatment studies. It is worth mentioning that an 
important limitation in these experiments is the fact that DTIC needs to be bioactivated 
in the liver (Marchesi et al., 2007) so the use of the drug directly on its target cancer cell 
type is not an ideal experimental model for studying its therapeutic effectiveness. On 
the other hand, almost half of melanoma patients carry a mutation (V600E) in the BRAF 
oncogene. Consequently, there has been growing interest in developing new drugs 
capable of targeting this mutation and inhibiting the continuous activation of 
MAPK/ERK signaling pathways which can lead to accelerated tumor growth (Taube et 
al., 2009, Ascierto et al., 2012). Two BRAF-targeted drugs, currently administered in 
melanoma patients, are Vemurafenib and Dabrafenib both of which have been approved 
by FDA (in 2011 and 2013 respectively) (NIH, 2011 & 2013). We decided to include 
these two targeted drugs in our study model in order to examine whether their efficacy 
could be enhanced in combination with hyperthermia. Our results demonstrated that the 
application of 43oC induced a potentiation effect on the cytotoxicity of both targeted 
drugs, in A375 cells, but it was quite limited as it was recorded to be 10% difference in 
cell viability rates at 48h post exposure (Fig.3.3.4). Because these two drugs target the 
same mutated form of BRAF, it was assumed that they would not be capable of exerting 
any cytotoxic effects if administered to cells carrying the wild type gene. Indeed, when 
HaCaT cells were treated with the same concentrations of drugs there was no significant 
cytotoxicity observed as this cell line does not carry a mutated BRAF gene (Fig.3.3.5). 
However, it should be mentioned that during a recent study there was development of 
non-melanoma skin cancer after Vemurafenib administration and according to these 
data, treatment of HaCaT cells with low doses of Vemurafenib (2μM) resulted in an 
increased activation of CRAF kinase accompanied by elevated growth rates and 
invasive capacity of cells (Roh et al., 2015). In addition, Dabrafenib appeared to have 
the same effects as reported by a different group of investigators (King et al., 2013). 
Finally, we sought to test the cytotoxic action of another experimental but novel 
chemotherapeutic agent based on palladium (II) saccharinate complex of terpyridine. 
Once again, our data demonstrated that hyperthermia at 43oC was able to increase the 
drug’s cytotoxicity in A375 cells (Fig.3.3.6). In fact, hyperthermia was shown to 
enhance the drug’s effectiveness to a slightly greater extent compared to both targeted 
drugs in these melanoma cells, however it did also present higher cytotoxicity levels 
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when used in the control, immortalized keratinocyte (HaCaT) cells (Fig.3.3.6). These 
findings revealed the therapeutic potential of this experimental drug in the development 
of new strategies in melanoma treatment as this is the first study utilizing its potential 
use against this type of cancer. When comparing the cytotoxicity profile of the drug 
obtained in A375 cells with that of lung and breast carcinomas, it becomes apparent that 
it was more potent in melanoma cells (Ulukaya et al., 2011b, Ari et al., 2014). More 
specifically, its EC50 levels in the other cancer cell types were much higher compared 
to that of melanoma. For instance, the EC50 values in lung and breast cancers were 
recorded as 1.8-2.1μM and 2.71-46.5μM respectively whereas those in melanoma as 
approximately 0.2μM. However, data from another study demonstrated that the EC50 
value of the complex dropped to 0.1-1.0μM when treating fibrosarcoma cell lines 
(Coskun et al., 2013), which suggests that the therapeutic effectiveness of the complex 
is cell type dependent and can potentially exert anti-cancer effects against other types of 
tumors as well. Finally, a considerable advantage of our in vitro model is that 
keratinocytes were also exposed at the same experimental conditions in order to 
determine the safety levels (i.e. free of any associated cytotoxicity) of the treatment 
protocol. It is noteworthy that the previously mentioned reports lack the addition of 
such non-tumorigenic, control cell line in their in vitro models. Currently, there are no 
scientific reports investigating the underlying mechanisms leading to the induction of 
cell death after the application of hyperthermia in combination with any of the 
previously mentioned therapeutic agents (Vemurafenib, Dabrafenib and novel 
palladium-complex) in malignant melanoma. All data, thus far, are based on viability 
assays and so it remained largely unclear if the observed potentiation of cytotoxicity 
was due to the triggering of programmed cell death (apoptotic) pathways. To this end, 
we determined protein expression levels of several caspases involved at various stages 
of the apoptotic cascade and soon became obvious that each of the different therapeutic 
agents showed a different pattern of caspase activation. As previously described, in the 
case of Vemurafenib, hyperthermia’s potentiation effect was observed by the activation 
of initiator caspase-9 but not -8 suggesting primarily the activation of the intrinsic 
apoptotic pathway (Fig.3.3.7). Futhermore, effector caspases-6 and -7 were unaffected 
whereas a minor activation of caspase-3 was detected (Fig.3.3.8 & 3.3.9). Despite the 
observed activation of intrinsic apoptosis, clearly further experiments are required in 
order to better characterize the involvement of proteins downstrean in this pathway. The 
reduction in pro-caspase-3 protein expression content confirms the participation of this 
apoptotic pathway in response to the combined hyperthermia and Vemurafenib 
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treatment as there was no activation of the extrinsic (caspase-8-dependent) pathway. 
Evidence from a recent report revealed the importance of caspase-3 activation in 
triggering cell death as the use of PAC-1 (a pro-caspase-3 activator) along with 
Vemurafenib increased the drug’s anti-cancer activity in melanoma cells (Peh et al., 
2016). Our findings agree with the results from another report showing that the 
administration of Vemurafenib in melanoma cells was responsible for triggering the 
intrinsic apoptotic pathway while also initiating the ER stress response in melanoma 
cell lines (Beck et al., 2013). Thus, it may be that the combination of hyperthermia and 
Vemurafenib can be a more effective therapeutic strategy against melanoma due to the 
combined elevation of the ER stress-based and intrinsic apoptotic activation. In the case 
of Dabrafenib, caspase-8 (rather than caspase-9) appeared to be activated, thus 
indicating the stimulation of the extrinsic apoptotic pathway (Fig.3.3.7). In addition, a 
reduction in the protein levels of Lamin A/C suggests the activation of effector caspase-
6 (although this was not evident perhaps due to technical reasons) (Fig.3.3.8). 
Intriguingly, there was no significant activation of caspase-3 either (Fig.3.3.9), an 
observation that has previously been reported to be the case in Dabrafenib-induced cell 
death (King et al., 2013). However, although the conflicting data between our study and 
the work of others, there is data suggesting that Dabrafenib is capable of preventing 
necroptosis and partially apoptosis in melanoma cells. This is due to the inhibition of 
RIP3, which acts by regulating the induction of necroptosis when completion of 
apoptosis is prevented, by Dabrafenib (Geserick et al., 2015). On the other hand, if this 
is the reason for the absence of caspase-3 activation, caspase-8 should have remained 
inactive since it does not take part in the necroptotic pathway (Vandenabeele et al., 
2010). An interplay between the stimulation of apoptotic and necroptotic pathways 
could explain these findings while additional experiments focusing on the relation of the 
two pathways are necessary. Last but not least, the combination of hyperthermia with 
the palladium-complex appeared to provoke the induction of the extrinsic apoptotic 
pathway which was indicated by reduced protein levels of pro-caspase 8. In addition, 
effector caspases-6 and -7 were found to be active whereas caspase-9 and -3 appeared to 
be unaffected. Even though there is no data pertaining to the cytotoxicity induced by 
this complex in melanoma cells the involvement of death receptor pathway was 
documented when breast cancer cells were treated with this drug agent. More 
specifically, various death receptor genes were found to be up-regulated while caspase-3 
was also shown to be active (Ulukaya et al., 2011a, Ari et al., 2013). The results from 
our study agree, in part, with these findings as we provided evidence for the extrinsic 
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pathway’s participation in mediating cell death via active caspase-8 although in the 
absence of caspase-3 activation. This could be due to experimental discrepancies or 
different experimental conditions required for the detection of the active form of the 
enzyme (i.e. different concentration or incubation period, etc.). Another reason could be 
the fact that effector caspases-6 and -7 rather than caspase-3 drive the final stages of the 
apoptotic process in melanoma cells. Collectively, our data show that each drug triggers 
the activation of different caspases and consequently different apoptotic pathways. In 
order to better understand how the effectiveness of these drugs is potentiated, in our 
experimental human malignant melanoma model, more elaborate experiments have to 
be performed while focusing on the molecular mechanisms underlining the interplay 
amongst these apoptotic pathways.  
Finally, in the last part of our study, we utilized two different in vivo rodent models 
in order to evaluate the significance of our previous in vitro findings regarding 
hyperthermia’s therapeutic effectiveness. Firstly, we demonstrated that hyperthermia at 
43oC and 45oC had a comparable effect on viability levels of mouse melanoma (B16-
F10) cells to that observed in human melanoma (A375) cells (Fig.3.4.1.A). However, it 
should be noted that the duration of the exposure was reduced to 1h due to the excessive 
cell death observed at the 2h exposure period suggesting that the mouse melanoma cells 
were more sensitive to our previously-described hyperthermia exposure protocol. 
Studies, by other groups, have also utilized this mouse cell line in documenting 
hyperthermia’s effect on proliferation and therapeutic potential in these cells (Garcia et 
al., 2012, Jin et al., 2013). After cells were exposed to hyperthermia, they were injected 
in female C57BL/6 mice for the induction of tumors. Then, the size of the excised 
tumors, from the different hyperthermia-treated groups together with the control group, 
was determibed. Results showed a remarkably prominent difference in tumor volume 
which was temperature-dependent (Fig.3.4.1.B & 3.4.1.C). As expected, tumors from 
the 45oC-hyperthermia treated group appeared to be considerably smaller in size 
compared to those from the group treated at 43oC. These observations further support 
the significance of hyperthermia’s therapeutic potential in an in vivo xenograft murine 
model of malignant melanoma. Several scientific reports have also provided evidence 
regarding hyperthermia’s beneficial effects on tumor growth inhibition utilizing the 
same animal model, however it should be noted that the majority of such studies were 
mainly focused on determining potential enhancement in the efficacy of various 
therapeutic protocols when combined with hyperthermia (Portela et al., 2013, Kim et 
al., 2015, Haghniaz et al., 2016, Misir Krpan et al., 2012, Werthmoller et al., 2016). 
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According to our findings, the observed inhibition in tumor growth was due to the 
stimulation of the apoptotic pathway, as there was a clear activation of caspase-3 
detected in the samples from both hyperthermia-treated groups (Fig.3.4.2). Active 
caspase-3 was found to be expressed to a greater extent in tumors from the 45oC 
hyperthermia-treated group which is in accordance with our previous in vitro findings. 
Also, the excised tumors in this experimental group were of considerably smaller size 
when compared to those from the group treated at 43oC. Our data are consistent with 
various studies showing the involvement of caspase-3 in triggering the apoptotic 
response in a number of hyperthermia-based therapeutic protocols (Portela et al., 2013, 
Haghniaz et al., 2016). In contrast to caspase-3, COX-2 was shown to be expressed in 
significantly lower levels in the tumors of both hyperthermia-treated groups when 
compared to those of the control group (Fig.3.4.2). There is evidence showing that 
COX-2 is highly expressed in metastatic melanoma lesions as well as various melanoma 
cell lines while being undetected in lesions at primary stages (Goulet et al., 2003) and 
thus its use as a prognostic marker for melanoma development has been suggested 
(Becker et al., 2009). Furthermore, results from a recent study monitoring COX-2 
expression in a broad number of clinical samples have associated its increased detection 
with poor prognosis and high metastatic risk (Kuzbicki et al., 2016). For this reason the 
observed decline in COX-2 protein levels after hyperthermia treatment further supports 
its potential as a promising melanoma therapy. Interestingly, there appeared to be a 
remarkable increase in the protein content of phospho-H2A.X (Ser139) in tumors 
excised from both hyperthermia-treated groups and particularly from the group treated 
at 45oC (Fig.3.4.2). This increase indicates an elevation in double-stranded DNA breaks 
as a response to hyperthermic exposures which also appears to be temperature-
dependent. A large number of previous studies have demonstrated that exposing cells to 
hyperthermic conditions (>40oC) can lead to the generation of double-stranded DNA 
breaks which, in turn, can induce cell death as shown in several in vitro models 
(Takahashi et al., 2004, Takahashi et al., 2008, El-Awady et al., 2001). Other scientific 
reports have argued that the observed increase in double-stranded DNA breaks is not a 
direct effect of hyperthermia but the consequence of its effects on other cellular 
processes such as DNA repair pathways (Laszlo and Fleischer, 2009, Hunt et al., 2007, 
Furusawa et al., 2012). Nonetheless, our findings illustrate the significance of 
implementing hyperthermia as a therapeutic strategy perhaps by targeting the DNA of 
tumor cells. Finally, in an attempt to investigate if hyperthermia would exert a 
beneficial therapeutic effect against a cancer type other than melanoma, we also utilized 
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an in vivo murine model of colon carcinoma. The same hyperthermia-based exposure 
protocol was utilized for the induction of tumors in female BALB/c mice. According to 
our data, murine colon carcinoma cells (CT-26) presented a similar pattern of 
cytotoxicity as the one observed with the mouse melanoma cells (Fig.3.4.3.A). Overall, 
there was significant inhibition of tumor growth in both hyperthermia-treated groups 
and the reduction in tumor size was more profound in the hyperthermia-treated group at 
45oC (Fig.3.4.3.B & 3.4.3.C). Furthermore, numerous studies have also utilized the 
same in vivo murine colon carcinoma model for investigating hyperthermia’s role in 
improving the therapeutic outcome of other standard treatment protocols when applied 
in combination (Costa Lima et al., 2017, Lim et al., 2014, Nie et al., 2014, Tsang et al., 
2015, Li et al., 2011). These studies have also provided evidence about the induction of 
apoptosis and particularly the induction of caspase-3 in triggering the apoptotic cell 
death response. Moreover, the expression of COX-2 was decreased while this of 
phospho-H2A.X (Ser139) was increased (Fig.3.4.4) thus displaying a similar pattern of 
expression as with the in vivo mouse melanoma model (between control and 
hyperthermia-treated groups). Similarly, there is clear evidence for the role of elevated 
COX-2 expression levels concominant with an increased metastatic potential and poor 
prognosis in colorectal carcinomas (Rahman et al., 2012, Wang and Dubois, 2010). 
However, the remarkable decrease in COX-2 in the hyperthermia-treated groups 
provides evidence for hyperthermia’s role as a more efficient therapeutic strategy. On 
another note, according to the results from a recent report, elevated phospho-H2A.X 
levels in clinical samples from colon carcinoma patients at various stages is associated 
with poor prognosis and is more evident in metastatic stages as well (Lee et al., 2015). 
However, because an increased expression of the protein was detected in the 
hyperthermia-treated groups (while remaining at low levels in the control group) it can 
be argued that hyperthermia could lead in the generation of double-stranded DNA 
breaks or even perhaps interfere with DNA repair mechanisms (Schaaf et al., 2016, 
Devun et al., 2014). Collectively, our data from both in vivo xenograft murine models 
provide strong support for the significance of hyperthermia’s anti-tumor effects as a 
very promising therapeutic modality against melanoma and colon carcinomas.  
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5. Conclusions 
 
Utilization of hyperthermia, either alone or in combination with chemotherapy 
or radiation, has been the subject of extensive studies during the last few decades due to 
its promising effects in cancer therapy. A number of studies have provided evidence 
about hyperthermia’s capacity to enhance the cytotoxicity of other therapeutic regimens 
when applied in combination with them. Despite its advantages in terms of negligible 
side effects and non-evasiveness, it is not used as a routine therapeutic strategy in 
cancer treatment currently. The main reasons for that are the insufficient heating of 
tumor areas as well as the lack of knowledge regarding the molecular mechanisms 
underlying hyperthermia-induced cell death. A large number of studies have 
demonstrated that the application of hyperthermia in killing cancer cells results in the 
induction of cell death via the activation of the apoptotic pathway. However, the 
underlying molecular mechanisms still remain unclear. The significance of our study is 
that it enhances our current understanding of how hyperthermia exerts its therapeutic 
effectiveness in malignant melanoma by characterizing and elucidating the underlying 
molecular mechanisms in regulating the apoptotic pathway(s) involvement by utilizing 
an in vitro as well as an in vivo model of human and rodent malignant melanomas 
respectively.  
Our study provides evidence about hyperthermia’s therapeutic potential against 
malignant melanoma (A375) as well as non-melanoma (A431) cell lines by exerting its 
cytotoxic effects. However, non-tumorigenic keratinocytes (HaCaT) have been shown 
to be less sensitive against heat induction. This is of great importance as it suggests that 
the application of hyperthermia in treating melanoma does not result in damaging 
healthy, normal cells that surround melanocytes like in the case of keratinocytes. This, 
in turn, constitutes hyperthermia a safe treatment option. Obviously, additional 
experiments can be performed in focusing on examining hyperthermia-induced 
cytotoxicity in cell lines obtained from melanoma metastatic sites (e.g. brain, lung, 
lymph nodes, etc.) and/or other primary tumors. In fact, such studies would indicate if 
this treatment modality can be equally effective against a potentially more aggressive 
cell population (metastatic cells) originating from the same primary tumor site. 
Activation of the complex apoptotic cascade was demonstrated to be the major 
signaling pathway responsible for hyperthermia’s cytotoxicity. In particular, both 
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intrinsic and extrinsic apoptotic pathways were induced in response to hyperthermic 
conditions at 43oC and 45oC in melanoma cells. Moreover, different caspases were 
shown to be activated upon different exposure temperatures. According to our findings, 
exposure to higher temperatures led to the activation of all major caspases, death 
receptor related proteins and pro-apoptotic factors, thus indicating the complete 
activation of the cascade. On the other hand, exposure at 43oC presented a more 
“orchestrated” effect in terms of apoptotic induction as only specific caspases were 
activated in a time-dependent manner. Furthermore, we observed the induction of the 
ER-mediated apoptotic pathway as a response to hyperthermic exposure conditions. 
Similarly to our previous findings, there was a differential pattern of protein activation 
according to the degree of hyperthermic temperatures. Finally, although the majority of 
heat shock proteins were activated, at both hyperthermic conditions, they were shown to 
be expressed in higher levels at 43oC. Overall, our data support the presence of an 
intricate interplay amongst various proteins participating in different signaling cascades. 
It is obvious that the most important factor for the activation of each one of these 
proteins is temperature dependance. To this end, at 45oC of hyperthermia it was shown 
that cells could not manage to adapt effectively to such altered conditions whereas at 
43oC of exposure the cells appeared to be able to adapt more efficiently to hyperthermia 
by being able to regulate the apoptotic response in a more efficient manner. A 
promising direction, for future experiments, could be studying the underlying 
mechanisms of caspase-6 induction which was shown to be the only effector caspase 
activated at 43oC. As for the ER-mediated apoptotic pathway, further work could be 
focused on investigating the role of CHOP induction in the stimulation of cell death 
processes as its up-regulation is associated with subsequent transcription and translation 
of several genes implicated in death pathways.  
Furthermore, our findings from the combinational treatment protocols involving 
hyperthermic exposures followed by the administration of various therapeutic agents, in 
melanoma cells, supported further hyperthermia’s potentially promising application in 
clinical practice. In most cases, the use of hyperthermia combined with other therapeutic 
modalities (e.g. targeted and non-targeted) in melanoma was accompanied by a variable 
degree of potentiation in the drug’s cytotoxicity profile. Consequelty, this is of great 
importance as lower drug concentrations can achieve very effective therapeutic profiles 
without the presence of unwanted side effects in melanoma patients. In addition, we 
have shown that the observed potentiation effect of hyperthermia was associated with 
the activation of different caspases at various apoptotic pathways according to the 
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specific drug agent that was utilized in our experimental conditions. Most importantly, 
the application of combinational treatments was shown to be significantly safer for 
normal, healthy cells as the cytotoxicity observed with various treatment protocols was 
significantly lower than when compared to malignant melanoma cells. Obviously, 
future studies can utilize an in vivo rodent model to investigate further into the 
complexity of the interplay between different cell death pathways involved in enhancing 
the therapeutic effectiveness of combinational treatment protocols in melanoma therapy.  
Finally, our in vitro findings were validated by utilizing an in vivo model of rodent 
malignant melanoma as hyperthermic exposures were demonstrated to affect tumor 
growth by activating the apoptotic cascade in a caspase-dependent manner. 
Interestingly, a marker (COX-2) associated with poor prognosis of the disease was 
found to be downregulated in response to hyperthermic exposures thus providing 
promising evidence about hyperthermia’s therapeutic potential in melanoma treatment. 
Moreover, the detection of DNA damage markers due to heat treatments could be the 
basis for the design of more targeted and efficient compounds which, if applied in 
combination with hyperthermia, will result in a targeted way of causing damage to 
tumor cells specifically. Last but not least, we utilized an additional murine in vivo 
model of colon carcinoma which was also highlighted the significance of 
hyperthermia’s therapeutic effectiveness. This additional observation, although not 
directly relevant to malignant melanoma, it does nevertheless warranty the clinical 
significance of our results in documenting the great potential of hyperthermia as a 
therapeutic modality in other types of human cancers as well.   
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